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The Functional Biology of IL-25
Abstract
CD4+ T helper (Th) 2 cells secrete interleukin (IL)-4, IL-5 and IL-13 and promote immunity to
gastrointestinal helminth infections and chronic inflammation associated with asthma and allergic
disorders. However, the innate immune pathways that promote Th2 cell responses remain poorly
characterized. The non-hematopoietic cell-derived cytokines thymic stromal lymphopoietin (TSLP), IL-33
and IL-25 (IL-17E) have been implicated in promoting Th2 cell-dependent inflammation at mucosal sites
[1-4], but how these cytokines influence innate immune responses are less well defined. Studies in
Chapter 2 and 3 examined the cellular mechanisms through which IL-25 promotes Th2 cell responses and
demonstrated that IL-25 promotes the accumulation of a previously unrecognized non-B/non-T cell
(NBNT) c-kit+ cell population in the gut-associated lymphoid tissue (GALT). Adoptive transfer of
IL-25-elicited c-kit+ cells promoted Th2 cytokine responses and conferred protective immunity to helminth
infection in normally susceptible Il17e-/- mice. In Chapter 3, characterization of the IL-25-elicited c-kit+
cells revealed these cells to be a lineage negative (Linneg) multi-potent progenitor (MPP) cell population.
This cell population, termed MPPtype2 cells, exhibited multi-potent capacity, giving rise to cells of
monocyte/macrophage and granulocyte lineages both in vitro and in vivo. These data indicate the
IL-25-elicited MPPtype2 cells may contribute to extramedullary hematopoiesis in vivo. The relationships
between MPPtype2 cells and other recently identified innate cell populations, including natural helper cells
(NHCs), nuocytes, and innate type 2 helper (Ih2) cells were examined in Chapter 4. MPPtype2 cells were
found to be phenotypically distinct from nuocytes, NHCs and Ih2 cells. Further, stimulation of
IL-25-elicited MPPtype2 cells with TSLP and IL-33 resulted in the differentiation of these cells into a T1/
ST2+ IL7Rα+ NHC/nuocyte-like cell population, indicating that MPPtype2 cells could be progenitors of
NHC/nuocytes. Combined, the results presented in this thesis demonstrate that IL-25 induces the
emergence of a previously unrecognized multi-potent progenitor cell population and suggests that
extramedullary hematopoiesis is an evolutionary conserved pathway that promotes Th2 cytokine
responses at mucosal sites.
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ABSTRACT

THE FUNCTIONAL BIOLOGY OF IL-25
Steven A. Saenz

David Artis, PhD

CD4+ T helper (Th) 2 cells secrete interleukin (IL)-4, IL-5 and IL-13 and promote
immunity to gastrointestinal helminth infections and chronic inflammation associated with
asthma and allergic disorders. However, the innate immune pathways that promote Th2
cell responses remain poorly characterized.

The non-hematopoietic cell-derived

cytokines thymic stromal lymphopoietin (TSLP), IL-33 and IL-25 (IL-17E) have been
implicated in promoting Th2 cell-dependent inflammation at mucosal sites [1-4], but how
these cytokines influence innate immune responses are less well defined. Studies in
Chapter 2 and 3 examined the cellular mechanisms through which IL-25 promotes Th2
cell responses and demonstrated that IL-25 promotes the accumulation of a previously
unrecognized non-B/non-T cell (NBNT) c-kit+ cell population in the gut-associated
lymphoid tissue (GALT). Adoptive transfer of IL-25-elicited c-kit+ cells promoted Th2
cytokine responses and conferred protective immunity to helminth infection in normally
susceptible Il17e-/- mice. In Chapter 3, characterization of the IL-25-elicited c-kit+ cells
revealed these cells to be a lineage negative (Linneg) multi-potent progenitor (MPP) cell
population. This cell population, termed MPPtype2 cells, exhibited multi-potent capacity,
giving rise to cells of monocyte/macrophage and granulocyte lineages both in vitro and
in vivo.

These data indicate the IL-25-elicited MPPtype2 cells may contribute to

extramedullary hematopoiesis in vivo.

The relationships between MPPtype2 cells and

v

other recently identified innate cell populations, including natural helper cells (NHCs),
nuocytes, and innate type 2 helper (Ih2) cells were examined in Chapter 4. MPPtype2
cells were found to be phenotypically distinct from nuocytes, NHCs and Ih2 cells.
Further, stimulation of IL-25-elicited MPPtype2 cells with TSLP and IL-33 resulted in the
differentiation of these cells into a T1/ST2+ IL7Rα+ NHC/nuocyte-like cell population,
indicating that MPPtype2 cells could be progenitors of NHC/nuocytes. Combined, the
results presented in this thesis demonstrate that IL-25 induces the emergence of a
previously unrecognized multi-potent progenitor cell population and suggests that
extramedullary hematopoiesis is an evolutionary conserved pathway that promotes Th2
cytokine responses at mucosal sites.

vi

Table of Contents
Acknowledgements........................................................................................................iii
ABSTRACT.......................................................................................................................v
Table of Contents ..........................................................................................................vii
List of Tables ...................................................................................................................x
List of Figures.................................................................................................................xi
Chapter 1 Introduction ....................................................................................................1
1.1 Helminth infections and allergic disorders .........................................................2
1.1.1 Helminth infections ...........................................................................................3
1.1.2 Asthma, allergies and allergic disorders ...........................................................4
1.2 CD4+ T helper cell subsets....................................................................................5
1.2.1 T helper cell differentiation................................................................................6
1.2.2 Th2 cell differentiation and type 2 inflammation ...............................................7
1.2.3 Helmiths as a model for CD4+ Th2 cell-dependent immunity............................8
1.3 Functional biology of TSLP ................................................................................12
1.3.1 Cellular sources and regulation of TSLP expression......................................14
1.3.2 Cellular targets and TSLP-TSLPR signaling...................................................15
1.4 Functional biology of IL-33 .................................................................................16
1.4.1 Cellular sources and regulation of IL-33 expression ......................................18
1.4.2 Cellular targets and IL-33-T1/ST2 signaling ...................................................19
1.5 Functional biology of IL-25 .................................................................................21
1.5.1 Role of IL-25 in immunity to helminth parasites and allergic disorders ..........23
1.5.2 Cellular sources and regulation of IL-25 expression ......................................26
1.5.3 Cellular targets and IL-25-IL-17RB signaling..................................................28
1.5.4 Undefined targets of IL-25 ..............................................................................29
1.6 EC-derived cytokines: Cross-regulation and interplay....................................31
1.7 Extramedullary hematopoiesis ..........................................................................32
1.8 Outline of Thesis .................................................................................................35
Chapter 2 IL-25 promotes Th2 cytokine responses through the induction of a
lineageneg innate c-kit+ cell population ........................................................................41
2.1 Abstract ................................................................................................................41
2.2 Introduction..........................................................................................................41
2.3 Methods ................................................................................................................44

vii

2.3.1 Mice and administration of exogenous cytokine .............................................44
2.3.2 Flow cytometry................................................................................................44
2.3.3 Mast cell differentiation assays.......................................................................45
2.3.4 Ovalbumin (OVA) immunization, helminth infections and adoptive transfer...45
2.3.5 Histology and cytospin preparation ................................................................46
2.3.6 Real-time PCR................................................................................................46
2.3.7 Statistical analysis ..........................................................................................47
2.4 Results..................................................................................................................47
2.4.1 IL-25 promotes type 2 inflammation in vivo through the induction of a c-kit+
cell population in the GALT......................................................................................47
2.4.2 Induction of the c-kit+ cell population is dependent on IL-25/IL-25R signaling
pathway ...................................................................................................................48
2.4.3 IL-25-induced c-kit+ cells do not represent NKT cell, basophil, eosinophil or
mast cell populations ...............................................................................................49
2.4.4 IL-25-elicited c-kit+ cells promote Th2 cytokine-dependent responses in vivo.
.................................................................................................................................52
2.5 Discussion ...........................................................................................................53
Chapter 3 IL-25-elicited c-kit+ cells represent a previously unrecognized multipotent progenitor cell population ................................................................................67
3.1 Abstract ................................................................................................................67
3.2 Introduction..........................................................................................................68
3.3 Methods ................................................................................................................70
3.3.1 Mice, exogenous cytokines and BrdU labeling ...............................................70
3.3.2 Flow cytometry, cell sorting and cytospin preparations ..................................70
3.3.3 HSC differentiation assays .............................................................................71
3.3.4 CD4+ T cell co-cultures ...................................................................................72
3.3.5 Real-time PCR................................................................................................72
3.3.6 Statistical analysis ..........................................................................................73
3.4 Results..................................................................................................................73
3.4.1 IL-25-elicited c-kit+ cells display a MPP-like surface phenotype, but IL-25 does
not affect HSC populations in the bone marrow ......................................................73
3.4.2 IL-25-elicited c-kit+ cells exhibit multi-potent capacity and differentiate into
myeloid and/or granulocyte populations ..................................................................75

viii

3.4.3 Progeny from IL-25-elicited c-kit+ GFPneg cells promote Th2 cell differentiation
in a MHC class II-dependent manner ......................................................................78
3.5 Discussion ...........................................................................................................79
Chapter 4 MPPtype2 cells are functionally distinct from, but can differentiate into
natural helper cells........................................................................................................96
4.1 Abstract ................................................................................................................96
4.2 Introduction..........................................................................................................97
4.3 Methods ................................................................................................................99
4.3.1 Mice, administration of exogenous cytokine, antibody blockade ....................99
4.3.2 Flow cytometry and cell sorting ....................................................................100
4.3.3 In vitro differentiation assays ........................................................................100
4.3.4 In vivo adoptive transfers..............................................................................101
4.3.5 Real-time PCR..............................................................................................101
4.4 Results................................................................................................................102
4.4.1 IL-25-elicited MPPtype2 cells are distinct from natural helper cell/nuocyte
populations. ...........................................................................................................102
4.4.2 IL-25 and IL-33 differentially elicit distinct populations of nuocytes and
MPPtype2 cells in the MLNs .....................................................................................103
4.4.3 IL-25-elicited MPPtype2 cells have the capacity to differentiate into a
NHC/nuocyte-like cell population...........................................................................106
4.5 Discussion .........................................................................................................108
Chapter 5 Summary, Discussion and Future Directions .........................................125
5.1 Characterization of the innate immune cell populations elicited by IL-25 ...125
5.2 Relationship(s) between the MPPtype2 cells and the other previously
unrecognized innate cell populations ...................................................................128
5.3 MPPtype2 cells and extramedullary hematopoiesis..........................................132
5.4 Subsets of innate lymphoid cell populations .................................................138
5.5 Concluding Remarks.........................................................................................142
Bibliography.................................................................................................................147

ix

List of Tables
Table 1. Summary of cellular sources, stimuli that induce expression and cellular
targets of TSLP, IL-25, and IL-33. ............................................................... 40
Table 2. Comparison of MPPtype2 cells, nuocytes, Ih2 cells and NHCs............. 112

x

List of Figures
Figure 1. Epithelial cells as a source of TSLP, IL-33 and IL-25 in vivo............... 37
Figure 2. Downstream signaling pathways activated following receptor ligation by
TSLP, IL-33 and IL-25. ................................................................................ 38
Figure 3. Cross-regulation between TSLP, IL-33 and IL-25. .............................. 39
Figure 4. IL-25 preferentially elicits a non-B/non-T c-kit+ cell population. ........... 57
Figure 5. IL-25 promotes type 2 inflammation in vivo. ....................................... 58
Figure 6. IL-25 elicits c-kit+ cells in the GALT that display heterogeneous
expression of IL-4/eGFP.............................................................................. 59
Figure 7. IL-17RB and IL-17RA are required for IL-25-mediated induction of the
c-kit+ cell population and Th2 cytokine responses....................................... 60
Figure 8. IL-25-induced c-kit+ cells do not represent NKT cell, basophil,
eosinophil or mast cell populations. ............................................................. 61
Figure 9. IL-25-induced c-kit+ cells do not represent a classical mast cell
population. ................................................................................................... 63
Figure 10. IL-25/IL-17RB signaling does not influence the differentiation of c-kit+
FcεRI+ mast cell populations........................................................................ 64
Figure 11. IL-25-elicited c-kit+ cells promote Th2 cytokine-dependent responses
in vivo........................................................................................................... 65
Figure 12. IL-25-elicited c-kit+ cells are Linneg. .................................................... 83
Figure 13. IL-25-elicited c-kit+ cells display a surface phenotype consistent with
multi-potent progenitor cells......................................................................... 84
Figure 14. Administration of recombinant IL-25 results in increased BrdU+ c-kit+
cells in the MLNs but not in the bone marrow.............................................. 85
Figure 15. IL-25 does not affect the frequencies of bone marrow resident
hematopoietic stem cells. ............................................................................ 87
Figure 16. IL-25-elicited c-kit+ cells exhibit multi-potent capacity and differentiate
into myeloid and/or granulocyte populations. .............................................. 89
Figure 17. IL-25-elicited c-kit+ GFPneg cells possess monocyte/macrophage
potential. ...................................................................................................... 91
Figure 18. IL-25-elicited c-kit+ GFPneg cells display multi-potent potential in vivo.
..................................................................................................................... 92
xi

Figure 19. Progeny from IL-25-elicited c-kit+ GFPneg cells promote Th2 cell
differentiation in a MHC class II-dependent manner.................................... 93
Figure 20. IL-25-elicited c-kit+ cells possess multi-potent potential and promote
Th2 cell differentiation.................................................................................. 95
Figure 21. IL-25-elicited c-kit+ cells are distinct from natural helper cells. ........ 113
Figure 22. IL-25 elicits a c-kit+ cell population in the mesentery, but does not
affect natural helper cell populations. ........................................................ 114
Figure 23. IL-25-elicited MPPtype2 cells, but not nuocytes, possess multi-potent
potential. .................................................................................................... 115
Figure 24. IL-25 and IL-33 differentially elicit nuocytes and MPPtype2 cells in the
MLNs. ........................................................................................................ 116
Figure 25. IL-33 signaling is not required for the IL-25-mediated induction of
MPPtype2 cell or nuocyte cell populations. .................................................. 117
Figure 26. IL-25-elicits c-kitint cell populations independent of IL-33................ 118
Figure 27. IL-25 signaling is not required for the IL-33-mediated induction of c-kit+
nuocyte population..................................................................................... 119
Figure 28. IL-25-elicited MPPtype2 cells and nuocytes express the receptor for
TSLP. ......................................................................................................... 120
Figure 29. IL-25-elicited MPPtype2 cells represent a direct progenitor population of
nuocytes. ................................................................................................... 121
Figure 30. IL-25-elicited nuocytes do not display multi-potent potential. .......... 123
Figure 31. IL-25-elicited MPPtype2 cells differentiate into T1/ST2+ IL-7Rα+
nuocytes in vivo. ........................................................................................ 124
Figure 32. Potential lineage relationships between MPPtype2 cells, NHCs,
nuocytes and Ih2 cells. .............................................................................. 144
Figure 33. Do MPPtype2 cells represent a homogeneous or heterogeneous multipotent progenitor cell population?.............................................................. 145
Figure 34. MPPtype2 cells display heterogeneous expression of Ly6C. ............. 146

xii

Chapter 1
Introduction
Innate and adaptive immune cells located at the mucosal surfaces of the airways and
the gastrointestinal tract play pivotal roles in the detection and elimination of invading
pathogens.

However, in the steady state these immune cell populations remain

hyporesponsive to a vast array of innocuous environmental stimuli to which they are
simultaneously exposed including allergens, pollutants and beneficial microbial
communities [5]. The consequences of dysregulated immunologic hyporesponsiveness
can result in inflammatory responses associated with food allergy, inflammatory bowel
disease and cancer [6-10].

Based on their location at the interface between host tissues and external environment,
it is now recognized that epithelial cells (ECs) are a critical cell population that can
influence the initiation, regulation and resolution of innate and adaptive immune cell
responses at mucosal sites. There has been particular interest in EC-derived cytokines
including thymic stromal lymphopoietin (TSLP), IL-33 and IL-25 as recent data support
roles for these cytokines in influencing Th2 cytokine responses at mucosal sites through
the induction of distinct innate cell populations [11-17]. For instance, TSLP has been
shown to selectively promote basophilia in the periphery, while IL-33 elicits eosinophils
[11]. In contrast, the cellular mechanisms through which IL-25 promotes CD4+ T helper
(Th) 2 cytokine responses remain poorly characterized.

Increased understanding of

early cellular and molecular mechanisms that promote Th2 cytokine responses, and the
mechanisms by which TSLP, IL-33 and IL-25 influence this process, may offer insight
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into novel therapeutic approaches to modulate Th2 cytokine-mediated inflammation
associated with asthma, allergic disorders and helminth infections.

This chapter will provide an introduction to the global health impact of helminth infections
and allergic disorders, the functions and development of CD4+ T helper cell subsets, and
Trichuris muris as a model system of Th2 cytokine-dependent immunity. In addition, this
chapter will discuss the cellular sources, targets, signaling pathways, functional biology
and potential cross-regulatory pathways of the epithelial cell-derived cytokines TSLP, IL33 and IL-25.

Lastly, extramedullary hematopoiesis and recently identified innate

lymphoid cell populations will be discussed as potential mechanisms for the initiation of
rapid local immune responses at mucosal sites.

1.1 Helminth infections and allergic disorders
The mucosal lining of the lungs and gastrointestinal tract represent a vast interface
between host tissues and the external environment. As such, the mucosal immune
system plays a pivotal role in the detection and elimination of invading pathogens.
However, not only must the immune system successfully recognize pathogens, it must
also recognize innocuous antigens from food, commensal microbes and allergens while
remaining hyporesponsive to these stimuli [5]. ECs located at barrier surfaces such as
the intestines, lung and skin are a critical cell population that can initiate and regulate
immune responses. Among the potential immune challenges encountered by ECs at
barrier surfaces, helminth parasites and food allergies pose significant human health
concerns. Understanding the pathways that regulate and initiate Th2 cytokine-mediated
inflammation associated with these diseases will greatly benefit efforts aimed at
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developing therapeutics to control and prevent helminth infections and allergic
inflammatory diseases.

1.1.1 Helminth infections
Parasitic helminth infections such as roundworms, hookworms, whipworms, blood flukes
and schistosomes are considered neglected tropical diseases (NTDs) that, collectively,
represent the some of the most prevalent infectious diseases worldwide [18].

For

instance, it is estimated that approximately two billion individuals worldwide are infected
with soil-transmitted helminths [18-20]. While helminth infections typically do not have
high mortality rates, they can elicit chronic morbidities including chronic anemia and
inflammation, malnutrition, disfigurement, blindness, infertility, growth retardation, delays
in cognitive development, enteropathy, chronic dysentery or rectal prolapse [21-27].
Moreover, soil-transmitted helminth infections and schistosomiasis impact agricultural
productivity not only through human disease and morbidity, but also through infection of
livestock, causing reduced food production and economic losses.

The human whipworm Trichuris trichiura infects approximately 600 million people
worldwide and an additional three billion individuals are at risk of infection [28, 29].
Currently, developing regions of Asia, Africa and Latin America have the highest rates of
Trichuris trichiura infection and the highest incident rates found in rural areas [19].
Treatment with anti-helminth drugs is effective to induce the expulsion of parasitic worms
[19], however, to date there are no successful vaccines to prevent infection with soiltransmitted helminths and efforts aimed at controlling these diseases have fallen behind
those aimed at eradicating HIV/AIDS and malaria.

As a result, increased efforts to

control helminth infections can have a dramatic impact on global health, especially
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considering that helminth infections cause as significant a public health burden as
HIV/AIDS and malaria in terms of the number of life years lost due to disability or death.
For example, while 64 million disability adjusted life years (DALYs) have been attributed
to HIV/AIDS, and soil-transmitted helminth account for 20 million DALYS and T. trichiura
alone results in an estimated 6.4 million DALYs [20]. Thus, there is a growing need to
identify novel vaccine and therapeutic approaches in defense against helminth
infections.

1.1.2 Asthma, allergies and allergic disorders
Asthma and allergic diseases are among the major causes of illness and disability in the
US for all ages.

Major allergic diseases include asthma, allergic rhinitis, chronic

rhinosinusitis, atopic dermatitis, and food allergy. A recent nationwide survey found that
more than half (54 percent) of all US citizens test positive to one or more allergens,
which is thought to be a predictor for the eventual development of subsequent or
additional allergic conditions [30, 31]. In addition, the prevalence and severity of food
allergies has increased in the past two decades. Reports from the US and Europe have
shown approximately a two-fold increase in the number of children with peanut allergy
alone while reports in the EU indicate the prevalence of food allergy is 7.5% in children
and 2–4% in adults [32-34]. Further, asthma affects approximately 7% of adults and
nearly 10% of children in the US [34] and since 1980 the incidence of asthma in the US
has nearly tripled [35], with more than 23 million people affected with this disease. In
Europe, the prevalence of children with asthma rose from less than 5% to 25% in 30
years [36].
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Individuals with atopic dermatitis are predisposed to developing food allergies [37, 38]
and atopic dermatitis is typically the first diagnosed allergic disorder in children.
Moreover, atopic dermatitis and food allergies have also been linked to the development
of asthma. This progression from atopic dermatitis to the development of food allergies,
asthma and other allergic disorders is a phenomenon termed ‘the allergic march’. For
instance, sensitivity to food allergens, including wheat, eggs, milk and peanuts is
predictive of the development of asthma and these children are more likely to develop
asthma or allergic inflammation [39]. Further, approximately one third of children with
food allergy have asthma and children with asthma and food allergy are more likely to
have fatal allergic reactions to food [38, 40].

Moreover, epidemiologic studies have

linked obesity with the development and severity of asthma [41]. As the adverse impact
of asthma and allergic diseases on public health continues to grow, there is an urgent
need to develop novel approaches to treat and, eventually, prevent these diseases.
Better understanding of the cellular and molecular events that regulate the development
of Th2 cytokine responses will enable the scientific community to develop targeted
therapeutics to prevent the onset of multiple inflammatory conditions.

1.2 CD4+ T helper cell subsets
The ability of the host to recognize and respond to distinct pathogens is a central part of
mammalian host defense. Within the adaptive immune response, following infection or
exposure to allergens, naïve CD4+ T helper (Th) cells can differentiate into one of
various specialized effector cell subsets, including Th1, Th2 or Th17 cells as well as
regulatory T cells (Treg), IL-22-producing T cells (Th22) and T follicular helper cells
(Tfh). These subsets are defined by their unique expression of transcription factors,
cytokine production profiles and effector functions. The development of CD4+ T helper
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cell subsets is dependent upon three specific molecular signals: 1) T cell receptor (TCR)
engagement, 2) co-stimulation and 3) cytokine signaling. Depending on the context of
infection, these stimuli specify the appropriate T helper cell fate required to combat the
invading pathogen [42, 43]. This section will discuss the molecular mechanisms and
cytokine signals involved in the development of CD4+ Th1, Th2 and Th17 cell subsets,
as well as their functions in immunity and inflammation.

1.2.1 T helper cell differentiation
Subsets of CD4+ T cells were first described in 1986 and their classification was based
on differential effects on B cell responses. These subsets were termed Th1 and Th2
cells and were defined by their unique expression of the cytokines interferon (IFN)-γ and
interleukin (IL)-4, respectively [44]. While, Th2 cell differentiation will be discussed in
more detail in the following section, subsequent studies demonstrated that Th1 cell
differentiation requires the expression of the T-box binding transcription factor T-bet, as
well as the IL-12/STAT4 signaling and IFN-γ/STAT1 signaling pathways [45-47]. Th1
cell differentiation results from IFN-γ/STAT1 signaling on TCR-activated T cells leading
to increased expression of T-bet and the upregulation of IL-12Rβ2 [48]. This increased
responsiveness to APC-derived IL-12 results in IFN-γ production from the CD4+ T cells
and blocks their differentiation into Th2 cells by inhibiting IL-4 expression and GATA3
[49, 50]. Th17 cell differentiation is dependent on expression of the transcription factor
RORγt and was originally thought to be dependent on the IL-23/STAT3 signaling
pathway.

However subsequent studies have identified that optimal Th17 cell

differentiation occurs following stimulation with TGFβ or IL-1β combined with IL-6 [5153], while IL-23 acts to sustain RORγt and IL-17A expression and Th17 cell survival.
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Th1 and Th17 cell subsets are associated with protective immunity and/or inflammation
and the use of in vivo infection models first demonstrated the biological significance and
pathogen-specificity of these subsets. For instance, CD4+ Th1 cells mediate immunity to
the intracellular protozoan parasites such as Leishmania major and Toxoplasma gondii
[54, 55]. Th1 cell responses are characterized by expression of their signature cytokine
IFN-γ and are required for immunity to intracellular pathogens such as viruses, bacteria
and parasites. Th17 cells are characterized by their signature cytokine profile IL-17A, IL17F, IL-21 and IL-22 and are associated with defense against certain extracellular
bacteria and fungal pathogens [56-58].

In addition, recent studies have also

demonstrated that Th17 cells are responsible for inflammation associated with multiple
inflammatory and autoimmune diseases. For instance, Th17 cytokine responses are
associated with experimental autoimmune encephalitis (EAE), inflammatory bowel
disease (IBD), psoriasis and arthritis, diseases that were previously thought to be
mediated by Th1 cytokine responses [8, 59]. These findings highlight that increased
understanding of the molecular mechanisms that promote immunity and/or disease will
benefit the development of more targeted and efficacious therapeutics.

1.2.2 Th2 cell differentiation and type 2 inflammation
CD4+ T helper 2 cells are characterized by their production of the effector cytokines IL-4,
IL-5, IL-9 and IL-13. Th2 cell differentiation requires expression of the transcription factor
GATA3, the master regulator of Th2 cell differentiation, and signaling through the IL4/STAT6 pathway.

IL-4/STAT6 signaling following TCR stimulation results in the

upregulation of GATA3 and increased production of IL-4, IL-5 and IL-13, however,
several additional transcription factors including NFAT, AP-1 and c-Maf can contribute to
optimal/sustained IL-4 production [49, 60, 61]. Th2 cells are known to be required for

7

resistance to helminth parasites, but similar to Th17 cells, Th2 cells can also play dual
roles in immunity: being either protective or pathologic.

In the context of helminth

infections, IL-4, IL-5 and IL-13 production from CD4+ T cells promotes expulsion of
parasitic helminths through the induction of goblet cell hyperplasia, increased mucin
production, increased smooth muscle contractility, alternative activation of macrophages
(AAMacs), fibrosis, eosinophilia and mast cell degranulation.

Collectively, these

downstream effects of IL-4, IL-5 and IL-13 are termed ‘type 2 inflammation’. However,
while the mechanisms involved in the initiation of innate immune responses following
exposure to viral, bacterial or protozoan infections are well characterized [62-67], the
innate immune pathways that promote Th2 cytokine responses in the context of allergy
or helminth infection remain less well-characterized.

1.2.3 Helmiths as a model for CD4+ Th2 cell-dependent immunity
Many of the discoveries regarding the identification of effector functions and the
regulation of Th2 cytokine responses have been made by studying murine models of
helminth infections. For example, using the Schistosoma mansoni, Nippostrongylus
brasiliensis and Trichuris muris infection models, investigators have demonstrated that
Th2 cytokine responses and type 2 inflammation are responsible for mediating immunity
and type 2 inflammation following helminth infections.

Studies in this thesis employ the Trichuris muris infection model to investigate the in vivo
functional biology of IL-25-elicited innate cell populations (see Chapter 2). Trichuris, a
soil transmitted helminth, is a natural pathogen of mice and being biologically similar to
species that infect humans (Trichuris trichiura), provides a natural well-defined in vivo
model for studying the development of Th2 cytokine responses [68]. Trichuris utilizes a
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fecal/oral route of transmission whereby Trichuris eggs are ingested orally by the host
and hatch in the distal small intestine. Larval parasites burrow into intestinal epithelial
cells (IEC) that line the crypts of the cecum and proximal colon. Adult worms remain
intimately associated with the IECs as they form syncytial tunnels and are in direct
contact with IEC cytoplasm. The posterior end of the worms remains in the lumen to
allow for mating and the deposition of eggs that propagate the Trichuris life-cycle [68].

Experimental infection with Trichuris provides a tractable model of CD4+ T celldependent immunity in the gut whereby resistance or susceptibility to Trichuris infection
is determined by specific immune responses. For instance, susceptible mouse strains
such as AKR mount a Th1 response characterized by production of IL-12 and IFN-γ and
are unable to clear the parasites resulting in chronic infection. In contrast, resistant mice
(B6 or BALB/c) develop a Th2 cell response (IL-4, IL-5, IL-9, and IL-13) and successfully
expel parasites by day 21 post-infection [69, 70]. CD4+ T cells are required for immunity
to Trichuris, as mice that lack T cells or depletion of CD4+ T cells in vivo results in an
inability to expel parasites. Conversely, adoptive transfer of CD4+ T cells into severe
combined immunodeficient mice (SCID) mice, which lack all B and T lymphocytes,
resulted in the development of protective immunity during Trichuris infection [71].
These findings suggest that not only are CD4+ T cells alone necessary and sufficient to
promote immunity to Trichuris, but that B cells are not required for immunity in this
setting.

Subsequent studies analyzing the role of CD4+ T cells in infection have revealed that
immunity to Trichuris is critically dependent on the generation of CD4+ Th2 cells
(reviewed in [72-74]) and their production of IL-4, IL-5 and IL-13 [69, 71, 75, 76].
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However, additional signaling pathways including MyD88, Notch and other cytokines
play a role in the development of protective Th2 cytokine responses in the context of
Trichuris infection. While MyD88 and TLR-4 signaling renders mice more susceptible to
infection [77], blockage of Notch signaling pathways in T cells through the use of a
dominant negative MAML protein demonstrated that this pathway is required for Th2 cell
differentiation [78]. As a result, following infection with Trichuris, these mice exhibited
increased production of IFN-γ and were susceptible to helminth infection [78], implicating
roles for Notch signaling pathways in the development of protective Th2 cytokine
responses.

Collectively, Trichuris has provided a useful model to investigate the

requirements of innate and adaptive immune components in the development of Th2
cytokine responses.

1.2.4 Epithelial cell-mediated responses to Trichuris muris
Due to the intimate association between adult Trichuris worms and IECs [68], IECs were
suspected to be an important cell population in the initiation of protective Th2 cytokine
responses following Trichuris infection. Indeed, in vivo manipulation of the epithelial cellderived cytokines such as TSLP, IL-33 and IL-25 has emphasized the importance of
IECs in resistance to infection [4, 79-81], and highlighted roles for TSLP, IL-33 and IL-25
in promoting Th2 cytokine responses (discussed in detail in Chapter 1.3-1.5).

For

instance, mice in which NFκB signaling was ablated only in intestinal epithelial cells
(IkkbΔIEC) display decreased expression of TSLP [4]. As a result, these mice are unable
to expel Trichuris parasites, as TSLP was shown to be critical in regulating the
production of the pro-inflammatory cytokine IL-12p40 from DCs [4, 79]. Administration of
IL-33 to susceptible mice was also demonstrated to promote immunity to Trichuris [80]
by promoting Th2 cytokine responses and reducing parasite-specific Th1 responses.
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While IL-33 is known to promote immunity it is currently not known whether IL-33 is
necessary for immunity to helminth infections.

Similar to IL-33, administration of exogenous IL-25 could confer immunity to normally
susceptible mice strains infected with Trichuris [81]. In addition, mice deficient in IL-25
signaling also display an impaired ability to expel Trichuris parasites as they were unable
to mount protective Th2 cytokine responses compared to infected WT mice [81].
However, similar to TSLP, treatment of Trichuris infected IL-25-deficient mice with
neutralizing antibodies against IL-12p40 or IFN-γ was able to restore immunity [81],
indicating that IL-25 was not essential for the development of protective Th2 cell
responses. Collectively, these data highlight the roles for TSLP, IL-33 and IL-25 in the
development of immunity to helminth infections. While it is through the induction of Th2
cytokine responses and the concomitant type 2 inflammation, including increased
production of IgE and IgG1, mastocytosis, alternatively activated macrophages, goblet
cell hyperplasia, RELMβ and mucus production, and increased epithelial permeability
and turnover [82-86] that ultimately result in expulsion of Trichuris, the cellular
mechanisms by which TSLP, IL-33 and IL-25 promote these responses are not
completely understood.

Despite being distinct cytokines and sharing little or no homology to one another, role for
TSLP, IL-33 and IL-25 in the promoting Th2 cytokine-mediated responses are well
documented. However, in order to fully understand how these cytokines initiate and
support the development of these immune responses, it is critical to recognize both their
cellular sources and targets in vivo. The following sections will focus on the functional
biology, cellular sources and targets of TSLP, IL-33 and IL-25.
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1.3 Functional biology of TSLP
TSLP has been shown to play a role in the regulation of pro-inflammatory cytokine
production and resultant inflammation during helminth infections, allergic asthma, atopic
dermatitis and chemically-induced colitis [4, 79, 87, 88]. Increased levels of TSLP were
observed in human patients with atopic dermatitis [1] and in the airways of asthmatic
patients, which correlated with disease severity [89]. Suggesting that TSLP is directly
promoting Th2 cytokine responses, the targeted overexpression of TSLP in epithelial
cells of the skin or lung in murine systems resulted in the development of severe Th2cytokine mediated inflammation resembling atopic dermatitis or asthma, respectively [88,
90, 91]. Combined, these results establish a more causative relationship between TSLP
and Th2 cytokine-mediated disease. Specifically, the increased expression of TSLP
resulted in the development of CD4+ Th2 cells, inflammatory cell infiltration, eosinophil
infiltration, increased IgE production and tissue damage [88, 90, 91]. The link between
increased TSLP expression and disease has been further strengthened by the
association of genetic TSLP polymorphisms in humans with the development of asthma
[92] as well as the phenotype of transgenic mice with overproduction of TSLP [90]. In
addition, mice deficient in the receptor for TSLP (Tslpr-/-) were shown to be less
susceptible to an ovalbumin (OVA)-induced model of allergic asthma. In this model,
Tslpr-/- animals failed to produce Th2 cell-associated cytokines and did not exhibit lung
inflammation [87, 91], supporting a role for dysregulated TSLP production contributing to
disease outcome.

While reports of TSLP-induced Th2 cytokine-mediated diseases have been largely
restricted to the skin and the lung, there are new reports emerging that indicate that

12

TSLP may play a role in the pathogenesis of other allergic diseases. For example,
increased TSLP expression has been reported in the nasal epithelium in a mouse model
of allergic rhinitis, and neutralization of TSLP using a monoclonal anti-TSLP antibody
inhibited the development of disease [93]. Also, increased TSLP expression has been
documented in the synovial fluid of human patients with rheumatoid arthritis [94].
Furthermore, genetic variants of TSLP and its receptor (TSLPR) correlate with the
development of eosinophilic esophagitis and biopsies from patients suffering from
eosinophilic esophagitis displayed increased expression of TSLP compared to control
tissues [95].

Although TSLP expression in the skin and the lung has been linked to pathologic Th2
cytokine-mediated responses, TSLP expression in the intestine appears to play an
important role in protective host immunity. Recent work has highlighted the importance
of intestinal ECs in influencing immune cell homeostasis and immunity to helminth
parasites [4, 96, 97], however, TSLP does not appear to be required for immunity to
some helminth infections, such as S. mansoni, Heligmosomoides polygyrus and N.
brasiliensis [98, 99].

As discussed above, IEC-specific deletion of IKKβ resulted in

susceptibility to the intestinal dwelling nematode Trichuris and was correlated to
decreased expression of TSLP [4]. Despite being on a genetically resistant background,
Tslpr-/- mice challenged with Trichuris develop a Th1 cytokine response characterized by
high expression levels of IL-12p40 and IFN-γ, and were unable to clear infection at day
21 post-infection [4, 79]. The strong induction of TSLP mRNA upon infection [80] and its
requirement for efficient early worm clearance [4], indicate that TSLP is a critical
component of protective Th2 cytokine-mediated protective immune responses in the
intestine.
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1.3.1 Cellular sources and regulation of TSLP expression
While TSLP was initially identified and characterized as a novel cytokine produced by
thymic stromal cells [100, 101], it is predominantly expressed in epithelial cells of the
skin (keratinocytes), lung (small airway epithelial cells), and intestine (intestinal epithelial
cells) [1, 101-103]. In the steady state, basal expression of TSLP mRNA and protein
has been detected in epithelial cells of the tonsils, skin, lung, and intestine [4, 96, 102
2002, 104, 105].

Mast cells, basophils and ECs have all been reported to express TSLP. Cross-linking of
the IgE receptor on mast cells results in elevated levels of TSLP mRNA [1] and
basophils stimulated with papain upregulate TSLP mRNA and protein [106]. Increased
TSLP expression in ECs can be induced through exposure to viral, bacterial, or parasitic
pathogens as well as following ligation of Toll-like receptors (TLRs) [80, 107-109] and
exposure to proinflammatory or Th2 cell-associated cytokines has also been shown to
induce expression of TSLP [104, 107, 110, 111] (Fig. 1A). Interestingly, treatment of a
lung epithelial cell line MLE12 with IL-25 also resulted in increased TSLP expression
[112], suggesting a potential link between these two EC-derived cytokines (see Crossregulation and interplay section below). Moreover, there is speculation that TSLP can
influence wound healing since expression is upregulated by damage or trauma to ECs
[108]. Although the molecular mediators and mechanisms of action remain unknown,
recent work suggests that mast cells may also induce TSLP expression in ECs as mast
cell-deficient mice fail to upregulate TSLP in a model of allergic rhinitis [93]. Given the
findings that TSLP can be induced by both exogenous stimuli (damage, infection, TLR
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ligation) and host-derived signals (Fig. 1A), TSLP production by ECs and its regulation
represent a critical pathway through which ECs modulate immune responses.

1.3.2 Cellular targets and TSLP-TSLPR signaling
High affinity ligand binding of TSLP and subsequent signaling requires a heterodimeric
receptor consisting of the IL-7Rα chain and a unique TSLPR chain that resembles the
common cytokine receptor γ chain (γc) [103, 113]. Despite poor sequence homology
between human and mouse TSLPR, both activate similar signaling pathways. Ligation
of TSLPR leads to the downstream phosphorylation and activation of STAT5 in mice and
humans and STAT3 in humans [114, 115] and appears to be JAK-independent, but may
require a Tec kinase [102, 103, 114, 115] (Fig. 2A).

Initially, TSLPR expression was thought to be limited to immature B cells and myeloid
cells such as monocytes and dendritic cells (DCs) [102, 103, 113], however, more recent
work has demonstrated TSLPR expression on mast cells, basophils and CD4+ T cells
[102, 106, 108, 116]. DCs and mast cells appear to express TSLPR constitutively [1,
106, 108], however, CD4+ T cells require TCR stimulation to induce receptor expression
and become sensitive to TSLP treatment [102, 116, 117]. Additionally, human mast
cells have been recently demonstrated to express the functional TSLPR complex and
produce IL-5 and IL-13 as well as IL-6 and GM-CSF following exposure to TSLP [108].

More recent data has suggested that in vivo, TSLP selectively promotes the population
expansion of basophils [11, 12].

These studies demonstrated that administration of

recombinant TSLP or injection of a cDNA plasmid encoding TSLP resulted in increased
frequencies of basophils in the blood and spleen [11, 12].
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Studies performed by

Siracusa et al. also demonstrated that TSLP could promote peripheral basophilia in the
absence of IL-3 signaling [12], a cytokine previously shown to regulate basophil
development. Moreover, TSLP-elicited basophils expressed higher levels of T1/ST2 and
produced more IL-4 and IL-6 in response to IL-3, IL-18 and IL-33 [12], indicating that
TSLP-elicited basophils were functionally distinct from IL-3-elicited basophil populations.
Collectively, while these reports identify multiple cellular targets for TSLP in vivo, they
highlight that TSLP selectively induces basophil populations to influence Th2 cytokine
responses.

1.4 Functional biology of IL-33
IL-33 was first described in 2005 and, along with IL-1 and IL-18, belongs to the IL-1
cytokine family [2]. IL-33, similar to its other family members IL-1 and IL-18, has been
shown to promote Th2 cytokine responses [2, 80, 118-121]. Members of the IL-1 family
are expressed as prodomains and only become functionally mature proteins following
proteolytic processing by caspase-1.

Consistent with other IL-1 family members,

Schmitz et al. [2] demonstrated that in vitro incubation of IL-33 with caspase-1 yielded an
18 kDa mature protein from a 30 kDa precursor. IL-33, like other members of the IL-1
family, shares the IL-1/FGF β-trefoil fold structural motif consisting of 12 β-strands
forming a single domain [122, 123].

Interestingly, IL-33 has also been ascribed

transcriptional repressor properties based on nuclear localization to heterochromatin and
using a yeast two-hybrid system, it was shown that IL-33 repressed transcription in a
manner consistent with IL-33 associating with heterochromatin [124]. Despite this work,
the functional significance of IL-33 nuclear localization and the role this phenomenon
plays in the context of immunity or inflammation is not fully understood.
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IL-33 is produced by ECs and has been implicated in the promotion of Th2 cytokine
associated responses, although IL-33 has also been shown to inhibit proinflammatory
cytokine responses. IL-33 treatment was found to reduce atherosclerotic plaque size,
the number of infiltrating macrophages and T cells and production of IFN-γ [125]. In
addition, IL-33 signaling has also been reported to regulate T. gondii-mediated
inflammation [126] and has been linked to inflammatory bowel disease (IBD) [127] and
lupus [128]. The link between IL-33 and Th2 cytokine production was formed from in
vivo studies, in which administration of IL-33 to mice resulted in increased expression of
IL-4, -5, and -13, elevated serum levels of IgE and IgA and additional hallmarks for type
2 inflammation including increased goblet cell hyperplasia, mucus secretion and
eosinophilia [2].

While data suggest that IL-33 promotes Th2 responses in vivo, in the systems tested, IL33 does not appear to be strictly required for the initiation of Th2 cytokine-mediated
responses in vitro [129] or in vivo [130]. IL-33 expression is induced following infection
with Trichuris [80], and administration of recombinant IL-33 early during infection
conferred resistance to normally susceptible Trichuris-infected AKR mice [80], similar to
the effects observed following early treatment with IL-25 [81], however, Hoshino et al.
found no effect on the outcome of infection in mice deficient in IL-33 signaling [131].
Moreover, IL-33 treatment was insufficient to mediate expulsion of Trichuris in the
absence of adaptive immunity highlighting the necessity of CD4+ T cells for resistance.
Interestingly, IL-33 treatment increased the expression of TSLP and TSLPR mRNA in
the colons of Trichuris-infected mice [80] demonstrating a potential association between
two cytokines known to drive Th2 cytokine responses.
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Increased expression of the IL-33 receptor (T1/ST2) has been reported in the serum of
patients with asthma [132] and in mouse models of airway inflammation [133]. Further,
two studies have demonstrated that neutralization of T1/ST2 resulted in the decreased
levels of IL-4 and IL-5 in the bronchio-alveolar lavage fluid (BAL) and a reduction in
eosinophil infiltration in an airway inflammation model [134, 135]. However, another
report found no relationship between T1/ST2 expression and increased airway
inflammation [131]. In support of the association between IL-33 and airway inflammation
there was a recent report indicating that IL-33 induced airway hyperresponsiveness
(AHR) associated with increased airway resistance and Th2 cytokine expression in the
lungs [136].

Along with promoting protective Th2 cytokine responses, IL-33 can also have a
pathologic role in vivo. Consistent with its ability to promote IL-13 production, IL-33 was
found to be expressed in fibrotic liver tissue and promote collagen deposition [137],
however, IL-33 was also expressed in the synovial joints of arthritis patients [138].
Moreover, blockade of T1/ST2 signaling attenuated inflammation observed in a mouse
model of collagen-induced arthritis [138], highlighting a role for the IL-33 signaling
pathway inflammatory diseases.

1.4.1 Cellular sources and regulation of IL-33 expression
Expression of IL-33 mRNA has been reported in tissues such as the CNS, lymph nodes,
lung, skin, and colon, and in dendritic cells, macrophages, lung ECs and adipocytes [2,
41, 139], however, both helminth and influenza infections have been reported to
increase production of IL-33 [80, 139]. Infection with Trichuris increased IL-33 mRNA
with peak expression reported at day 3 post-infection compared to naïve controls [80]

18

(Fig. 1B). This infection-induced increase in IL-33 appears to be transient and temporal,
suggesting a regulatory pathway to dampen its production following induction of immune
responses. In addition, the H3N1-strain of influenza was also reported to increase IL-33
production from alveolar macrophages. Interestingly, while lung ECs were reported to
produce IL-33 under homeostatic conditions, their production levels of IL-33 remained
unchanged following flu infection [139].

1.4.2 Cellular targets and IL-33-T1/ST2 signaling
IL-33 signals through T1/ST2, a receptor closely related to IL-1R1 and IL-18Rα [140142], but it does not bind IL-1 or IL-18. This receptor family is characterized by the
presence of an intracellular Toll-IL-1R (TIR) domain [143, 144], and requires two
components for effective signaling: a ligand binding chain and a second subunit, which
mediates the downstream signaling events but does not physically interact with the
ligand itself (reviewed in [145]) (Fig. 2B). Both a membrane form and soluble form of
T1/ST2 exist in vivo [146, 147], however, the function of the soluble form of T1/ST2 is
unclear.

One potential role is to function as a decoy receptor, thus regulating

constitutive IL-33 signaling in vivo (Fig. 2B). In its membrane form, T1/ST2 is present on
Th2 polarized cells and mast cells independently of IL-4 [134, 148, 149]. IL-33 was
found to associate with T1/ST2 [2], and receptor ligation resulted in activation of NF-κB
[2].

IL-1R accessory protein (IL-1RAcP) was subsequently identified as the second

component of the functional IL-33R complex, as treatment with IL-33 did not induce a
Th2 cytokine response in the absence of IL-1RAcP [150]. Therefore, the IL-33 signaling
receptor complex is comprised of T1/ST2 and IL-1RAcP (Fig. 2B). Furthermore, MyD88
and TRAF6, as well as IL-1R associated kinase 4 (IRAK4), form a complex with IL-33
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and T1/ST2 to mediate further downstream signaling events. IL-33 stimulation has also
been demonstrated to result in the phosphorylation of ERK1/2, p38, and IκBα (Fig. 2B).

T1/ST2 is expressed by Th2 cells and mast cells. Incubation of Th2 cells with IL-33
increased production of IL-5 and IL-13 and reduced production of IFN-γ [2]. Additionally,
mature mast cells and their precursors express T1/ST2 and treatment of human mast
cells or CD34+ mast cell progenitors [108] with IL-33, but not IL-18, resulted in increased
survival and cytokine production even in the absence of stem cell factor (SCF) [149].
Furthermore, Ho et al. demonstrated that murine mast cells responded to IL-33 in a
MyD88-dependent manner [151]. Similar increases in cytokine production observed in
basophils following treatment with IL-33 were also shown to require MyD88 [136, 152].
These studies suggest that MyD88 plays an important role in IL-33-mediated cytokine
production in innate cell populations.

Interestingly, inclusion of TSLP into IL-33-

containing cultures could enhance cytokine production from mast cells [108], supporting
a synergistic relationship between IL-33 and TSLP.

Recent reports have also

demonstrated that IL-33 stimulation can promote macrophages to adopt an alternative
activation phenotype, characterized by expression of the mannose receptor and IL-4Rα
[153] and demonstrated effects of IL-33 on basophils [12, 136, 154], eosinophils [155]
and recently identified innate cell populations (discussed in Chapter 1.7), termed natural
helper cells, nuocytes and innate type 2 helper cells [13-15].

Collectively, these findings illustrate the ability of TSLP and IL-33 to promote Th2
cytokine responses and type 2 inflammation in vivo by targeting multiple cell populations,
however, more recent data suggests that TSLP and IL-33 elicit distinct innate cell
populations to influence Th2 cell differentiation.
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Moreover, the cellular mechanisms

used by TSLP and IL-33 to promote Th2 cytokine responses represent viable targets for
therapeutics aimed at modulating Th2 cytokine-mediated inflammation associated with
asthma, allergic disorders and helminth infections.

1.5 Functional biology of IL-25
IL-25 is a member of the IL-17 cytokine family (reviewed in [156, 157]), which contains
six members that were discovered through analysis of genomic databases [3, 158-161],
with IL-17A being the first discovered through sequence homology to a Herpesvirus
samirii open reading frame [162]. While this family bears no close similarity to other
known cytokines, the discovery of several homologues to IL-17 and two IL-17-receptor
homologues within the Strongylocentrotus purpuratus (purple sea urchin) genome
underscores the evolutionarily conserved nature of this cytokine family [163]. Within this
cytokine family individual members share approximately 40-50% sequence identity
although IL-25 possesses the lowest degree of homology to IL-17A at 17% [156, 157].
The greatest similarity between these cytokines is observed in a conserved cysteine-rich
C-terminus, which forms a cysteine-knot structure and is related to a structural motif
present several growth factors [156, 157]. All members exist as homodimers ranging in
molecular weight from 20 to 35 kDa, however recent data suggests that IL-17A and IL17F form heterodimers [164, 165].

Although originally described to promote type 2 inflammation, IL-25 has also been
implicated in regulating intestinal inflammation during helminth infection as well as the
pathogenesis observed during experimental autoimmune encephalomyelitis (EAE) [10,
81, 166].

Further supporting an immunoregulatory role for IL-25 are data that

demonstrate that mice lacking commensal bacteria exhibit reduced expression of IL-25
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in intestinal EC and exaggerated IL-23 and IL-17A levels, suggesting bacterial-derived
signals may influence this immuno-regulatory pathway [167].

In addition, patients

suffering from intestinal inflammation (i.e. Crohn’s disease or ulcerative colitis) express
less IL-25 than control patients and display higher expression levels of IL-23 [168, 169].
Moreover, treatment of human CD14+ monocytes with IL-25 reduced their expression of
pro-inflammatory cytokines and IL-25 could ameliorate disease in chemically-induced
colitis models in mice [168]. Interestingly, however, there are no known associations
between genetic polymorphisms in the IL-25 gene and the development of inflammatory
diseases [170], despite the location of the IL-25 gene within an IBD susceptibility locus
[170]. Nevertheless, combined, these data highlight a role for IL-25 in the regulation of
pro-inflammatory immune responses in both mice and humans.

Similar to TSLP and IL-33, in addition to its immuno-regulatory properties, IL-25 has also
been shown to promote the development of Th2 cytokine responses at mucosal sites
through the induction of IL-4-producing innate immune cells [106, 171-175]. However,
compared to TSLP and IL-33, the cellular mechanisms through which IL-25 mediates
type 2 inflammation are less well characterized.

For instance, TSLP treatment

selectively elicits IL-4-producing basophils that expressed MHC class II and were
capable of promoting Th2 cytokine responses [11, 12], IL-33 was shown to elicit
eosinophils in the blood [11] and activate basophils [136] and natural helper cells
(NHCs) [13].

In contrast, there are conflicting reports of IL-4-producing innate cell

populations elicited by IL-25, among them a c-kitneg CD11b+ Ly6C+ monocyte-like cell
population [176], CD4+ NKT cells [171] and a NBNT c-kit+ cell suggested to be a mast
cell or mast cell precursor population [11, 16].

Thus, the innate cell populations

responsible for promoting Th2 cytokine responses in response to IL-25 remain unclear.
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This section will discuss the role of IL-25 in helminth infections and allergic disorders, its
cellular sources and the cellular pathways targeted by IL-25 to initiate Th2 cytokine
responses.

1.5.1 Role of IL-25 in immunity to helminth parasites and allergic disorders
IL-25 was originally reported to promote Th2 cytokine responses and type 2
inflammation using in vivo administration of exogenous cytokine. Mice treated with IL-25
exhibited increased expression of IL-4, -5, and -13 in the lung, spleen, and liver, as well
as elevated serum levels of IgE, increased goblet cell hyperplasia, mucus secretion and
eosinophilia [3, 158]. Subsequent studies demonstrated that IL-25 is required for the
development of a protective Th2 cytokine-mediated response and protective immunity
following Trichuris infection as mice deficient in IL-25 (Il17e-/-) fail to clear infection and
display significantly reduced levels of IL-4 and IL-13 [81]. In the converse experiment,
IL-25 treatment conferred resistance to genetically susceptible AKR mice. IL-25-treated
AKR mice displayed increased Th2 cytokine production and elevated goblet cell
numbers, resulting in efficient worm expulsion. Interestingly, SCID mice treated with IL25 were unable to clear helminth infections and did not develop increased goblet cell
number or increased mucus production indicating the requirement for adaptive immunity
in IL-25-mediated expulsion of helminth infections [81].

However, Il17e-/- mice can

develop a protective Th2 cytokine response upon blockade of endogenous Th1
cytokines, suggesting that IL-25 is not essential for the development Th2 cytokine
responses [81]. In contrast to persistent infection of normally susceptible AKR mice,
which results in minimal intestinal inflammation, Trichuris-infected Il17e-/- mice
developed a chronic infection characterized by development of severe intestinal
inflammation and elevated expression of IFN-γ and IL-17A [81]. Consistent with a role
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for IL-25 in protective immunity to helminth infections, IL-25 has also been shown to
influence immunity to N. brasiliensis. Compared to WT mice, which expel parasites by
day 10 post-infection, N. brasiliensis-infected Il17e-/- mice remain infected at this time
point and display delayed expulsion of the parasites, taking until days 15-20 to clear
infection.

Moreover, treatment with IL-25 resulted in accelerated expulsion of N.

brasiliensis infection, but this effect was dependent on Th2 cytokines (IL-4, -5, -9 or -13)
[16].

As exogenous IL-25 elicited a granulocyte infiltration into the lungs, increased mucus
production, and airway constriction, it was thus proposed that IL-25 played a role in the
promotion of Th2 cytokine mediated allergic airway inflammation. This hypothesis was
also supported by results showing that administration of exogenous IL-25, or forced
over-expression of IL-25, resulted in elevated levels of IL-4, IL-5 and IL-13 which
corresponded with increased antibody isotype switching and circulating eosinophil
numbers [3, 177, 178].

Moreover, intravenous or intratracheal instillation of an

adenoviral construct encoding IL-25 resulted in similar physiologic changes as
intraperitoneal injection of recombinant protein and was correlated with increase
expression of IL-5 and IL-13, as well as proteins involved in eosinophil recruitment and
migration [3, 158].

Consistent with the initial characterization of IL-25, elevated expression of IL-25 and IL17RB are observed in patients with chronic asthma and atopic dermatitis [179]. The link
between IL-25 and Th2 cytokine-mediated inflammation was further supported by
findings implicating IL-25 in murine models of allergic airway inflammation. Intranasal
administration of IL-25 to mice results in the development of airway hyperreactivity
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(AHR) [158]. Additionally, in a model of sensitization and challenge with OVA plus alum
to induce airway inflammation, Tamachi et al. [180] demonstrated that IL-25 mRNA
expression was upregulated following OVA challenge. Critically, neutralization of IL-25
with a soluble IL-17RB fusion protein reduced eosinophil and CD4+ T cell recruitment
into the lungs [180]. Neutralization of IL-25 also reduced levels of IL-5 and IL-13 in the
BAL fluid and decreased goblet cell numbers. Subsequent studies using antibodies
directed against murine IL-25 again demonstrated that neutralization of IL-25 reduced
AHR [181].

While administration of anti-IL-25 mAb during the aerosolized OVA-

challenge could ameliorate AHR, the effect was specific to the bronchio-constriction as
no decrease in cytokine production, eosinophil recruitment or goblet cell numbers was
observed [181]. Moreover, it was shown that IL-25 could induce AHR independent of IL4, IL-5, IL-9 and IL-13 [181]. These findings suggest that IL-25 is playing a major role in
the initiation and outcome of disease in this model. Further supporting a critical role for
IL-25 in allergic airway inflammation, transgenic mice with lung-restricted expression of
IL-25 exhibited exacerbated OVA-induced airway inflammation leading to increases in
IL-4, IL-5 and IL-13 levels and increased cellular infiltrates in the BAL fluid [180]. It is
important to note however that overexpression of IL-25 alone was not sufficient to
mediate similar effects [180], indicating that IL-25 may not initiate immunological
responses but may instead promote or sustain an ongoing response. Combined, these
studies identify a role for IL-25 in mediating allergic inflammation in the lung.

While IL-25 is clearly involved in allergic airway inflammation, the mechanism whereby
IL-25 elicits a Th2-mediated immune response remains unclear.

CD4+ T cells have

been proposed to mediate IL-25-induced type 2 inflammation [180], however, previous
findings indicate that the effects of IL-25 are independent of T cells [3, 177, 178]. The
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cell populations that IL-25 targets to promote Th2 cytokine responses will be discussed
in more detail in Chapter 1.5.3 and will be the focus of this thesis.

1.5.2 Cellular sources and regulation of IL-25 expression
While IL-17A and IL-17F are associated with increased levels of IL-6 and TNFα, IL-25
has been implicated in promoting Th2 cell-mediated inflammation [3, 81, 158, 180, 182].
Consistent with these findings, exposure to allergens and air pollutants has been
reported to increase IL-25 expression [112, 158, 180, 183], as has infection with the
helminth N. brasiliensis [158] (Fig. 1C) or following viral infections [184]. Conversely,
mice that lack commensal bacterial communities or mice treated with dextran sodium
sulfate to induce colitis were found to have decreased expression levels of IL-25 in the
colons [167, 185], indicating that commensal bacteria or epithelial barrier damage
regulate IL-25 expression. While no induction of IL-25 message was observed in the
Trichuris infection model, it was noted that compared to Trichuris resistant mice,
susceptible mice exhibited decreased expression of IL-25 and its cognate receptor, IL17RB, in colon [81]. While allergens and helminth infection have been shown to induce
IL-25, the downstream factors responsible for regulating IL-25 expression remain poorly
characterized. Analysis of the genomic sequence upstream of the IL-25 encoding region
revealed putative STAT6, GATA-3, and NF-κB binding sites (unpublished data).
However, the functional requirement of these transcription factors in the induction of IL25 has not been investigated. Collectively, these studies support a role for IL-25 in the
initiation of Th2 cytokine responses by highlighting the induction of IL-25 expression
following exposure to stimuli that elicit type 2 immune responses.
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Based on cDNA libraries, the original reports on IL-25 suggested restricted expression of
IL-25 to Th2 polarized CD4+ T cells [3, 158]. However, subsequent studies identified
that murine and human lung ECs express IL-25 following exposure to allergens or
helminth infections [112, 186] and macrophages, microglia, and CD8+ and CD4+ T cells
have all been reported to express IL-25 [81, 112, 166, 183].

Granulocytic cell populations have also been demonstrated to produce IL-25. Mast cell
lines, as well as bone marrow-derived mast cells, express IL-25 at levels comparable to
polarized Th2 cells. A limitation of these studies, however, was that they were only
performed in in vitro-derived cell populations and were not able to measure IL-25 protein
[187]. Moreover, these mast cell populations required chemical stimulation with PMA
and a Ca2+ ionophore or IgE cross-linking to express IL-25 [187]. Human eosinophils
and basophils, two cell populations known to play a role in allergic inflammation, have
also been shown to express IL-25 [179], but again focused only at the mRNA level.
Unlike TSLP or IL-33, T cells and antigen presenting cells (APC) have been reported to
express IL-25. Utilizing a lacZ reporter system, CD4+ and CD8+ T cells were found to
constitutively express IL-25 in the cecal patch, a lymphoid follicle similar to the human
appendix [81]. The major caveat of these studies, however, was that they employed a
reporter protein and relied on an enzymatic reaction to detect IL-25 protein levels.
Additionally, alveolar macrophages [183] and microglia cells, the main antigenpresenting cells within the central nervous system (CNS), express IL-25 [166]. While
various cell lineages are capable to producing TSLP, IL-25, and IL-33, their involvement
and significance in augmenting immune responses remains unclear. Thus, while the
contribution of these potential sources of TSLP, IL-25, and IL-33 warrants further
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investigation, it is ECs, based on their location at the mucosal barrier, that represent a
significant source of these potent cytokines.

1.5.3 Cellular targets and IL-25-IL-17RB signaling
IL-25 signals through IL-17RB, which is expressed in the lung and gastrointestinal tract
and exists as both a membrane bound and soluble form [159, 188]. Initially it was
thought that receptor ligation resulted in homodimerization and activation of signaling
cascades, but the observation of shared receptor usage among IL-17 family members
and the formation of heterodimeric receptor complexes suggests more complex
interactions [164, 189, 190] (Fig. 2C). In fact, subsequent studies identified that IL-25
signals through a heterodimeric receptor composed of IL-17RB and IL-17RA [191]. T
cells, APC, epithelial cells and airway smooth muscle cells (ASMC) also express IL17RB [3, 158, 159, 187, 192]. IL-25-IL-17RB interactions have been shown to activate
NF-κB, STAT6, GATA-3, NFATc1, and JunB, as well as the MAPK and JNK pathways
[112, 159, 179, 193]. Additionally, IL-17RB associates with TNF receptor-associated
factor (TRAF) -6 (Fig. 2C). These findings are consistent with our own unpublished data
as exposure of macrophages to IL-25 led to modest IκBα degradation and the
phosphorylation of ERK1/2 (our own unpublished data).

The mechanism whereby IL-25 elicits a Th2-mediated immune response remains
unclear.

Previous findings indicating that the IL-25-mediated induction of type 2

inflammation is independent of T cells [3, 177, 178], however, CD4+ T cells express IL17RB and this expression is reportedly increased on polarized Th2 cells or T cells
stimulated with TSLP-treated DC [112, 179], and substantially upregulated (over 1000fold) on Th2 memory cells [194]. Moreover, IL-25 treatment resulted in the production of
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IL-4, IL-5, and IL-13 and was dependent on IL-4 and STAT6 [112], suggesting that either
IL-17RB ligation results in STAT-6 phosphorylation or that IL-25-mediated effects are the
result of increased IL-4 production.

However, it is important to note fundamental

differences in the respective conclusions drawn by these authors. Angkasekwinai et al.
[112] conclude that IL-25 acts during in the initiation of Th2 cell polarization, whereas
Wang et al. [179] postulate that IL-25 acts to sustain Th2 cell differentiation, leading to
the development to Th2 memory cells. These conclusions are by no means mutually
exclusive and need further examination to dissect the role of IL-25 in T cell differentiation
and Th2 memory cell formation.

Lung ECs have been shown to be responsive to IL-25 [112] and studies by Cheung et al.
suggests direct effects of IL-25 on human eosinophils [182], which have been shown to
express the receptor for IL-25 [195]. Purified eosinophils treated with IL-25 displayed
increased survival and selectively increased expression of ICAM-1, but down-regulated
ICAM-3 and L-selectin. Another report has demonstrated that airway smooth muscle
cells (ASMC) express the receptor for IL-25 [196] and although IL-25 did not have a
dramatic effect on the production of extracellular matrix proteins by ASMC, this finding is
consistent with previous data in which neutralization of IL-25 during airway challenge
specifically decreased airway resistance [181]. Taken together, these data indicate that
IL-25 signaling in ASMC results in increased bronchio-constriction.

1.5.4 Undefined targets of IL-25
Additional IL-25-responsive populations have also been reported.

In the original

description of IL-25, a non-B/non-T cell (NBNT) population produced IL-13 in response
to systemic IL-25 administration [3]. Moreover, this NBNT cell population was capable of

29

mediating the physiologic changes in the lung and intestine independent of lymphocytes.
Further characterization of this cell population excluded it as basophils, mast cells, or
neutrophils [3, 158]. However, a subsequent report identified the IL-25-responsive cell
population as a putative mast cell precursor (being c-kit+ and FcεR1-), which was
induced independently of IL-4, IL-5, IL-9, and IL-13 [16]. In addition to this mast cell
progenitor population, in a subsequent study which employed a model of chronic airway
hyper-responsiveness, IL-25 was found to elicit a c-kitneg CD11b+ Ly6C+ monocyte-like
cell population [176]. This CD11b+ Ly6C+ cell population was found to be a source of IL4 in the lungs following chronic allergen exposure [176]. In another model of airway
hypersensitivity reaction (AHR), IL-25 was shown to promote IL-4 production in CD4+
NKT cells. This subset of NKT cells preferentially expressed IL-17RB and was critical to
the development of AHR, as adoptive transfer of this cell population into NKT celldeficient mice successfully reconstituted AHR [171].

In addition, three independent

laboratories identified c-kit+ innate cell populations (discussed in Chapter 1.7), termed
natural helper cells, nuocytes and innate type 2 helper cells [13-15], that respond to IL25 and promote type 2 inflammation.

Collectively, these data illustrate that IL-25 can target multiple cell lineages to initiate
and/or influence immune responses (Table 1), however, the identity of the predominant
cellular target of TSLP, IL-33 and IL-25 remains unclear. In addition, the contribution of
these various cellular targets to the development of immune responses initiated by IL-25
are poorly defined and warrant further investigation. The cellular mechanisms through
which IL-25 promotes CD4+ Th2 cytokine responses and type 2 inflammation is the
focus of this thesis and will be tested in Chapters 2 and 3. Moreover, while EC-derived
TSLP, IL-25, and IL-33 have unique responsive cell populations, they also share
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common cellular targets indicating that they could potentially act through common
cellular mechanisms to promote and/or amplify the magnitude of a developing Th2
cytokine-associated inflammation at mucosal sites.

1.6 EC-derived cytokines: Cross-regulation and interplay
EC-derived TSLP, IL-25, and IL-33 each license Th2 cytokine responses yet appear to
do so through distinct mechanisms. However, the coordinated expression of this triad of
EC-derived cytokines, coupled with cross-regulation of expression of ligands and
receptors, suggests that a complex interplay exists between TSLP, IL-33 and IL-25.
Moreover, recent data suggests that TSLP, IL-33 and IL-25 may not function
independently of one another. For instance, both IL-25 [112] and IL-33 [80] can induce
TSLP mRNA in ECs (Fig. 3) suggesting that IL-25 and IL-33 signal upstream of TSLP.
IL-33 treatment induced increased levels of TSLPR in the colons of Trichuris-infected
mice [80], and IL-33 can also sensitize mast cells to TSLP stimulation [108], suggesting
regulation of TSLP-TSLPR signaling by IL-33. Additionally, TSLP, IL-25, and IL-33 are
each able to upregulate IL-17RB [150, 177, 179] indicating that sensitization to IL-25
expression is an important and common effect of each EC- derived cytokine.

Beyond the ability of TSLP, IL-25 and IL-33 to regulate expression and to augment
cellular responsiveness to each other, this triad also targets similar innate and adaptive
cell populations (Table 1 and Fig. 3). TSLP and IL-25 both signal and influence antigen
presenting cells such as macrophages and DCs [1, 96, 192, 197] to promote permissive
conditions for Th2 cell differentiation. TSLP and IL-25 are also both able to directly
influence naïve CD4+ T cell populations. TSLP can induce GATA-3 and IL-4 in naïve
CD4+ T cells [102] while IL-25 induces the production of IL-4, IL-5 and IL-13 [112].
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Differentiated Th2 cells are also sensitive to IL-33, which increases their secretion of IL-5
and IL-13 [2].

TSLP, IL-25, and IL-33 also directly influence the biology of innate cell populations
including mast cells, eosinophils, and basophils.

TSLP, in conjunction with IL-33

induces mast cell production of IL-4, IL-5, IL-13, and production of TH2 cell attracting
chemokines [108], while both IL-25 and IL-33 have been reported to modulate eosinophil
biology they induce different downstream events. IL-25 acts to increase the survival of
eosinophils as well as the production of chemokines [195, 198] and IL-33 induces
degranulation and superoxide production [155].

While evidence exists to support a degree of cross-regulation between these EC-derived
cytokines, the complexities of the relationship(s) between these cytokines has not yet
been clearly defined.

Future analysis of the cross-regulation that operates between

these EC-derived cytokines is necessary to determine biological significance of these
interactions, however the ability of TSLP and IL-33 to influence the biology of IL-25elicited innate cell populations will be tested in Chapter 4. The emerging understanding
of these inter-relationships suggests that combined targeting or overexpression of TSLP,
IL-33 and IL-25 may offer a novel and highly effective therapeutic approach to modulate
the onset, progression or severity of Th2 cytokine-mediated inflammation associated
with asthma, allergic disorders, and helminth infections at mucosal sites.

1.7 Extramedullary hematopoiesis
Hematopoietic stem cells (HSCs) are a rare long-lived cell population with the capacity
for multi-lineage differentiation and self-renewal.
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HSCs give rise to a series of

progenitors that gradually lose their lineage differentiation and self-renewal potential.
HSCs and other progenitors are responsible for replenishing cells of both the innate and
adaptive immune system [199]. For example, HSC populations can be fractionated into
both long-term and short-term populations.

Both populations possess multi-potent

lineage potential but are designated so based on their ability to sustain reconstitution in
multiple sequential hosts.

Further, multi-potent progenitors (MPPs) still maintain the

ability to generate all known hematopoietic lineages, but have lost their capacity for selfrenewal. MPPs subsequently give rise to myeloid progenitors (MPs) and early lymphoid
progenitors (ELPs). MPs give rise to either megakaryocyte and erythrocyte progenitors
(MEPs) or granulocyte and macrophage progenitors (GMPs) [200], while ELPs yield T, B
and NK cells give rise to pro-lymphocytes or common lymphoid progenitors (CLPs) that
can then become pre-B cells [201, 202]. Progression from HSCs and commitment to a
specific lineage differentiation pathway is regulated by various growth and differentiation
factors.

HSCs and other progenitors are primarily bone marrow-resident, however, HSCs are not
entirely restricted to the bone marrow. HSC populations have been found to constantly
recirculate between the bone marrow and blood [203, 204] and blood collected from
adult mice contains a small, but stable population of functional HSCs [205, 206].
Moreover, HSCs have been recovered from extramedullary sites, such as the muscle,
liver and spleen [204, 207, 208] and mobilization of HSCs into the periphery thus
allowing for collection and transplantation through the administration of exogenous
growth factors has long been employed as a treatment strategy against leukemia or
following chemotherapy [209-214].

Thus, HSCs represent a highly migratory cell

population, however, why HSCs traffic through the blood and peripheral tissues and the
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biological significance of these circulating cells play remains less well understood.
Studies have suggested that circulating HSCs may be acting in a role of
immunosurveillance. Nagai et al. demonstrated that HSC populations expressed Tolllike receptors (TLRs) and were able to respond to and differentiation in response to
stimulation with TLR-ligands [215]. Further, HSCs recovered from the thoracic duct,
which originated in the bone marrow, were found to traffic to and differentiate in sites of
TLR-ligand challenge in secondary hosts [216]. Not only are HSC populations capable
of differentiating in response to pathogen-derived signals, but progenitor populations
themselves have been observed to possess effector functions. For instance, CD34+
progenitor cells derived from asthmatic patients have been shown to produce IL-5 and
IL-13 and have been reported to Th2-associated cytokines following stimulation with
TSLP and IL-33 [217].

Data in Chapter 3 demonstrates that IL-25 elicits a multi-potent progenitor type 2
(MPPtype2) cell population and along with the recent identification of other previously
unrecognized innate cell populations, natural helper cells (NHCs), nuocytes, and innate
type 2 helper (Ih2) cells (discussed in Chapter 4) has provided new insights into our
understanding of the cellular mechanisms that lead to the development of CD4 + Th2 celldependent immunity and/or inflammation at mucosal sites [13-15, 17]. Briefly, NHCs
were found in fat-associated lymphoid clusters (FALC) in the mesentery and in fatty
deposits in the peritoneal cavity and surrounding the kidneys [13]. Nuocytes and Ih2
cells were found to be an IL-13-producing cell population that could promote the
development of protective Th2 cytokine responses following infection with N. brasiliensis
[14, 15].
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MPPtype2 cells, nuocytes, Ih2 cells and NHCs all express c-kit, but lack expression of
known hematopoietic cell lineage markers [13-15, 17]. These populations all respond to
IL-25 and/or IL-33 and could promote CD4+ Th2 cell-dependent immunity and/or
inflammation [13-15, 17]. Based on these recent findings, a fundamental question to be
addressed is whether NHCs, MPPtype2 cells, nuocytes or Ih2 cells are the same cell
population, related cell lineages, or represent four distinct and unrelated cell lineages.
The relationships between MPPtype2 cells, NHCs, nuocytes and Ih2 cells will be
discussed in Chapters 4 and 5. Further, how the epithelial-cell derived cytokines TSLP
and IL-33 regulate the functions of these distinct cell populations have not been
examined. In Chapter 4, IL-25-elicited MPPtype2 cells were found to possess lymphoid
potential, in addition to the myeloid potential of IL-25-elicited MPPtype2 cells described in
Chapter 3. Together, reports of circulating ‘sentinel’ HSCs and Th2-cytokine associated
multi-potent progenitors and other ILC subsets in mice and humans suggests a
mechanism of extramedullary hematopoiesis in the elicitation and propagation of
immune response whereby HSCs, and potentially other precursor cells, are able to
recognize and respond to pathogen-derived signals and directly contribute to protective
or pathologic immune responses.

Therefore, extramedullary hematopoiesis may

represent an ancient evolutionarily conserved pathway to initiate a very localized and
rapid immune response, which arose prior to the compartmentalization of hematopoiesis
to the bone marrow niche.

1.8 Outline of Thesis
This thesis will explore the cellular mechanisms through which IL-25 promotes CD4+ Th2
cytokine responses, with an emphasis on previously unrecognized innate cell
populations that influence the development of CD4+ Th2 cell differentiation. Chapter 2
will address whether IL-25 promotes Th2 cytokine responses through mast cell-
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dependent mechanisms.

The IL-25-mediated initiation of Th2 cytokine responses

through the induction of a multi-potent progenitor cell population will be investigated in
Chapter 3.

Lastly, Chapter 4 will examine the relationships between the recently

described cell populations, MPPtype2 cells, natural helper cells, nuocytes and innate
helper type 2 cells, and the effects of TSLP and/or IL-33 stimulation on these cell
populations.
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Figure 1. Epithelial cells as a source of TSLP, IL-33 and IL-25 in vivo.

Figure 1. TSLP expression is induced following helminth infection, tissue
damage, and exposure to Th2 and pro-inflammatory cytokines (A). To date
only Trichuris infection has been shown to upregulate expression of IL-33 in
intestinal ECs (B). Nippostrongylus-infection and exposure to common
allergens upregulates expression of IL-25 (C). EC, epithelial cell; IL,
interleukin; TSLP, thymic stromal lymphopoietin.
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Figure 2. Downstream signaling pathways activated following receptor
ligation by TSLP, IL-33 and IL-25.

Figure 2.
Binding of TSLP to its receptor complex results in the
phosphorylation of STAT-5 and STAT-3, although the involvement of a
specific JAK has not been elucidated (A). TRAF-6 and MyD88 are both
required for intact IL-33 signaling. Additionally, IL-33 can activate both the
MAPK and JNK pathways (B). IL-25-mediated activation of NF-κB is
dependent on TRAF-6, whereas activation of the MAPK pathway does not
require TRAF-6 (C). STAT, signal transducers and activators of transcription;
JAK, Janus kinase; MAPK, mitogen-acitvated protein kinase; TRAF, TNF
receptor associated factor.
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Figure 3. Cross-regulation between TSLP, IL-33 and IL-25.

Figure 3. Target cell populations are indicated including a summary of the
effects of each of these cytokines on that cell lineage.
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Table 1. Summary of cellular sources, stimuli that induce expression and
cellular targets of TSLP, IL-25, and IL-33.
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Chapter 2
IL-25 promotes Th2 cytokine responses through the induction of
a lineageneg innate c-kit+ cell population

2.1 Abstract
CD4+ T helper (Th) 2 cells secrete interleukin (IL)-4, IL-5 and IL-13 and are required for
immunity to gastrointestinal helminth infections.

However, Th2 cells also promote

chronic inflammation associated with asthma and allergic disorders.

The non-

hematopoietic cell-derived cytokines thymic stromal lymphopoietin (TSLP), IL-33 and IL25 have been implicated in inducing Th2 cell-dependent inflammation at mucosal sites
[1-4], but how these cytokines influence innate immune responses remains poorly
defined. In this Chapter, we show that IL-25, a member of the IL-17 cytokine family,
promotes Th2 cytokine responses that correlates with the accumulation of a non-B/nonT cell (NBNT) c-kit+ cell population in the gut-associated lymphoid tissue (GALT). The
NBNT c-kit+ cell population was distinct from known innate cell populations and lacked
markers associated with basophils, eosinophils and mast cells. Further, the induction of
this cell population required IL-17RB and IL-17RA, but did not require signaling through
SCF or IL-3, cytokines required for mast cell differentiation. In addition, adoptive transfer
of IL-25-elicited c-kit+ cells into normally susceptible Trichuris-infected Il17e-/- mice
conferred protective immunity to helminth infection, suggesting that IL-25 promotes Th2
cytokine responses at mucosal sites through the induction of this novel c-kit+ cell
population.

2.2 Introduction
There has been intense interest in the mechanisms that promote and/or regulate
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adaptive immune responses at mucosal sites. However, in the steady-state these
immune cell populations remain hyporesponsive to a vast array of innocuous
environmental stimuli to which they are simultaneously exposed.

Based on their

localization to mucosal surfaces, epithelial cells (ECs) represent the first line of defense
between host tissues and external environment. As such, ECs play a pivotal role in the
detection of invading pathogens and are a critical cell population in the initiation,
regulation, and resolution of innate and adaptive immune responses at mucosal sites.
Not only do ECs express a wide range of immune response genes including MHC class I
and class II, co-stimulatory molecules, and chemokines, but they also secrete numerous
cytokines, including TSLP, IL-33 and IL-25, that promote the development of Th2
cytokine responses. Although diverse in amino acid sequence, structure, and patterns
of expression, rapidly emerging studies implicate TSLP, IL-33 and IL-25 as critical
regulators of Th2 cytokine-mediated inflammation through the induction of distinct innate
cell populations.

Consistently, dysregulated production of these three EC-derived

cytokines has been reported in multiple inflammatory disease states including
inflammatory bowel disease, asthma and atopic dermatitis.

As discussed in Chapter 1.4, epithelial cell-derived TSLP, IL-33 and IL-25 have been
reported to promote the development and regulation of Th2 cytokine responses at
mucosal sites through the induction of IL-4-producing innate immune cells [106, 171175]. Data from our laboratory demonstrated that TSLP treatment selectively elicits IL-4producing basophils in the blood. Moreover, TSLP-elicited basophils expressed MHC
class II and were capable of promoting Th2 cytokine responses, either through direct
interactions with CD4+ T cells or in cooperation with dendritic cells.

IL-33 elicits

eosinophils in the blood [11], but can also activate basophils [136] and natural helper
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cells (NHCs) [13]. In contrast, there are conflicting reports of IL-4-producing innate cell
populations elicited by IL-25. Initial reports of IL-25 described the induction of a NBNT
innate cell population that arose independently of the adaptive immune system.

In

subsequent studies employing a model of chronic airway hyper-responsiveness, IL-25producing eosinophils were found to elicit a c-kitneg CD11b+ Ly6C+ monocyte-like cell
population [176]. This CD11b+ Ly6C+ cell population was found to be a source of IL-4 in
the lungs following chronic allergen exposure [176].

In another model of airway

hypersensitivity reaction (AHR), IL-25 was shown to promote IL-4 production in CD4+
NKT cells. This subset of NKT cells preferentially expressed IL-17RB and was critical to
the development of AHR, as adoptive transfer of this cell population into NKT celldeficient mice successfully reconstituted AHR.

Other studies identified that IL-25

promotes the population expansion of a NBNT c-kit+ cell population [11, 16, 171]. Based
on c-kit expression, this IL-25-elicited NBNT cell population was suggested to be a mast
cell or mast cell precursor population [11, 16], however this cell population lacked
expression of FcεRIα, a common marker of mature mast cells. Thus, the innate cell
populations responsible for promoting Th2 cytokine responses in response to IL-25
remain unclear.

In this Chapter, we show that administration of IL-25 results in the accumulation of a
NBNT c-kit+ cell population in the gut-associated lymphoid tissue (GALT) and correlated
with the development of Th2 cytokine responses. The NBNT c-kit+ cell population was
distinct from known innate cell populations, as it lacked markers associated with
basophils, eosinophils and mast cells.

Further, the induction of this cell population

required IL-17RB and IL-17RA, but did not require the cytokines SCF or IL-3, which are
required for mast cell differentiation. In addition, adoptive transfer of IL-25-elicited c-kit+
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cells into normally susceptible Trichuris-infected Il17e-/- mice conferred protective
immunity to helminth infection, indicating that IL-25 promotes Th2 cytokine responses
through the induction of this previously unrecognized c-kit+ cell population.

2.3 Methods
2.3.1 Mice and administration of exogenous cytokine
Balb/c, C57BL/6 and Wsh mice were obtained from the Jackson Laboratory and IL4/eGFP reporter mice were obtained from M. Mohrs (Trudeau Institute). Il17e-/- mice
were provided by R.A. Kastelein (Schering-Plough Biopharma).

Il17ra-/- and Il17rb-/-

mice were provided by J.E. Tocker and A.L. Budelsky (Amgen). IL-3Rβc-/- mice were
provided by Taku Kambayashi (UPenn).

Animals were bred and housed in specific

pathogen-free conditions at the University of Pennsylvania.

All experiments were

performed under Institutional Animal Care and Use Committee (IACUC) approved
protocols and in accordance with the guidelines of the IACUC of the University of
Pennsylvania.

All mice used were 4-12 weeks of age.

Mice were treated

intraperitoneally with PBS or recombinant IL-25 (0.4 µg; R&D Systems) daily for 4 days.

2.3.2 Flow cytometry
Mesenteric lymph nodes (MLN) from IL-4/eGFP reporter mice were separated from the
mesentery, homogenized by passing through a 70 µm nylon mesh filter and stained with
anti-mouse fluorochrome-conjugated monoclonal antibodies against CD3ε, CD4, CD8,
TCRβ, TCRγδ, B220, CD19, CD11b, CD11c, MHC class II, Gr-1, NK1.1, FcεRIα, c-kit,
CD45.2, CD49b and CCR3 (eBioscience and BD Bioscience). Peritoneal exudate cells
(‘peritoneum’) were collected using peritoneal lavage with injection of 10 mL PBS and
aspirated using the same syringe. Mesentery was processed as previously described
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[13]. Cells were run on a BD FACSCanto II using DiVa software (BD Bioscience) and
analyzed with FlowJo software (Version 8.7.1; Tree Star, Inc.).

2.3.3 Mast cell differentiation assays
Femurs, tibias and spleens were harvested from WT C57Bl/6 mice. The heads of the
bones were removed and the bone marrow was flushed with media from the bones
using a syringe and needle. Marrow and spleens were homogenized by passing the
tissue through a 70 µm filter. An aliquot of the homogenized cells was stained with
fluorescent-labeled antibodies against CD4, CD8, CD19, CD11b, c-kit and FcεRIα
(eBioscience) to assess for ‘ex vivo’ (input) levels of mast cells.

1x106 cells were

cultured in the presence of SCF (50 ng mL-1; R&D systems), IL-3 (10 ng mL-1; R&D
systems) and/or IL-25 (100 ng mL-1; R&D systems). Following in vitro culture, resultant
progeny were assessed for expression of CD4, CD8, CD19, CD11b, c-kit and FcεRIα
(eBioscience) by flow cytometry as described above.

2.3.4 Ovalbumin (OVA) immunization, helminth infections and adoptive
transfer
3-5 x106 CFSE-labeled OVA-specific CD45.2 CD4+ T cells were transferred i.v. into
CD45.1 congenic recipient mice and 24 hours later immunized i.p. with 100 µg OVA
emulsified in IFA, with one cohort receiving 5x104 IL-25-elicited c-kit+ cells
intraperitoneally (i.p.).

IL-25-elicited c-kit+ cell populations were sorted using a

FACSAria (BD Bioscience). Proliferation of OVA-specific CD4+ T cells in the spleen was
assessed two days post-immunization and cytokine production was measured by ELISA.
Trichuris muris infections were performed as previously described [81]. Briefly, mice
were infected with 250 embryonated Trichuris eggs via oral gavage. Trichuris-infected

45

Il17e-/- mice were left untreated or given 5x104 IL-25-elicited c-kit+ cells i.v. at day 10
post-infection. Worm counts were performed at day 20 post-infection. MLN cells were
collected at necropsy, plated in medium alone or polyclonally stimulated with 1 µg ml-1
each of αCD3 and αCD28 (eBioscience). After 48 hours, cell-free supernatants were
assessed for cytokine production by sandwich ELISA (eBioscience). Trichuris-specific
IgG1 antibody titers were analyzed by ELISA as described previously [81]. Total serum
IgE was measured using the OptEIA IgE ELISA kit according to the manufacturer's
instructions (BD Biosciences).

For Nippostrongylus brasiliensis infections, WT mice

were infected s.c. with 500 infective third-stage larvae (L3) (provided by Joseph Urban,
USDA) and treated with 0.5 mg/day of anti-IL-25 or control IgG (from J.E. Tocker and
A.L. Budelsky; Amgen) on days 0, 2, 4, 6 and 8. MLN cells from infected mice were
assessed at day 10 post-infection for the induction of c-kit+ cells.

2.3.5 Histology and cytospin preparation
Colon sections were fixed in 4% (vol/vol) paraformaldehyde and embedded in paraffin
wax. 4 µm sections were stained with Periodic acid-Schiff/Alcian blue.

2.3.6 Real-time PCR
RNA from colonic tissues of mice was isolated by TRizol extraction (Invitrogen) or
collected from sorted cell populations using RNeasy Mini kit (Qiagen). Whole tissues
were homogenized with a tissue homogenizer (TissueLyzer; Qiagen) and cDNA was
prepared with SuperScript Reverse Transcriptase (Invitrogen).

Quantitative real-time

PCR analysis used commercial QuantiTect primer sets for Il4, Il5, and Il13 (Qiagen) and
SYBR Green chemistry (Applied Biosystems). All reactions were run on an ABI 7500
Fast Real-Time PCR System (Applied Biosystems). Target genes were normalized for
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endogenous β-actin levels and relative quantification of samples were compared to
controls.

2.3.7 Statistical analysis
Results are shown as means ± s.e.m for individual animals. Statistical significance was
determined by Student’s t-test. Results were considered significant at P < 0.05.

2.4 Results
2.4.1 IL-25 promotes type 2 inflammation in vivo through the induction of a ckit+ cell population in the GALT
To address which innate cell populations express IL-4 following administration of IL-25,
we employed IL-4/eGFP reporter mice [218] in which an enhanced green fluorescent
protein (eGFP) coding region has been inserted behind the fourth exon of the IL-4 gene.
This system allows for the tracking, identification and characterization of cells expressing
eGFP as a marker for the capacity to express IL-4. Following administration of IL-25 to
IL-4/eGFP mice, a 1.8-fold increase in the total cell numbers was observed in the MLN,
with equivalent increases in the total numbers of CD4+ and CD8+ T cells, CD19+ B cells
and NBNT CD11b+ macrophages (Fig. 4A). In contrast, IL-25-treatment resulted in a 56fold increase in a NBNT c-kit+ cell population (Fig. 4B), indicating that the NBNT c-kit+
cells exhibited the greatest relative population expansion following IL-25 administration,
and consistent with previous reports. The IL-25-mediated population expansion of the
NBNT c-kit+ cells was associated with the development of Th2 cytokine-dependent
inflammation characterized by increased expression of Il4, Il5 and Il13 mRNA in the
large intestine (Fig. 5A), elevated levels of serum IgE (Fig. 5B) and increased mucin
production in the large intestine (Fig. 5C), a finding consistent with previous reports [3].
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Administration of IL-25 to IL-4/eGFP reporter mice increased the frequency of c-kit+ cells
in all compartments of the GALT examined including the MLN (4% versus 28% of NBNT
cells) (Fig. 6A), the Peyer’s patches (11% versus 54%) (Fig. 6B) and cecal patch (10%
versus 36%) (Fig. 6C). However, IL-25 did not elicit this population in the spleen or bone
marrow (data not shown), suggesting that IL-25-responsive cells may be located in the
GALT.

Further, analysis of the IL-25-elicited c-kit+ cells in the GALT revealed two

distinct cell populations distinguished by expression of IL-4/eGFP (Fig. 6A-C, right
panels; GFPneg, blue gates; GFP+, green gates), indicating that the IL-25-elicited c-kit+
cells are a heterogeneous population.

2.4.2 Induction of the c-kit+ cell population is dependent on IL-25/IL-25R
signaling pathway
Previous studies have shown that infection with the gastrointestinal helminth parasite
Nippostrongylus brasiliensis results in increased Th2 cell responses that are associated
with the population expansion of macrophage, basophil and mast cell populations [173,
174, 219]. Further, increased expression of IL-25 and increased frequencies of a c-kit+
cell population have been reported following exposure to N. brasiliensis [16, 158].
Therefore to test whether N. brasiliensis infection results in increased frequencies of ckit+ cells and whether this induction is dependent on IL-25, mice were infected with 500
infective stage L3 larvae and treated with either isotype control antibody or anti-IL-25
monoclonal antibody and assessed for the induction of c-kit+ cells in the MLNs at d10
post-infection. Similar to administration of exogenous IL-25, increased frequencies and
absolute numbers of a NBNT c-kit+ cell population were observed in the MLN of WT
mice following infection with Nippostrongylus (Fig. 6D and E). Further, the total cell
number of Nippostrongylus-induced c-kit+ cells was reduced following administration of
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anti-IL-25 monoclonal antibody (WT infected + control IgG, 58981 ± 4975; WT infected +
anti-IL-25 mAb, 26109 ± 3039), indicating that IL-25 signaling was necessary for the
induction of the c-kit+ cell population following helminth infection.

Initial reports identified IL-17RB as the receptor for IL-25; however, more recent data
have suggested that IL-25 signals through the heterodimeric receptor composed of IL17RA and IL-17RB subunits [191]. In addition, both IL-17A and IL-17F signal though IL17RA, and IL-17A and IL-17F have been found to heterodimerize [164, 165]. Therefore,
to determine whether IL-17RB, IL-17RA and/or IL-17A are required for the IL-25mediated induction of the c-kit+ cells and type 2 inflammation, WT, Il17rb-/-, Il17ra-/-, and
Il17a-/- mice were treated with exogenous IL-25 and assessed for the induction of type 2
inflammation. Administration of IL-25 to Il17a-/- mice resulted in increased frequencies of
c-kit+ cells (data not shown), however, both Il17rb-/- and Il17ra-/- mice failed to exhibit IL25-elicited population expansion of the c-kit+ cells (Fig. 7A) or the development of IL-13
and mucin responses (Fig. 7B and C), indicating that both IL-17RB and IL-17RA, but not
IL-17A, are required for the IL-25-mediated induction of the c-kit+ cell population.

2.4.3 IL-25-induced c-kit+ cells do not represent NKT cell, basophil, eosinophil
or mast cell populations
We sought to determine whether IL-25-elicited c-kit+ cells expressed surface markers
associated with other known immune cell lineages. IL-25-elicited c-kit+ GFPneg or c-kit+
GFP+ cells lacked expression of CD4 (Fig. 8A), indicating that they were distinct from the
IL-4-producing CD4+ NKT cell populations described in AHR [171]. Moreover, neither
the c-kit+ GFPneg cells nor c-kit+ GFP+ cells expressed other surface markers expressed
on CD4+ lymphocytes (CD3ε, TCRβ, TCRγδ, CD69 and CD62L) (Fig. 8A). Further, the
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IL-25-elicited c-kit+ populations did not express CD19 (a marker for B lymphocytes) (Fig.
8B) or markers associated with basophil, eosinophil or mast cell lineages (CD49b, CCR3
and FcεRIα, respectively) (Fig. 8C). Taken together, these data indicate that IL-25elicited c-kit+ cells are not T- or B-lymphocytes, NKT cells, basophils or eosinophils.

Analysis of the IL-25-elicited cells revealed that in comparison to c-kit+ mast cells, this
cell population exhibited intermediate expression of c-kit (Fig. 9A).

This finding,

combined with the lack of surface expression of FcεRIα, indicates that the IL-25-elicited
c-kit+ cells are distinct from mature mast cell populations and that IL-25 may promote the
population expansion of this c-kit+ cells population independently of the factors that
regulate mast cell differentiation in vivo, stem cell factor (SCF) and IL-3. To test whether
the c-kit+ cell population could arise in response to IL-25 in the absence of the factors
that regulate mast cell biology in vivo, mast cell deficient mice, W-sash (Wsh) and IL3Rβc-/-, were utilized [220, 221]. Wsh mice carry a spontaneously generated loss-offunction mutation in the white spotting (W) locus leading to impaired c-kit expression and
decreased responsiveness to SCF.

This impaired expression ultimately results in a

deficiency in multiple cell lineages including both connective tissue and mucosal mast
cells [222]. IL-3Rβc-/- mice lack both the common β chain (βc), shared by IL-3, IL-5 and
granulocyte-macrophage colony-stimulating factor (GM-CSF) and a redundant β subunit
of the IL-3 receptor (βIL-3) found only in mice, but not humans. Thus, these mice are fully
deficient in IL-3 signaling, and as a result lack mucosal mast cell populations, but not
connective tissue mast cells.

WT mice, Wsh and IL-3Rβc-/- mice were treated daily with IL-25 for 4 days. Delivery of
IL-25 elicited increased frequencies of c-kit+ cells in Wsh and IL-3Rβc-/- mice (Fig. 9B)
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and induced equivalent expression of Il13 mRNA and mucin responses in WT, Wsh and
IL-3Rβc-/- mice (Fig. 9C and D) compared to untreated controls. Taken together, these
findings demonstrate that IL-3 and SCF signaling are not required for IL-25 to induce this
c-kit+ cell population and support the hypothesis that IL-25 acts independently of
classical mast cell populations to promote Th2 cytokine responses in vivo.

While SCF and IL-3 were not required for IL-25-mediated induction of the c-kit+ cells in
vivo, it did not rule out the possibility that IL-25 played a role in mast cell development.
Therefore, we sought to investigate the role of IL-25/IL-17RB interactions in mast cell
development. Bone marrow or spleen from WT mice were harvested, homogenized and
cultured in vitro in the presence of SCF and IL-3 in the presence of absence of IL-25.
Following 8 days in vitro, mast cell differentiation was assessed by flow cytometry. At
day 0, no mast cells (c-kit+ FcεRIα+) were observed in either the bone marrow or spleen
from WT mice (Fig. 10A and B, “ex vivo”). As expected, following 8 days in vitro, c-kit+
FcεRIα+ mast cell populations were observed from bone marrow and spleen cultured
with SCF and IL-3 (Fig. 10A and B). Interestingly, IL-25 alone did not result in the
differentiation of mast cells (data not shown), nor did the inclusion of IL-25 affect mast
cell differentiation in the presence of SCF and IL-3 (Fig. 10A and B), suggesting that IL25 is neither sufficient for nor plays a role in mast cell development.

Interestingly,

repeated exposure to IL-25 alone or in combination with SCF and IL-3 in vitro did not
preferentially increase the frequency of c-kit+ FcεRIα- cells in bone marrow or spleen
cultures (Fig. 10A and B), indicating that an additional factor(s) was necessary for IL-25
to drive the induction of the c-kit+ population in vivo. Collectively, these data support the
hypothesis that IL-25 acts independently of mast cells to elicit the c-kit+ cells and
associated type 2 inflammation.
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2.4.4 IL-25-elicited c-kit+ cells promote Th2 cytokine-dependent responses in
vivo.
To address the role IL-25-elicited c-kit+ cells might play in the development of Th2
cytokine responses in vivo, a well-established model was adopted in which OVA
immunization induces an antigen-specific Th2 cytokine response [223-226]. This model
provides a system whereby the effects of IL-25-elicited c-kit+ cells on the kinetics or
magnitude of Th2 cytokine responses can be tested. First, CFSE-labeled OVA-specific
TCR transgenic T cells were transferred alone or in combination with IL-25-elicited c-kit+
cells into naïve congenic recipients. Both cohorts were subsequently immunized i.p.
with OVA/IFA and T cell proliferation and cytokine responses were measured 48 hours
post-immunization. OVA-specific CD4+ T cells began to proliferate (Fig. 11A, left panel)
and accumulated at the site of immunization (Fig. 11B). However, in mice that also
received IL-25-elicited c-kit+ cells, OVA-specific CD4+ T cell proliferation was augmented
(Fig. 11A, right panel) and there was a significant increase in the accumulation of
antigen-specific cells at the site of immunization (Fig. 11B). Further, MLN cells isolated
from mice receiving both OVA-specific CD4+ T cell and IL-25-elicited c-kit+ cells secreted
elevated levels of IL-13 compared to those cells isolated from mice that received OVAspecific CD4+ T cells alone (Fig. 11C). These data indicate that IL-25-elicited c-kit+ cells
could promote antigen-specific Th2 cytokine responses in vivo and suggest that the
presence of these cells is able to influence the kinetics of a developing Th2 cytokine
response.

In a second approach, we utilized the Trichuris infection model to investigate whether IL25-elicited c-kit+ cells could promote protective immunity in the context of a helminth
infection. As discussed above (see section 1.2.3), Trichuris infection provides a model
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to study the development of CD4+ Th2 cytokine responses and IL-25 is required for the
development of a protective immunity following Trichuris infection as Trichuris-infected
Il17e-/- mice display significantly elevated levels of IFN-γ, reduced levels of IL-4 and IL13 and are unable to clear infection. Moreover, these mice develop a chronic infection
characterized by development of severe intestinal inflammation and elevated production
of IFN-γ and IL-17A in the intestinal mucosa and MLN. Therefore, to test whether IL-25elicited c-kit+ cells could promote Th2 cytokine responses in vivo, WT or Il17e-/- mice
were infected with Trichuris, with one Trichuris-infected Il17e-/- cohort receiving IL-25elicited c-kit+ cells, and immunity was assessed at d20 post-infection. As expected,
Trichuris-infected Il17e-/- mice produced low levels of Th2 cytokines (Fig. 11D), reduced
parasite-specific IgG1 (Fig. 11E), impaired mucin responses (Fig. 11F) and were
susceptible to infection (Fig. 11G). Adoptive transfer of IL-25-elicited c-kit+ cells from
WT mice into Trichuris-infected Il17e-/- mice resulted in elevated production of Trichurisspecific IL-4, IL-5 and IL-13 in the MLN (Fig. 11D), elevated serum parasite-specific
IgG1 (Fig. 11E), increased mucin responses (Fig. 11F) and host protective immunity
(Fig. 11G). Taken together, these data indicate that IL-25-elicited c-kit+ cells could
promote protective immunity to helminth infection in vivo.

2.5 Discussion
Multiple distinct cell lineages, including airway smooth muscle cells, ECs and T cells, are
reported to be responsive to IL-25 [112, 182], illustrating the potential for multi-faceted
effects of IL-25 in vivo.

However, in the original report of IL-25 it was noted that

administration of exogenous IL-25 resulted in the induction of an IL-13-producing cell
population that lacked expression of markers for B- and T- cells. Moreover, this cell
population was capable of mediating physiologic changes independent of T- and B-cells,
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the first indication that IL-25 acted through an innate cell population. However, further
characterization of this cell population determined that it did not represent a basophil,
mast cell or neutrophil [3, 158].

Subsequent studies identified various innate cell

populations that were induced by IL-25 and could promote Th2 cytokine responses
involved in allergic inflammation or immunity to helminth infection.

For instance, employing a model of chronic airway hyper-responsiveness, a c-kitneg
CD11b+ Ly6C+ monocyte-like cell population was found to be responsive to IL-25 and to
be the source of IL-4 in the lungs following exposure to allergens [176]. In another
model, AHR, CD4+ NKT cells were shown to preferentially express IL-17RB, produce IL4 in response to IL-25 and to be critical to the development of AHR. Yet another study
identified that IL-25 promotes the population expansion of an undefined NBNT c-kit+ cell
population [11, 16, 171], which was induced independently of IL-4, -5, -9, and -13 [16].
Based on c-kit expression, this IL-25-elicited NBNT cell population was proposed to be a
mast cell or mast cell precursor population [11, 16]; however this cell population lacked
expression of FcεRIα, a common marker of mature mast cells. Thus, the innate cell
populations responsible for promoting Th2 cytokine responses following IL-25
stimulation remain unclear.

Here we show that administration of IL-25 resulted in the induction of a c-kit+ cell
population, which did not express markers for T cells, B cells or markers associated with
basophil, eosinophil or mast cell lineages. These data were consistent with previous
reports indicating that IL-25 acted through an unidentified innate cell population. The
finding that IL-25 elicited a c-kit+ cell population was consistent with the cell population
identified by Fallon et al. [16].

Both cell populations expressed c-kit but lacked
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expression of FcεRIα and as a result, also lacked surface bound IgE. Moreover, based
on c-kit expression, the IL-25-elicited c-kit+ cells were distinct from the IL-25-responsive
CD11b+ Ly6C+ monocyte-like cell population identified in chronic allergen exposure
[176]. Further, this c-kit+ cell population lacked expression of CD4, indicating that these
cells were not the IL-4-producing CD4+ NKT cell populations described in AHR [171]. In
addition, the IL-25-elicited c-kit+ cell population was initially hypothesized to represent a
mast cell or mast cell precursor population.

However, we showed that IL-25 was

capable of inducing this cell population in W sh and IL-3R-deficient mice, indicating that
IL-25 elicits this cell population independently of SCF or IL-3, factors that regulate mast
cell differentiation. These data indicate that IL-25-elicited c-kit+ cells do not represent
classical mast cells.

One possible explanation for the differences observed between these multiple reports
could be in the timing at which IL-25-responsive innate cell populations are investigated.
Of note, the CD11b+ Ly6C+ monocyte-like cell population was identified using model of
chronic allergen exposure. In this model, the mice were sensitized and challenged with
allergens over the course of 4 weeks [176], compared to the 4 days of IL-25
administration used in our studies. Therefore, the timing at which the IL-25-responsive
innate cell populations are investigated may influence the innate cell populations
identified. Thus, these disparate results may indicate that at different timepoints, IL-25
may act on different cell populations. Alternatively, these data may indicate that the
initial IL-25-elicited cells undergo differentiation to become different cell lineages at later
timepoints.
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In addition, interestingly, the IL-25-elicited c-kit+ cell population displayed heterogeneity
in its expression of IL-4/eGFP, with approximately 50% being GFPneg and 50% being
GFP+, suggesting that the IL-25-elicited c-kit+ population might be composed of distinct
cell populations or may represent the same cell populations in differential activation
states. The functional significance of the heterogeneity in IL-4/eGFP expression will be
discussed in Chapter 3. Collectively, data presented in Chapter 2 indicate that the IL25-elicited c-kit+ cells are not T- or B-lymphocytes, NKT cells, basophils, eosinophils or
mast cells, and suggest that IL-25-elicited c-kit+ cells represent a previously
unrecognized innate cell population.
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Figure 4. IL-25 preferentially elicits a non-B/non-T c-kit+ cell population.

Figure 4. A, B, Mesenteric lymph node (MLN) cell numbers from control or
IL-25-treated IL-4/eGFP reporter mice. Numbers of total MLN cells or of T
cells (CD4+ or CD8+), B cells (CD19+) and macrophages (CD11b+ MHC
class II+) (A) and total numbers of non-B non-T (NBNT) c-kit+ cells (B). *, P
< 0.05. Error bars indicate s.e.m. Data in A-B are representative of more
than five independent experiments (control, n=16; IL-25-treated, n=34).
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Figure 5. IL-25 promotes type 2 inflammation in vivo.

Figure 5. A-C, IL-4/eGFP reporter mice were treated daily with recombinant
IL-25 for 4 days. Real-time PCR analysis of Il4, Il5 and Il13 mRNA expression
from proximal colon sections of control or IL-25-treated IL-4/eGFP reporter
mice (A). Total serum IgE levels measured by ELISA (B). Periodic acidSchiff/Alcian blue staining of proximal colon sections from control or IL-25treated IL-4/eGFP reporter mice (C). Scale bar, 50 μm. Error bars indicate
s.e.m.
Data in A-C are representative of at least two independent
experiments (control, n=4; IL-25-treated, n=7).
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Figure 6. IL-25 elicits c-kit+ cells in the GALT that display heterogeneous
expression of IL-4/eGFP.

Figure 6. A-C, Frequency of c-kit+ GFPneg or c-kit+ GFP+ cells in the NBNT cell
compartment from the MLNs (A), Peyer’s patches (PP) (B) and cecal patch
(CP) (C) was assessed by flow cytometry. D, E, Induction of the c-kit+ cell
population in WT Balb/c mice following infection with N. brasiliensis.
Frequency of the c-kit+ cell population (D) and total numbers (E) in the MLN of
control (Crtl) or infected (INF) mice. Plots shown are gated on live, CD4neg
CD8neg CD11bneg CD11cneg and B220neg cells or as indicated. *, P < 0.05.
Error bars indicate s.e.m. Data in A-C are representative of more than five
independent experiments (control, n=16; IL-25-treated, n=34). Data in D-E are
representative of at least two independent experiments (Crtl, n=2; INF, n=6).
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Figure 7. IL-17RB and IL-17RA are required for IL-25-mediated induction of
the c-kit+ cell population and Th2 cytokine responses.

Figure 7. A-C, C57BL/6 (WT), Il17rb-/-, and Il17ra-/- mice were treated daily with
recombinant IL-25 for 4 days. MLN cells were analyzed for c-kit and FcεRI
expression (A). Plots shown are gated to exclude CD4, CD8, B220, CD11b
and CD11c positive cells. Real-time PCR analysis of Il13 mRNA expression
(B). Periodic acid-Schiff/Alcian blue staining of proximal colon sections from
control or IL-25-treated mice (C). Scale bar, 50 μm. Error bars indicate s.e.m.
Not detected, N.D. Data in A-C are representative of at least two independent
experiments (control, n=2; IL-25-treated, n=6).
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Figure 8. IL-25-induced c-kit+ cells do not represent NKT cell, basophil,
eosinophil or mast cell populations.
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Figure 8. A-C, Expression of surface markers on c-kit+ GFPneg (blue line) or
c-kit+ GFP+ (green line) cells from IL-25-treated mice analyzed by flow
cytometry. Shaded histograms indicate the positive control for each
respective surface marker (A, gated on CD4+ T cells expressing each
respective marker; B, gated on B cells; C, CD49b, gated on CD49+ FcεRI+
basophils; CCR3, gated on c-kitneg CCR3+ eosinophils; FcεRI, gated on c-kit+
FcεRI+ mast cells. IL-25-elicited c-kit+ cells in (A and B) were FACS-purified
prior to surface staining. Positive controls in (A and B) were derived from
whole splenocytes stained ex vivo. Cells in (C) were surface stained ex vivo.
Plots shown in (C) are gated on live CD4neg CD8neg B220neg CD11bneg and
CD11cneg cells. Data are representative of at least two independent
experiments.
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Figure 9. IL-25-induced c-kit+ cells do not represent a classical mast cell
population.

Figure 9. Expression of c-kit by mature mast cells (from peritoneum, red line),
NBNT c-kit+ cells (from MLN, green line) and B220+ cells (from MLN, shaded
line) from IL-25-treated IL-4/eGFP reporter mice (A). B-D, Recombinant IL-25
was administered daily to C57BL/6 (WT) or Wsh mice for 4 days. MLN cells
were analyzed for c-kit and FcεRI surface expression by flow cytometry (B).
Plots shown are gated to exclude CD4, CD8, B220, CD11b, and CD11c
positive cells or as indicated. Numbers are frequencies of c-kit+ FcεRIneg cells
of total NBNT population. Real time-PCR analysis of Il13 mRNA (C).
Periodic acid-Schiff/Alcian blue staining of proximal colon sections from
control or IL-25-treated mice (D). Scale bar, 100 µm. Error bars indicate
s.e.m. Data in (A) are representative of 10 independent experiments (control,
n=16; IL-25-treated, n=34). Data in B-D are representative of at least two
independent experiments (control, n=2; IL-25-treated, n=6-8).

63

Figure 10. IL-25/IL-17RB signaling does not influence the differentiation of
c-kit+ FcεRI+ mast cell populations.

Figure 10. Bone marrow cells from WT or Il17rb-/- mice were cultured in the
presence of SCF and IL-3 with or without the addition of recombinant IL-25
for 8 days were analyzed for c-kit and FcεRI surface expression by flow
cytometry. Plots shown are gated to exclude CD4, CD8, B220, CD11b and
CD11c positive cells.
Numbers indicate frequencies of total NBNT
population.
Data are representative of at least two independent
experiments.
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Figure 11. IL-25-elicited c-kit+ cells promote Th2 cytokine-dependent
responses in vivo.
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Figure 11. A-C, CFSE-labeled CD45.2 CD4+ OTII cells were adoptively
transferred i.v. into CD45.1 congenic recipients and mice were
subsequently immunized i.p. with OVA/IFA in the presence or absence of
transferred IL-25-elicited c-kit+ cells. Proliferation of donor CD45.2 CD4+
OTII cells isolated from the spleens of recipient mice receiving T cells
alone (red shaded histogram) or T cells and OVA/IFA immunization (black
histograms) was measured by flow cytometry (A). Frequency of CD4+
OTII cells per total CD4+ T cells isolated from the peritoneum (B). IL-13
production from αCD3/αCD28-stimulated MLN cells was measured by
ELISA (C).
Data in A-C are representative of two independent
experiments (n=7). *, P < 0.05, **, P < 0.01. D-G, Il17e-/- mice were
infected with Trichuris (INF) or were infected and received IL-25-elicited ckit+ cells (INF + c-kit+). Cytokine production by Trichuris antigen-stimulated
MLN cells (D), Trichuris-specific serum IgG1 antibody titers (E), Periodic
acid-Schiff/Alcian Blue staining of proximal colon sections of naïve or
infected mice plus or minus c-kit+ cells (F), and number of worms from
Trichuris-infected mice (G) were assessed at day 20 post-infection. Scare
bar, 50 µm.
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Chapter 3
IL-25-elicited c-kit+ cells represent a previously unrecognized
multi-potent progenitor cell population

3.1 Abstract
Previous data demonstrated that administration of IL-25 resulted in the population
expansion of NBNT c-kit+ cell population that was distinct from all known innate cell
populations, including basophils, eosinophils and mast cells. Further, IL-25-elicited c-kit+
cells were able to promote Th2 cytokine responses and confer protective immunity to
helminth infection.

However, the identity of this innate cell population and how it

promoted CD4+ Th2 cell responses remained unknown.

Hematopoietic stems cells

(HSCs) and multi-potent progenitors (MPPs) are characterized by their lack of
expression of known lineage markers and expression of c-kit and have been implicated
in immunosurveillance.

Peripheral HSCs express Toll-like receptors (TLRs) and are

capable of differentiating upon stimulation with microbial products. In this Chapter, the
characterization of the IL-25-elicited Linneg c-kit+ cells present in the periphery revealed
that they are MPP-like cell population. IL-25-elicited Linneg c-kit+ cells expressed Sca1
and CD34, but lacked expression of CD150, a phenotype consistent with BM-resident
MPPs. Further, IL-25-elicited c-kit+ GFPneg cells isolated from IL-4/eGFP reporter mice
exhibited multi-potent capacity, giving rise to cells of monocyte/macrophage and
granulocyte lineages both in vitro and in vivo. In addition, progeny derived from IL-25elicited c-kit+ GFPneg cells were competent antigen presenting cells and could promote
CD4+ Th2 cell differentiation. Therefore, IL-25-elicited c-kit+ GFPneg cells were termed
MPPtype2 cells.
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3.2 Introduction
While c-kit is commonly recognized as a marker for mature mast cells, many other cell
populations express c-kit, particularly during hematopoiesis.

Among these are

hematopoietic stem cells (HSCs). HSCs are a rare long-lived cell population found in
the bone marrow and are responsible for replenishing cells of both the innate and
adaptive immune system [199]. HSCs give rise to a series of progenitors that gradually
lose their lineage differentiation potential and self-renewal, which are separated into 3
classes, (i) long-term and (ii) short-term HSCs and (iii) multi-potent progenitors (MPP),
all of which are Lineageneg and Sca1+ c-kit+. This division is based on the capacity for
self-renewal and sustained ability for reconstitution of multiple hematopoietic lineages.
Both long-term and short-term HSC populations possess multi-potent lineage potential
but are designated so based on their ability to sustain reconstitution in multiple
sequential hosts, while MPPs have lost their capacity for self-renewal but still maintain
the ability to generate all known lineages.

Phenotypically, these populations are

classified based on expression of Sca1, c-kit, CD34 and CD150, where long-term HSC
are CD34neg CD150+, short-term HSC are CD34+ CD150+ and MPP are CD34+ CD150neg
[227].

Progression from HSCs and commitment to a specific lineage differentiation

pathway is regulated by various growth and differentiation factors. MPPs subsequently
give rise to myeloid progenitors (MPs) and early lymphoid progenitors (ELPs). MPs give
rise to either megakaryocyte and erythrocyte progenitors (MEPs) or granulocyte and
macrophage progenitors (GMPs) [200], while ELPs yield T, B and NK cells give rise to
pro-lymphocytes or common lymphoid progenitors (CLPs) that can then become pre-B
cells [201, 202].
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HSCs and other progenitors are primarily bone marrow-resident, however, HSCs are not
entirely restricted to the bone marrow and in fact represent a highly migratory cell
population. HSC populations constantly recirculate between the bone marrow and blood
[203, 204] and stable, albeit small populations of HSCs can be collected from the blood
or lymphatics of adult mice [205, 228]. Moreover, HSCs have been recovered from
extramedullary sites, such as the muscle [207], liver [208] and spleen [204], however
why HSCs traffic within the body and the biological significance of circulating HSCs
remains poorly understood. Several studies have suggested that circulating HSCs may
be acting in a role of immunosurveillance, as HSC populations have been reported to
express Toll-like receptors (TLRs) and were able to respond to and differentiate in
response to stimulation with TLR-ligands [215].

Further, HSCs recovered from the

thoracic duct, which originated in the bone marrow, were found to traffic to and
differentiate in sites of TLR-ligand challenge in secondary hosts [216]. Together, these
reports suggest that HSCs, and potentially other precursor cells, are able to recognize
and respond to pathogen-derived signals and thus initiate rapid local immune responses.
However, whether IL-25 influences the population expansion and/or differentiation of
peripheral HSC populations and whether these cells can influence CD4+ Th2 cell
responses has not been examined.

In this Chapter, we demonstrate that the IL-25-elicited c-kit+ cells display a surface
phenotype consistent with bone marrow-resident MPPs as they lack expression of
lineage markers, but expressed Sca1 and CD34.

Surprisingly, the frequencies and

surface marker expression of MPPs, short-term and long-term HSCs in the BM were
unchanged following administration of IL-25.

Moreover, analysis of proliferation as

measured by BrdU incorporation revealed that only c-kit+ cells in the periphery and not in
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the bone marrow were proliferating, suggesting that IL-25 promoted the expansion of an
MPP-like cell population in the periphery. IL-25-elicited c-kit+ GFP+ cells were found to
differentiation into mast cells, but interestingly, the c-kit+ GFPneg cells exhibited multipotent capacity, giving rise to cells of monocyte/macrophage and granulocyte lineages
both in vitro and in vivo. In addition, progeny derived from IL-25-elicited c-kit+ GFPneg
cells, but not c-kit+ GFP+ cells, were competent antigen presenting cells and could
promote CD4+ Th2 cell differentiation. Thus, the IL-25-elicited c-kit+ GFPneg cells were
termed MPPtype2 cells. These data indicate that IL-25 promotes Th2 cytokine responses
through the induction of a multi-potent progenitor cell population.

3.3 Methods
3.3.1 Mice, exogenous cytokines and BrdU labeling
Balb/c and C57BL/6 mice were obtained from Jackson Laboratory and IL-4/eGFP
reporter mice were obtained from M. Mohrs (Trudeau Institute).
congenic mice were obtained from NCI.

Ly5.2/Cr (CD45.1)

Animals were bred and housed in specific

pathogen-free conditions at the University of Pennsylvania.

All experiments were

performed under Institutional Animal Care and Use Committee (IACUC) approved
protocols and in accordance with the guidelines of the IACUC of the University of
Pennsylvania.

All mice used were 4-12 weeks of age.

Mice were treated

intraperitoneally with PBS or recombinant IL-25 (0.4 µg; R&D Systems) daily for 4 days.
For in vivo BrdU labeling, Mice were injected i.p. with 1 mg of BrdU (Sigma-Aldrich) on
day 1 and day 3 of IL-25-treatment. BrdU incorporation was analyzed using an APCBrdU kit as recommended by the manufacturer (BD Pharmingen).

3.3.2 Flow cytometry, cell sorting and cytospin preparations
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MLN from IL-4/eGFP reporter mice were separated from the mesentery, homogenized
by passing through a 70 µm nylon mesh filter and stained with anti-mouse fluorochromeconjugated monoclonal antibodies against CD3ε, CD4, CD8, TCRβ, TCRγδ, B220,
CD19, CD11b, CD11c, MHC class II, Gr-1, NK1.1, Ter119, FcεRIα, c-kit, Sca1, CD150,
CD34, CD45.2

(eBioscience

and

BD

Bioscience).

Peritoneal exudate

cells

(‘peritoneum’) were collected using peritoneal lavage with injection of 10 mL PBS and
aspirated using the same syringe.
described[13].

Mesentery was processed as previously

Cells were run on a BD FACSCanto II using DiVa software (BD

Bioscience) and analyzed with FlowJo software (Version 8.7.1; Tree Star, Inc.). IL-25elicited c-kit+ (GFP+ or GFPneg) cell populations were sorted using a FACSAria (BD
Bioscience) and for in vitro differentiation studies were incubated in the presence of SCF
(50 ng mL-1; R&D systems) and IL-3 (10 ng mL-1; R&D systems). Following in vitro
culture, progeny were assessed for expression of CD11b, MHC class II, CD115 (MCSFR), Ly6C, FcεRIα, and c-kit (eBioscience) by flow cytometry as described above.
Sort-purified IL-25-elicited c-kit+ (GFP+ or GFPneg) cell populations or their resultant
progeny were subjected to cytospin (Cytospin 3, Thermo Fisher Scientific) and stained
by Diff-quick for analysis of cellular morphology. For in vivo differentiation assays, 3x104
CD45.2 IL-25-elicited c-kit+ GFPneg cells were FACS-purified and transferred i.p. into
CD45.1 congenic recipient mice. Recipient mice were treated 4 times with 1 µg each of
SCF and IL-3 and differentiation of donor cells was assessed on day 6 post-transfer by
flow cytometry as described above.

3.3.3 HSC differentiation assays

FACS-purified cell populations were plated onto semi-confluent OP9 stromal cells
(ATCC # CRL-2749), as previously described [229]. Monolayers were irradiated (3000
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rad) prior to co-culture with FACS-purified populations.

Cells were incubated in the

presence of SCF (50 ng mL-1; R&D systems) and IL-3 (10 ng mL-1; R&D systems).

3.3.4 CD4+ T cell co-cultures
Naïve OVA-specific CD4+ T cells were isolated from DO11.10 mice as previously
described [11].

T cells were stained with fluorochrome-conjugated monoclonal

antibodies against CD4, CD62L, and CD44 (eBioscience), re-suspended in 2% FBS in
HBSS with 2 mM EDTA (Gibco) with DAPI (1 µg mL-1; Molecular Probes) and naïve T
cells sorted based on live cells (DAPIneg) CD4+ CD62Lhi CD44lo using a FACSAria (BD
Bioscience). T cells were labeled with CFSE (Molecular Probes) and co-cultured with in
vitro derived progeny from sorted IL-25-elicited c-kit+ (GFP+ or GFPneg) cell populations.
Culture were either untreated (media) or cultured in the presence of OVA peptide (1 µg
mL-1) with or without blocking antibodies against MHC class II (5 µg mL-1; M5/114;
eBioscience) or IL-4Rα (5 µg mL-1; mIL4R-M1; BD Bioscience) in complete medium
(DMEM Iscove’s with 10% (vol/vol) heat-inactivated FBS, 2 mM glutamine, 100 U mL-1 of
penicillin, 100 µg mL-1 of streptomycin, 25 mM HEPES and 50 µM β-mercaptoethanol).
Cell-free supernatants were assessed for cytokine production by standard sandwich
ELISA (eBioscience) following 4h stimulation with PMA (50 ng mL-1) and ionomycin (750
ng mL-1) (Sigma Aldrich).

3.3.5 Real-time PCR
RNA from colonic tissues of mice was isolated by TRizol extraction (Invitrogen) or
collected from sorted cell populations using RNeasy Mini kit (Qiagen). Whole tissues
were homogenized with a tissue homogenizer (TissueLyzer; Qiagen) and cDNA was
prepared with SuperScript Reverse Transcriptase (Invitrogen).
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Quantitative real-time

PCR analysis used commercial QuantiTect primer sets for Il4, Il5, Il13, Gata3, Maf,
Junb, Stat6 and Il1rl1 (Qiagen) and SYBR Green chemistry (Applied Biosystems). All
reactions were run on an ABI 7500 Fast Real-Time PCR System (Applied Biosystems).
Target genes were normalized for endogenous β-actin levels and relative quantification
of samples were compared to controls.

3.3.6 Statistical analysis
Results are shown as means ± s.e.m for individual animals. Statistical significance was
determined by Student’s t-test. Results were considered significant at P < 0.05.

3.4 Results
3.4.1 IL-25-elicited c-kit+ cells display a MPP-like surface phenotype, but IL-25
does not affect HSC populations in the bone marrow
C-kit, the receptor for stem cell factor (SCF), is commonly recognized as a marker for
mature mast cells, however, HSCs and MPP are also characterized by their expression
of c-kit. Therefore to determine whether IL-25-elicited c-kit+ cells represent HSCs, we
examined expression of progenitor cell-associated cell surface markers on IL-25-elicited
c-kit+ cells.

Consistent with an HSC-like phenotype [227, 230], IL-25-elicited c-kit+

GFPneg and c-kit+ GFP+ populations were found to lack expression of know lineages
markers including CD3ε, CD8α, CD8β, TCRαβ, TCRγδ, B220, CD19, CD11b, CD11c,
NK1.1, Gr-1, and Ter119, and were thus defined as Linneg/lo (Fig. 12). HSC populations
can be divided into three classes based on expression of Sca1, CD34 and CD150,
where long-term HSCs are CD150+ CD34neg, short-term HSCs are CD150+ CD34+ and
MPPs are CD150neg CD34+ [227]. Therefore, to more specifically characterize the IL-25elicited c-kit+ cells, these cells were assessed for expression of Sca1, CD150 and CD34.
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The majority of the IL-25-elicited c-kit+ GFPneg and c-kit+ GFP+ cells expressed Sca1,
were CD150neg, and exhibited heterogeneous expression of CD34 (Fig. 13A-C).
Therefore, the IL-25-elicited cell populations in the GALT exhibited a surface phenotype
most consistent with an MPP-like cell population.

To investigate whether IL-25 was acting to increase proliferation of progenitor
populations in the bone marrow or in the periphery, WT mice were treated daily with IL25 for 4 days and injected with bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU) on
days 1 and 3. BrdU is a synthetic nucleotide analog that is incorporated into newly
replicated DNA during the S phase of the cell cycle. Surprisingly, treatment with IL-25
did not increase the frequencies of c-kit+ cells in the bone marrow, nor did IL-25
treatment result in increased BrdU incorporation by the c-kit+ population (Fig. 14A). In
contrast, administration of IL-25 resulted in increased frequencies of c-kit+ cells at
peripheral sites, including the MLN (Fig. 14B) and increased frequencies of c-kit+ cells
that incorporated BrdU compared to c-kit+ cells from naïve mice (Fig. 14B). Thus, these
findings demonstrate that IL-25 results in increased proliferation of cells only in the
periphery.

One potential caveat, however, this that these data cannot rule out the possibility of
increased egress of proliferating (BrdU+) cells from the bone marrow.

Therefore, to

determine whether IL-25 influenced the frequencies of HSC populations in the bone
marrow or their surface phenotype we analyzed these populations in control and IL-25treated mice. We observed no change in the frequencies of total HSCs (defined by
Lineageneg Sca1+ c-kit+) following treatment with IL-25 (6.5% in controls compared to
7.8% in IL-25-treated) (Fig. 15A, left panels). Further, no changes were seen in any of
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the 3 HSC populations based on CD34 and CD150 expression (Fig. 15A, right panels),
indicating that IL-25 does not influence the frequencies of bone marrow-resident HSC
populations in vivo. However, as stated previously, the IL-25-elicited cells display an
intermediate expression of c-kit (see Fig. 9A). Therefore, we assessed the c-kitint cells in
the bone marrow of control and IL-25-treated animals (Fig. 15A and Fig. 15B) for surface
expression of CD34 and CD150. As previously observed, IL-25-treatment did not result
in increased frequencies of the c-kitint cells in the bone marrow (Fig. 15B) and only a
small proportion of the c-kitint cells in control mice expressed either CD34 or CD150 (Fig.
15B), indicating that c-kitint cells in the bone marrow do not represent any of the known
HSC populations. These data suggest that IL-25 does not alter HSC populations in the
bone marrow. This finding, combined the previous findings that administration of IL-25
results in the accumulation of a proliferative, MPP-like cell population in the GALT
suggests that IL-25 acts in the periphery to elicit the population expansion of a c-kit+
MPP-like cell population.

3.4.2 IL-25-elicited c-kit+ cells exhibit multi-potent capacity and differentiate
into myeloid and/or granulocyte populations
To assess the capacity of the IL-25-induced c-kit+ MPP-like cell population to exhibit
multi-potent potential, c-kit+ GFPneg or c-kit+ GFP+ cells from IL-25-treated IL-4/eGFP
reporter mice were sorted and cultured in vitro in the presence of SCF and IL-3 (Fig.
16A-F). Cytospin preparations were performed from FACS-purified populations revealed
that both c-kit+ GFPneg and c-kit+ GFP+ populations shared a similar cell morphology of a
small, agranular cell with a single, non-segmented nucleus (Fig. 16D and F, ‘input’)
which is consistent with previous reports [16]. As a positive control for the differentiation
of macrophages and mast cell, unfractionated bone marrow from naïve mice was used.
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Following exposure to SCF and IL-3, un-fractionated bone marrow cells differentiated
into a CD11b+ macrophage-like population (Fig. 16A, orange gate) and a CD11bneg
granulocyte population (Fig. 16A, black gate) that could be separated into c-kit+ FcεRI+
mast cells (Fig. 1A, blue gate) and c-kitneg FcεRI+ basophils (Fig. 16A, green gate) as
determined by surface marker expression and cell morphology (Fig. 16B). Sorted IL-25elicited c-kit+ GFP+ cells failed to give rise to CD11b+ progeny but did yield a CD11bneg ckit+ FcεRI+ population (Fig. 16C, blue gate). Consistent with flow cytometric analysis, the
progeny of c-kit+ GFP+ cells were morphologically similar to mast cells (Fig. 16D),
suggesting that this cell population is a precursor to mast cells. Interestingly, IL-25elicited c-kit+ GFPneg cells were distinguished from the c-kit+ GFP+ population by their
ability to give rise to multiple cell lineages including CD11b+ macrophages (Fig. 16E,
orange gate), CD11bneg c-kit+ FcεRI+ mast cells (Fig. 16E, blue gate) and CD11bneg ckitneg FcεRI+ basophils (Fig. 16E, green gate). The multi-potent potential of the IL-25elicited c-kit+ GFPneg cell population was confirmed by examination of the cell
morphology of the resultant progeny, which displayed characteristics of macrophages,
mast cells or basophils (Fig. 16F), including cell populations with non-segmented nuclei
and vacuolar cytoplasm (macrophages) as well as agranular cell populations with nonsegmented (mast cells) or segmented nuclei (basophils).

To further assess the myeloid lineage potential of the IL-25-induced c-kit+ GFPneg
population, we adopted both a liquid culture system and a co-culture system in which
FACS-purified cells were plated onto a monolayer of OP9 stromal cells in the presence
of cytokines and/or growth factors. While stromal cell contact is not always necessary
for differentiation, as is the case for mast cells [231], the OP9 stromal cell co-culture
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system provides the cell-cell interactions necessary for the myeloid and lymphoid
differentiation of HSCs to be examined [232-234]. This system has been used
extensively to investigate the development of HSCs into fully differentiated cell
populations [235-238]. Purified IL-25-elicited c-kit+ GFPneg and c-kit+ GFP+ populations
were cultured onto a semiconfluent monolayer of OP9 stromal cells in presence of SCF
and IL-3 and assessed for myeloid differentiation at day 8. As previously observed, IL25-elicited c-kit+ GFPneg cells seeded into liquid cultures containing SCF and IL-3
differentiated into CD11b+ cells (orange histograms) (Fig. 17A). Moreover, the majority
of these cells co-expressed additional markers for myeloid lineages including M-CSFR,
Ly6C and MHC II (Fig. 17A). Consistent with liquid cultures, IL-25-elicited c-kit+ GFPneg
cells seeded onto OP9 stromal cells generated CD11b+ progeny cells that were also MCSFR+, Ly6C+ and MHC II+ (Fig. 17B). Thus, these results support the hypothesis that
the IL-25-elicited c-kit+ GFPneg cells represent a cell population with myeloid
differentiation potential.

To determine whether the IL-25-elicited c-kit+ GFPneg cell population could exhibit multipotent potential in vivo, IL-25-elicited c-kit+ GFPneg cells were isolated from WT CD45.2
donor mice and adoptively transferred into naïve CD45.1 congenic recipients. Six days
following transfer, c-kit+ GFPneg donor cells were found to have differentiated into
CD11b+ cells as well as CD11bneg c-kit+ FcεRI+ cells (Fig. 18). These results support the
hypothesis that IL-25-elicited c-kit+ GFPneg cells represent a cell population that exhibits
multi-potent potential, capable of giving rise to cells of the monocyte/macrophage and
granulocyte lineages both in vitro and in vivo.
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3.4.3 Progeny from IL-25-elicited c-kit+ GFPneg cells promote Th2 cell
differentiation in a MHC class II-dependent manner
The ability of the IL-25-elicited c-kit+ GFPneg cells to differentiate into CD11b+ MHC II+
cells led to the hypothesis that these cells were capable of presenting antigen and
driving Th2 cell differentiation of naïve CD4+ T cells.

Therefore, to examine the

functional capacity of progeny derived from c-kit+ GFPneg- or c-kit+ GFP+ cells, the IL-25elicited c-kit+ cell populations were sorted (Fig. 19A, left panel) and cultured in vitro in
the presence of SCF and IL-3 for 8 days. The majority of the progeny derived from c-kit+
GFP+ cells were IL-4/eGFP+ but MHC class IIneg, while the c-kit+ GFPneg-derived progeny
contained both IL-4/eGFP+ and MHC class II+ cell populations (Fig. 19A, right panels),
indicating that progeny derived from c-kit+ GFPneg cells, collectively, may influence T cell
proliferation and/or differentiation. To test this, the c-kit+ GFPneg- or c-kit+ GFP+-derived
progeny were pulsed with OVA and co-cultured with CFSE-labeled OVA-specific TCR
transgenic CD4+ T cells. When co-cultured with the progeny from either c-kit+ GFP+ or ckit+ GFPneg cells in medium alone, T cells exhibited minimal proliferation (1% CFSEdim,
Fig. 19B and C, shaded histograms). In addition, when cultured with c-kit+ GFP+-derived
progeny cells in the presence of OVA peptide, no T cell proliferation was observed (Fig.
19B, black histogram) and no IL-4 or IL-13 protein was detected in culture supernatants
(data not shown), indicating that progeny derived from IL-25-elicited c-kit+ GFP+ cells
alone cannot promote Th2 cell differentiation.

In contrast, following co-culture with OVA peptide and progeny derived from c-kit+
GFPneg cells, 42% of CD4+ T cells were CFSEdim (Fig. 19C, black histogram) and the
observed increased T cell proliferation was associated with increased production of IL-4
and IL-13 (Fig. 19D), indicating that IL-25-elicited c-kit+ GFPneg cells could promote Th2
cell differentiation. Further, the ability of c-kit+ GFPneg-derived progeny to influence Th2
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cell differentiation was MHC class II-dependent (Fig. 19C and D), as inclusion of a
blocking antibody to MHC class II resulted in decreased proliferation and cytokine
production. Further, inclusion of anti-IL-4Rα mAb did not affect T cell proliferation in the
presence of OVA peptide (Fig. 19C), but resulted in decreased production of IL-4 and IL13 (Fig. 19D), indicating that both MHC class II and IL-4R signaling are required for the
c-kit+ GFPneg-derived progeny to promote Th2 cell differentiation. No IFN-γ was detected
in any culture conditions (data not shown), suggesting that IL-25-elicited c-kit+ cells
selectively promote Th2 cytokine responses. These results indicate that IL-25-elicited ckit+ cells contain a population of progenitors with multi-potent capacity whose progeny
act to promote CD4+ Th2 cell differentiation. Thus, this cell population has been termed
MPPtype2 cells.

3.5 Discussion
The inability to characterize the IL-25-elicited c-kit+ cells as any of the known innate cell
lineages raised fundamental questions in regards to the identity of this cell population.
C-kit

expression

is

commonly

associated

with

mature

mast

cells,

however,

hematopoietic stem cells (HSCs) in the bone marrow also express c-kit, as well as being
Linneg and Sca1+. HSCs are multi-potent cells and give rise to cells of both the innate
and adaptive immune system. HSCs have been shown to traffic within the body and it
has

been

suggested

that

circulating

HSCs

may

be

acting

in

a

role

of

immunosurveillance, as HSC populations have been reported to express Toll-like
receptors (TLRs) and were able to respond to and differentiate in response to stimulation
with TLR-ligands [215, 216]. Together, these reports suggest that HSCs, as well as
other precursor cells, are able to recognize and respond to pathogen-derived signals
and thus initiate rapid, local immune responses. However, whether IL-25-elicited c-kit+
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cells represent HSCs or other progenitors, both in surface phenotype or multi-potent
potential, and whether these cells can influence CD4+ Th2 cell responses has not been
examined.

Here we demonstrate that the IL-25 elicited a c-kit+ cell population in the periphery that
display a surface phenotype consistent with bone marrow-resident MPPs (being Linneg
Sca1+ CD34+). Surprisingly, the frequencies of bone marrow-resident MPP and HSC
populations were unchanged following administration of IL-25, suggesting that IL-25
promoted the expansion of an MPP-like cell population in the periphery. The IL-25elicited c-kit+ GFP+ cells were found to differentiate into mast cells, a finding consistent
with the hypothesis first proposed by Fallon et al. [16]. Additionally, the c-kit+ GFPneg
cells exhibited multi-potent capacity, giving rise to cells of monocyte/macrophage and
granulocyte lineages both in vitro and in vivo. In addition, progeny derived from IL-25elicited c-kit+ GFPneg cells, but not c-kit+ GFP+ cells, were competent antigen presenting
cells and could promote CD4+ Th2 cell differentiation. Thus, the IL-25-elicited c-kit+
GFPneg cells were termed MPPtype2 cells. Collectively, these data illustrate that IL-25elicited c-kitint cells are not terminally differentiated cells, but instead represent cell
populations that possess multi-potent progenitor properties and are capable of
promoting Th2 cytokine responses.

Interestingly, while IL-25-elicited c-kit+ GFPneg cells possess multi-potent potential, it
appears that these cells require a secondary stimulus in order to commence their
differentiation, as in the presence of media or IL-25 alone, these cells fail to undergo
differentiation. This finding suggests that IL-25 is acting to expand these populations in
vivo, and it is only in the context of an appropriate stimulus that this population can then
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differentiate. While the dependence on a secondary stimulation at first appears to be a
limitation of this cell, the implication of this suggests that the IL-25-elicited MPPtype2 cell
population may display plasticity in its differentiation potential.

For instance, in the

presence of SCF and IL-3, MPPtype2 cells were found to differentiate into monocytes and
granulocytes. However, it could be that in the presence of alternative cytokines that
differential progeny could arise. This implies that given the local cytokine milieu present,
IL-25-elicited MPPtype2 cells could ‘tailor’ their response appropriately to specify the
appropriate immune response.

Nevertheless, the finding that IL-25-elicited MPPtype2 cells possess multi-potent potential
(Fig. 20), coupled with reports that peripheral HSCs express TLRs and can respond to
microbial stimulation [215, 216], implicate extramedullary hematopoiesis as a previously
unrecognized mechanism to initiate the development of rapid and local type 2 immune
responses and/or to sustain effector cell populations at mucosal sites required for the
elimination of pathogens from host tissues.

Moreover, the identification of effector

functions in progenitor populations from helminth-infected individuals and asthmatic
patients [217, 239] further supports this hypothesis. Given the evolutionarily conserved
nature of the IL-17 cytokine family [163], the innate cell populations targeted by IL-25
may represent ancient evolutionary conserved pathways for the generation of effector
cell populations that preceded the development of the adaptive immune response or
compartmentalization of hematopoiesis to the bone marrow.

In support of this

hypothesis, another member of the IL-17 cytokine family, IL-17A, has been shown to
influence granulopoiesis [240], and emerging evidence supports the presence of other
‘primitive’ innate cell populations, including lymphoid tissue-inducer cells, NK22 cells and
innate lymphoid cell populations [241-244], which appear to be innate sources of Th1-
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and Th17-associated cytokines that may be involved in immunity to extracellular bacteria
and the promotion of intestinal inflammation.

Collectively, the data presented here

provide the first link between the IL-17 cytokine family, extramedullary hematopoiesis
and the development of type 2 inflammation.
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Figure 12. IL-25-elicited c-kit+ cells are Linneg.

Figure 12. Expression of combined lineage markers (CD3ε, CD8α, CD8β,
TCRβ, TCRγδ, B220, CD19, CD11b, CD11c, Gr-1, NK1.1 and Ter119) by ckitint GFPneg (blue line) and c-kitint GFP+ (green line) cells from mesenteric
lymph nodes of IL-25-treated IL-4/eGFP reporter mice. Plot shown is gated
on live cells. Data are representative of two independent experiments. (n=4-6
per group).
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Figure 13. IL-25-elicited c-kit+ cells display a surface phenotype consistent
with multi-potent progenitor cells.

Figure 13. A, B, Frequency of c-kit+ cell population from MLNs of control (A) or
IL-25-treated (B) IL-4/eGFP reporter mice. C, Expression of HSC markers by
c-kit+ GFPneg (blue histograms) or c-kit+ GFP+ (green histograms) cells from
IL-25-treated IL-4/eGFP reporter mice. Number (italics) indicates the mean
fluorescent intensity (MFI) of each respective marker. Plots shown are gated
on live, lineageneg cells (CD3ε, CD8α, CD8β, TCRβ, TCRγδ, B220, CD19,
CD11b, CD11c, Gr-1, NK1.1 and Ter119) or as indicated. Data in A-C are
representative of two independent experiments (control, n=4; IL-25-treated,
n=7).
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Figure 14. Administration of recombinant IL-25 results in increased BrdU+
c-kit+ cells in the MLNs but not in the bone marrow.
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Figure 14. A, B, C57BL/6 (WT) mice were treated daily with IL-25 for 4 days
and injected with the bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU) on
days 1 and 3. Bone marrow (A) or mesenteric LN (B) cells were analyzed
for BrdU incorporation in the NBNT cell compartment. Plots shown are
gated to exclude CD4, CD8, B220, CD11b, and CD11c positive cells or as
indicated. Data in A and B are representative of at least two independent
experiments.
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Figure 15. IL-25 does not affect the frequencies of bone marrow resident
hematopoietic stem cells.
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Figure 15. A, B, Expression of HSC markers by HSC or c-kitint cell populations
in the bone marrow of control (A) or IL-25-treated (B) IL-4/eGFP reporter mice
was analyzed by flow cytometry. Plots shown are gated on live lineageneg cells
(CD3ε, CD8α, CD8β, TCRβ, TCRγδ, B220, CD19, CD11b, CD11c, Gr-1, NK1.1
and Ter119) or as indicated. Data are representative of at least two
independent experiments. (control, n=4; IL-25-treated, n=6).
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Figure 16. IL-25-elicited c-kit+ cells exhibit multi-potent capacity and
differentiate into myeloid and/or granulocyte populations.
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Figure 16. A, C, E, Flow cytometric analysis of myeloid and granulocyte
differentiation of un-fractionated bone marrow from control mice (A) or FACSpurified live, lineageneg c-kit+ GFP+ (C) or c-kit+ GFPneg (D) cells from IL-25treated IL-4/eGFP reporter mice following in vitro culture in SCF (50 ng mL-1)
and IL-3 (10 ng mL-1). B, D, F, Cytospin preparation of progeny from cultures
seeded with un-fractionated bone marrow (B), IL-25-elicited c-kit+ GFP+ cells
(D) or IL-25-elicited c-kit+ GFPneg cells (F) following culture in vitro in the
presence of SCF and IL-3. Cells stained with Diff-quick. Scale bar, 20 µm.
Data in A-F are representative of at least three independent experiments.
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Figure 17. IL-25-elicited c-kit+ GFPneg cells possess monocyte/macrophage
potential.

Figure 17. A, B, c-kit+ GFPneg cell populations from the MLN of IL-25-treated
IL-4/eGFP mice were cultured in liquid culture (A) or co-cultured on OP9
stromal cells (B) in the presence of SCF (50 ng mL-1) and IL-3 (10 ng mL-1).
Cultures were assessed for surface expression of monocyte/macrophage
markers at day 8 by flow cytometry. Plots shown are gated on live cells or as
indicated. Numbers indicate the percentage of gated region of total population.
Data in A and B are representative of at least two independent experiments.
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Figure 18. IL-25-elicited c-kit+ GFPneg cells display multi-potent potential in
vivo.

Figure 18. CD45.1 congenic recipients were left untreated or given 2.5-3 x104
c-kit+ GFPneg cells i.p. from IL-25-treated CD45.2 mice. Recipient mice were
treated 4 times with 1 µg each of SCF and IL-3 and differentiation of donor cells
isolated from the peritoneal cavity was assessed on day 6 post-transfer. Plots
shown are gated on live cells or as indicated. Data are representative of at
least two independent experiments. (n=4).
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Figure 19. Progeny from IL-25-elicited c-kit+ GFPneg cells promote Th2 cell
differentiation in a MHC class II-dependent manner.
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Figure 19. A, FACS-purified IL-25-elicited c-kit+ cells were cultured for 8 days
in SCF and IL-3 and the resultant progeny from c-kit+ GFP+ (green line) or ckit+ GFPneg (blue line, shaded) cells were assessed for expression of IL4/eGFP and MHC class II. Plots are gated on total live population. Results in
(A) are representative of three independent experiments. B, C, CFSE-dilution
by OVA-specific CD4+ CD62Lhi CD44lo T cells following 4 day co-culture with
SCF and IL-3-derived progeny from FACS-purified IL-25-elicited c-kit+ GFP+
(B) or c-kit+ GFPneg (C) cells in the presence of OVA peptide with or without
addition of monoclonal antibodies against MHC class II or IL-4Rα. Cells were
analyzed by flow cytometry for surface expression of CD4 and CFSE dilution.
Plots are gated on CD4+ T cells. D, IL-4 and IL-13 protein in cell-free
supernatants from (C) was assayed by ELISA.
Results in B-D are
representative of at least two independent experiments.
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Figure 20. IL-25-elicited c-kit+ cells possess multi-potent potential and
promote Th2 cell differentiation.

Figure 20. Schematic of the mechanism whereby IL-25 promotes Th2 cytokine
responses in vivo. Mucosal epithelial cells have been shown to express TSLP,
IL-33, and IL-25. While TSLP and IL-33 have been shown to elicit basophils or
eosinophils, respectively, IL-25 elicits c-kit+ GFP+ and c-kit+ GFPneg cell
populations. While the c-kit+ GFP+ cells give rise to mast cells, the c-kit+
GFPneg cell population possesses multi-potent capacity, being able to
differentiate into monocyte/macrophages, mast cells and basophils that
collectively promote CD4+ Th2 cell differentiation.
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Chapter 4
MPPtype2 cells are functionally distinct from, but can differentiate
into natural helper cells

4.1 Abstract
The recent identification of previously unrecognized innate cell populations, termed
multi-potent progenitor type 2 (MPPtype2) cells, natural helper cells (NHCs), nuocytes,
and innate type 2 helper (Ih2) cells has provided new insights into our understanding of
the cellular mechanisms that lead to the development of CD4+ Th2 cell-dependent
immunity and/or inflammation at mucosal sites [13-15, 17]. All four cell populations are
activated by IL-25 and/or IL-33 and capable of promoting Th2 cytokine responses.
Based on these recent findings, a fundamental question to be addressed is whether
NHCs, MPPtype2 cells, nuocytes or Ih2 cells are the same cell population, related cell
lineages, or represent four distinct and unrelated cell lineages. In this chapter, we show
that IL-25-elicited MPPtype2 cells are phenotypically distinct from NHCs/nuocytes, based
on expression of T1/ST2, IL-7Rα, and CD90. In addition, administration of IL-25 or IL-33
to IL-4/eGFP reporter mice elicited distinct innate cell populations in the mesenteric
lymph nodes. While both IL-25 and IL-33 elicited increased frequencies of c-kit+ cells, a
finding consistent with published data [14-17], IL-33-treatment resulted in the induction
of a higher frequency of T1/ST2+ c-kit+ cells, a phenotype most consistent with a nuocyte
population. In contrast, the vast majority of IL-25-elicited c-kit+ cells lacked expression of
T1/ST2, a surface phenotype most consistent with MPPtype2 cells. In addition, IL-25elicited MPPtype2 cells and nuocytes both expressed the receptor for TSLP (TSLPR) and
upon stimulation with TSLP and IL-33, IL-25-elicited MPPtype2 cells differentiated into
nuocytes, while nuocytes did not display multi-potent potential. Together, these data
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indicate that MPPtype2 cells are distinct from and could represent a progenitor to NHC
populations.

4.2 Introduction
Along with the identification of MPPtype2 cells, three other independent laboratories
recently identified similar previously unrecognized innate cell populations that respond to
IL-25 and/or IL-33 and could promote CD4+ Th2 cell-dependent immunity and/or
inflammation [13-15, 17] (summarized in Table 2). These cell populations are termed
natural helper cells (NHCs), nuocytes, or innate type 2 helper (Ih2) cells. NHCs were
found in fat-associated lymphoid clusters (FALC) in the mesentery and in fatty deposits
in the peritoneal cavity and surrounding the kidneys.

Within the FALC, this cell

population was found in close proximity to T cells and B cells and was capable of
promoting the proliferation of B1 B cells and production of IgA [13]. In a second study
[14] it was demonstrated that treatment of IL-13/eGFP reporter mice with either
exogenous IL-33 or IL-25 increased the frequency of an IL-13/eGFP+ cell population in
the MLN and spleen. This cell population is termed ‘nuocytes’ after the 13th letter of the
Greek alphabet, nu, and could promote the development of protective Th2 cytokine
responses following infection with a related helminth parasite, Nippostrongylus
brasiliensis. Lastly, Ih2 cells were identified using the Rosa-floxed-stop-YFP system [15]
as an IL-13-producing innate cell population that was expanded in frequency in response
to IL-25, IL-33 or following N. brasiliensis infection.

Ih2 cells promoted increased

eosinophil numbers and immunity to helminth infection.

MPPtype2 cells, nuocytes, Ih2 cells and NHCs all express c-kit, but lack expression of
hematopoietic cell lineage markers including lineage-associated markers for T cells, B
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cells, macrophages, dendritic cells, NK cells, lymphoid tissue inducer (LTi) cells or
neutrophils. Further, these cells did not co-express FcεRIα, CD49b or CCR3 (markers
for mature mast cells, basophils and eosinophils, respectively) [13-15, 17], indicating
these novel cell populations were distinct from other known cell lineages. In addition, IL25- and/or IL-33-responsive MPPtype2 cells, NHCs, nuocytes, and Ih2 cells displayed the
common functionality of promoting the development of type 2 inflammation [13-15, 17].
For instance, adoptive transfer of IL-25-elicited MPPtype2 cells into normally susceptible
Trichuris muris-infected Il17e-/- mice conferred protective immunity as evidenced by
increased production of Th2 cytokines, which correlated with reduced numbers of
parasites. Similarly, nuocytes, Ih2 cells, and NHCs were found to produce high levels of
the Th2-associated cytokines IL-5 and IL-13 and adoptive transfer of either population
was associated with increased type 2 inflammation and/or development of immunity to
helminth infection.

Interestingly, however, further analysis of these cell populations revealed that while
nuocytes and NHCs expressed T1/ST2 (a subunit of the IL-33 receptor), IL-7Rα and
CD90, IL-25-elicited MPPtype2 cells lacked expression of these surface markers.

In

addition, only IL-25-elicited MPPtype2 cells were found to possess multi-potent potential
being able to generate progeny of myeloid and granulocyte lineages, suggesting that
MPPtype2 cells represent a distinct cell population.

The similarities and differences

between MPPtype2 cells, NHCs, nuocytes and Ih2 cells in surface phenotype and
functionality (see Table 2) provoke fundamental questions about the relationships
between these newly described innate cell populations. For instance, whether MPPtype2
cells, NHCs, nuocytes or Ih2 cells represent the same cell population, but represent
distinct stages of activation or represent four distinct unrelated cell lineages remains

98

poorly defined. Further, how distinct epithelial-derived cytokines, including TSLP, IL-33
and IL-25 regulate the relationships and functions of these distinct cell populations have
not been examined.

In this chapter, IL-25-elicited MPPtype2 cells are shown to be phenotypically and
functionally distinct from NHCs based on expression of T1/ST2, IL-7Rα, and CD90 and
their transcription factor expression profile. In addition, administration of IL-25 or IL-33
to IL-4/eGFP reporter mice elicited distinct innate cell populations in the mesenteric
lymph nodes. While both IL-25 and IL-33 elicited increased frequencies of c-kit+ cells, a
finding consistent with published data [14-17], IL-33-treated resulted in the induction of a
higher frequency of T1/ST2+ c-kit+ cells, a phenotype most consistent with a nuocyte
population. In contrast, the vast majority of IL-25-elicited c-kit+ cells lacked expression of
T1/ST2, a surface phenotype most consistent with MPPtype2 cells. In addition, IL-25elicited MPPtype2 cells and nuocytes both expressed the receptor for TSLP (TSLPR) and
upon stimulation with TSLP and IL-33, IL-25-elicited MPPtype2 cells differentiated into
nuocytes, while nuocytes did not display multi-potent potential. Combined these data
indicate the MPPtype2 cells are distinct from and represent direct progenitors to NHC
populations and that they may represent a progenitor for NHCs.

4.3 Methods
4.3.1 Mice, administration of exogenous cytokine, antibody blockade
Balb/c and C57BL/6 mice were obtained from Jackson Laboratory, C57BL/6 Ly5.2/Cr
(CD45.1) mice were obtained from NCI and IL-4/eGFP reporter mice were obtained from
M. Mohrs (Trudeau Institute).

Il33-/- mice were provided by D. E. Smith (Amgen).

Animals were bred and housed under specific pathogen-free conditions at the University
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of Pennsylvania. All experiments were performed under Institutional Animal Care and
Use Committee (IACUC) approved protocols and in accordance with the guidelines of
the IACUC of the University of Pennsylvania. All mice used were 4-12 weeks of age.
Mice were treated intraperitoneally with PBS, recombinant IL-25 or IL-33 (0.4 µg; R&D
Systems) daily for 4 days. For antibody-mediated blockade, mice were treated with 0.25
mg/day of anti-T1/ST2, anti-IL-25 or control IgG (from D. E. Smith and A. L. Budelsky,
Amgen) on days -3, -1, 0, 2 and 4.

4.3.2 Flow cytometry and cell sorting
MLN from IL-4/eGFP reporter mice were separated from the mesentery, homogenized
by passing through a 70 µm nylon mesh filter and stained with anti-mouse fluorochromeconjugated monoclonal antibodies against CD3ε, CD4, CD8, TCRβ, CD19, CD11b,
CD11c, NK1.1, FcεRIα, c-kit, Sca1, CD127 (IL-7Rα), TSLPR, CD90 and CD45.2
(eBioscience and BD Bioscience).
biotinylated

mAb

(MD

T1/ST2 staining was performed using T1/ST2

Biosciences)

and

eFluor450-conjugated

streptavidin

(eBioscience). Peritoneal exudate cells (‘peritoneum’) were collected using peritoneal
lavage with injection of 10 mL PBS and aspirated using the same syringe. Cells were
run on a BD LSR II using DiVa software (BD Bioscience) and analyzed with FlowJo
software (Version 8.7.1; Tree Star, Inc.). For cell sorting, MLNs and PECs from IL-25treated IL-4/eGFP reporter mice were isolated stained with DAPI (1 µg mL-1; Molecular
Probes) as described above and Live (DAPIneg) IL-25-elicited c-kitint (GFP+ or GFPneg)
cell populations were sorted using a FACSAria (BD Bioscience).

4.3.3 In vitro differentiation assays
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FACS-purified cell populations were seeded into 96-well flat bottom TC plates (BD
Falcon) and incubated in the presence of SCF (50 ng mL-1; R&D systems), IL-3 (10 ng
mL-1; R&D systems) TSLP (100 ng mL-1; R&D systems) and/or IL-33 (50 ng mL-1; R&D
systems) for eight days. Cytokines and culture media were replenished at days three
and six post-culture. Following in vitro culture, progeny were assessed for expression of
IL-4/eGFP, CD11b, FcεRIα, and c-kit, T1/ST2, CD127 (IL-7Rα) and CD90 by flow
cytometry as described above. Cell-free supernatants were assessed for IL-4, IL-5 and
IL-13 cytokine production by standard sandwich ELISA (eBioscience).

4.3.4 In vivo adoptive transfers
CD45.1 congenic recipient mice were treated via hydrodynamic tail vein injection with a
TSLP-encoding cDNA plasmid, as described previously. Seven days following cDNA
injection, 2 x104 FACS-purified IL-25-elicited MPPtype2 cells were transferred i.p. into
CD45.1 congenic recipient. Recipient mice were treated 4 times with 0.4 µg of
recombinant IL-33 and differentiation of CD45.2 donor cells was assessed on day 5
post-transfer.

4.3.5 Real-time PCR
RNA from colonic tissues of mice was isolated from sorted cell populations using
RNeasy Mini kit (Qiagen) and cDNA was prepared with SuperScript Reverse
Transcriptase (Invitrogen).

Quantitative real-time PCR analysis used commercial

QuantiTect primer sets for Il4, Il5, Il13, Gata3, Maf, Junb, Stat6 and Il1rl1 (Qiagen) and
SYBR Green chemistry (Applied Biosystems). All reactions were run on an ABI 7500
Fast Real-Time PCR System (Applied Biosystems). Target genes were normalized for
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endogenous β-actin levels and relative quantification of samples were compared to
controls.

4.4 Results
4.4.1 IL-25-elicited MPPtype2 cells are distinct from natural helper cell/nuocyte
populations.
Natural helper cells (NHCs) and nuocytes are a newly described innate cell population
that are defined by their expression of c-kit, T1/ST2, IL-7Rα, CD90 and CD44 [13, 14].
Both populations were responsive to IL-25 and IL-33, suggesting that these two
populations may be identical, but distinguished by their anatomical localization. While
NHCs were isolated from lymphoid clusters in the mesentery surrounding the MLNs and
intestines or the fatty omentum in the peritoneal cavity [13], nuocytes were found in the
MLN and spleen [14]. Analysis of the c-kit+ cells elicited by IL-25 revealed that the
majority of the IL-25-elicited MPPtype2 cells (c-kit+ GFPneg) were T1/ST2neg/lo and IL7Rαneg, and expressed little or no mRNA encoding Gata3, Junb, Maf, Stat6 and Il1rl1
(Fig. 21B), all of which are expressed by NHCs. Combined, these data suggest that IL25-elicited MPPtype2 cells are distinct from NHCs.

To test whether administration of IL-25 results in increased frequencies of c-kit+ cells or
NHCs in the peritoneum or mesentery, mice were treated with IL-25 and cells from these
compartments were analyzed for the presence of c-kit+ cells. Delivery of IL-25 resulted
in increased frequencies of c-kit+ cells in the peritoneum (4% versus 17%) (Fig. 22A) and
mesentery (6% versus 20%) (Fig. 22B). Although IL-25 treatment resulted in increased
cellularity in the mesentery, no changes were observed in the frequency of c-kit+ IL-7Rα+
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T1/ST2+ NHCs or in the expression of CD44 or CD90 on NHCs (Fig. 22C), indicating that
IL-25-elicited MPPtype2 cells are distinct from NHCs.

MPPtype2 cells were previously reported to possess multi-potent potential and could give
rise to multiple cell lineages, while NHCs and nuocytes were reported to be a terminally
differentiated cell population [13, 14].

To test this, IL-25-elicited MPPtype2 cells or

nuocytes were sort-purified (Fig. 23A,C), cultured in the presence of SCF and IL-3 and
assessed for differentiation into multiple lineages by flow cytometry. Following 8 days in
vitro, cultures seeded with MPPtype2 cells contained CD11b+ macrophages as well as
CD11bneg c-kit+ FcεRI+ mast cells, but did not yield T1/ST2+ IL-7R+ nuocytes (Fig. 23B).
However, analysis of the cultures seeded with NHC/nuocytes revealed that this cell
population could not differentiate into macrophages or mast cells, but retained
expression of T1/ST2 (Fig. 23D), indicating that NHCs/nuocytes are a terminally
differentiated cell population and are unable to give rise to other cell lineages.
Combined with the differences observed in surface phenotype, the finding that MPP type2
cells possess multi-potent potential further supports the hypothesis that MPPtype2 cells
are distinct from NHCs/nuocytes.

4.4.2 IL-25 and IL-33 differentially elicit distinct populations of nuocytes and
MPPtype2 cells in the MLNs
While previous reports have shown that both IL-25 and IL-33 can expand c-kit+ cell
populations capable of promoting Th2 cytokine responses, whether the composition of
the IL-25- versus IL-33-elicited c-kit+ cells is identical is not known. To directly test
whether IL-25 and IL-33 elicit distinct or similar c-kit+ cell populations in the MLNs, the
expression of T1/ST2, Sca1, IL-7Rα, CD90 and IL-4/eGFP was characterized on c-kit+
cells from the MLNs of IL-25- or IL-33-treated IL-4/eGFP reporter mice. As previously
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shown [14-17], compared to naïve mice, administration of IL-25 or IL-33 resulted in
increased frequencies of c-kit+ cells in the MLNs compared to untreated controls (Fig.
24A). Analysis of the IL-25- or IL-33-elicited c-kit+ cells revealed that 7% of the IL-25elicited c-kit+ cells were T1/ST2+, while administration of IL-33 resulted in increased
frequencies of T1/ST2+ c-kit+ cells (26% of c-kit+ cells compared to 7%) (Fig. 24A).
However, T1/ST2+ c-kit+ cells (black histograms) from either IL-25- or IL-33-treated mice
displayed a phenotype consistent with nuocytes as both populations expressed Sca1, IL7Rα, CD90 and IL-4/eGFP (Fig. 24B and data not shown). This finding is consistent with
published studies demonstrating redundancy in IL-25 and IL-33 to induce nuocyte cell
populations.

Critically, the majority (92%) of the IL-25-elicited c-kit+ cells in the MLN lacked
expression of T1/ST2, and analysis of this cell population (gray shaded histograms) for
expression of Sca1, IL-7Rα, CD90 and IL-4/eGFP revealed that the T1/ST2neg c-kit+ cells
expressed Sca1, but exhibited little to no expression of IL-7Rα, CD90 or IL-4/eGFP (Fig.
24B and data not shown), a phenotype consistent with MPP type2 cells. Collectively, these
data indicate that IL-33 more potently induces nuocytes, and the majority of IL-25elicited c-kit+ cells represent MPPtype2 cells, suggesting that while redundancy in induced
cell populations may exist, IL-25 and Il-33 elicit distinct populations of c-kit+ cells.

IL-25 and IL-33 were shown to act redundantly and independently to elicit nuocyte cell
populations [14]. To test the requirement for the IL-33-signaling pathway in the IL-25mediated induction of c-kit+ cells, IL-4/eGFP reporter mice were treated daily with either
an isotype control (IgG) or a neutralizing monoclonal antibody against T1/ST2 beginning
at day -2 and continuing throughout the course of IL-25-treatment.
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Consistent with

previous results, IL-25-treated mice displayed increased frequencies of c-kit+ cells (14%)
in the MLN compared to untreated control mice (2%) (Fig. 25A) and blockade of IL-33
signaling did not affect the IL-25-mediated induction of c-kit+ cells (Fig. 25A). In addition,
while the frequency of T1/ST2+ c-kit+ cells was reduced by treatment with the antiT1/ST2 antibody (from 17% to 8%), the expression of IL-7Rα, CD90 or IL-4/eGFP on the
T1/ST2neg c-kit+ (MPPtype2) cells (gray shaded histograms) and T1/ST2+ c-kit+ cells
(nuocytes) (black histograms) was not affected, compared to control treated mice (Fig.
25B). In addition, administration of IL-25 to WT C57Bl/6 or Il33-/- mice resulted in the
induction of c-kit+ cells at similar frequencies in the MLN (Fig. 26A).

Further, the

frequencies of MPPtype2 cells or nuocytes or their respective expression of IL-7Rα and
CD90 remained unchanged in the absence of IL-33 (Fig. 26B and C). Taken together,
these data indicate that IL-25 acts independently of the IL-33/T1/ST2 signaling pathway
to promote the induction of MPPtype2 cells.

Next, to address whether the IL-25 signaling pathway was necessary for the IL-33mediated induction of NHC/nuocytes, IL-4/eGFP reporter mice were treated daily with
either an isotype control (IgG) or a neutralizing monoclonal antibody against IL-25
beginning at day -2 and continuing throughout the course of IL-33-treatment regimen.
Again, consistent with previous results, IL-33-treated mice displayed increased
frequencies of c-kit+ cells (19%) in the MLN compared to naïve mice (5%) (Fig. 27A) and
the T1/ST2+ c-kit+ cells (black histograms) were IL-7Rα+, CD90+ and IL-4/eGFP+
consistent with a NHC/nuocyte surface phenotype (Fig. 27B).

Blockade of IL-25

signaling resulted in increased frequencies of c-kit+ cells (Fig. 27A) and elevated
frequencies of T1/ST2+ c-kit+ cells (Fig. 27A). However, neutralization of IL-25 did not
affect the expression levels of IL-7Rα, CD90 or IL-4/eGFP on the T1/ST2+ c-kit+ cells
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(black histograms) (Fig. 27B). Combined, these findings indicate IL-25 and IL-33 act
independently to elicit MPPtype2 cells or NHCs/nuocytes, respectively.

4.4.3 IL-25-elicited MPPtype2 cells have the capacity to differentiate into a
NHC/nuocyte-like cell population
Previous reports have identified potential interactions between TSLP, IL-25 and IL-33
(see Chapter 1.6). For example, IL-25 or IL-33 can induce TSLP expression in epithelial
cells and increase expression of a subunit of the TSLP receptor (TSLPR). Additionally,
TSLP, IL-25, and IL-33 are each able to upregulate IL-17RB (a subunit of the IL-25
receptor). These observations suggest the existence of complex interactions between
TSLP, IL-25 and IL-33 and indicate possible mechanisms whereby Th2 cytokine
responses initiated by TSLP, IL-25 or IL-33 can be amplified by the other EC-derived
cytokines. The finding that IL-25 and IL-33 act redundantly to elicit nuocytes and that
these cells express the receptors for both IL-25 and IL-33 further support the hypothesis
of cross-regulation between these signaling pathways. To address whether TSLP might
influence the IL-25-elicited c-kit+ cells, the expression of TSLPR on IL-25-elicited
MPPtype2 cells (T1/ST2neg c-kit+) and nuocytes (T1/ST2+ c-kit+) was characterized. IL-25elicited MPPtype2 cells (thin black histogram) and nuocytes (bold black histogram)
isolated from the MLNs expressed TSLPR (Fig. 28A and B). This finding indicates that
IL-25-elicited MPPtype2 cells and nuocytes express TSLPR and suggests that TSLP may
influence the proliferation, survival, cytokine production or differentiation of these cells.

TSLP is an IL-7-like cytokine that was initially described as a B and T lymphocyte growth
factor and was shown to promote B and T lymphopoiesis [102]. In addition, IL-33 has
been shown to influence the development and/or cytokine production of NHCs and
nuocytes [13, 14]. The ability of TSLP and IL-33 to promote lymphopoiesis and nuocyte
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development, respectively, combined with the TSLPR and T1/ST2 expression observed
on IL-25-elicited MPPtype2 cells and nuocytes suggested that TSLP and/or IL-33 might
influence the population expansion, proliferation or differentiation of MPPtype2 cells and
nuocytes. To test this, IL-4/eGFPneg T1/ST2neg MPPtype2 cells were sort-purified from IL25-treated IL-4/eGFP reporter mice (Fig. 29A) and cultured in the presence of IL-33
alone, TSLP alone, IL-33 plus TSLP, or in combination with SCF, IL-3, IL-33 and TSLP.
Following eight days in vitro, the resultant progeny were assessed for surface marker
expression by flow cytometry. When cultured in the presence of IL-33 alone, MPPtype2
cells yielded a small but identifiable CD11b+ macrophage-like cell population, but did not
give rise to a CD11bneg c-kit+ FcεRI+ mast cell population or a CD11bneg T1/ST2+ CD90+
nuocyte cell population (Fig. 29B). Culturing MPPtype2 cells in the presence of TSLP
alone resulted in increased cell recovery compared to stimulation with IL-33 alone and
the majority of these cells were CD11bneg T1/ST2+ with a proportion of them expressing
CD90, a phenotype consistent with nuocytes (Fig. 29B). These data demonstrate that
TSLP signaling renders MPPtype2 cells more responsive to IL-33 signaling and that
MPPtype2 cells may represent a progenitor of NHC/nuocytes.

To test the combined effect of TSLP and IL-33 on MPPtype2 cell differentiation, sortpurified MPPtype2 cells (c-kit+ T1/ST2neg GFPneg) were cultured in TSLP and IL-33 and
assessed for nuocyte differentiation. The inclusion of IL-33 with TSLP increased cell
survival/recovery compared to TSLP alone and resulted in the induction of a T1/ST2+ IL7Rα+ nuocyte-like cell population (Fig. 29B). Importantly, when cultured in the presence
of SCF, IL-3, IL-33 and TSLP, the multi-potent potential of MPPtype2 cells was restored as
progeny consistent with macrophage, mast cell, and nuocyte cell populations are
identified (Fig. 29B). These findings suggest that following IL-25-mediated induction of
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MPPtype2 cells, this cell population is capable of differentiating into a multiple of cell
lineages based on the subsequent stimuli encountered. In addition, when cultured in the
presence of SCF, IL-3, IL-33 and TSLP, sort-purified IL-25-elicited nuocytes (c-kit+ IL4/eGFP+ T1/ST2+) (Fig. 30A) retained expression of T1/ST2 but did not yield a CD11b+
macrophage-like cell population or a CD11bneg c-kit+ FcεRI+ mast cell population (Fig.
30B), indicating that this cell population is not multi-potent. Combined these findings
indicate that TSLP and IL-33 stimulation together results in MPPtype2 cell differentiation
into nuocyte cell populations.

To determine whether the MPPtype2 cells differentiate into nuocytes in vivo, MPPtype2 cells
were isolated from IL-25-treated CD45.2 donor mice and adoptively transferred into
TSLP-cDNA injected CD45.1 congenic recipients, which were treated daily i.p. with IL-33
from d0-4 (Fig. 31A). Four days following transfer, CD45.2 donor cells recovered from
the peritoneal cavity- draining lymph nodes were found to have differentiated into
CD11b+ cells as well as CD11bneg T1/ST2+ IL-7Rα+ nuocyte cells (Fig. 31B). Moreover,
CD45.2 donor cells isolated from the Peyer’s patches exclusively differentiated into
CD11bneg T1/ST2+ IL-7Rα+ nuocytes (Fig. 31C). These results support the hypothesis
that IL-25-elicited MPPtype2 cells represent a multi-potent progenitor cell population
capable of generating multiple cell lineages, including nuocytes, both in vitro and in vivo.

4.5 Discussion
The recent identification of MPPtype2 cells, NHCs, nuocytes and Ih2 cells has altered our
understanding of the cellular mechanisms that promote CD4+ Th2 cell-dependent
immunity and/or inflammation at mucosal sites.

However, the similarities between

MPPtype2 cells, NHCs, nuocytes and Ih2 cells have lead recent reports to conclude that
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MPPtype2 cells, nuocytes and NHCs are the same cell population [139, 245, 246].
MPPtype2 cells, NHCs, nuocytes and Ih2 cells all express c-kit, but lack expression of
surface markers for any known cell lineage [13-15, 17], indicating that these cell
populations were previously unrecognized innate cell populations. In addition, all four
cell populations displayed the common functionality of promoting the development of
type 2 inflammation, yet key differences have raised fundamental questions about
whether MPPtype2 cells, NHCs, nuocytes and Ih2 cells are the same cell lineage, related
lineages or represent four distinct and unrelated cell lineages.

Data presented in this chapter demonstrate that, based on expression of T1/ST2, IL7Rα, and CD90, IL-25-elicited MPPtype2 cells are phenotypically distinct from
NHCs/nuocytes.

Moreover, IL-25-elicited MPPtype2 cells, but not nuocytes, possess

multi-potent potential, further distinguishing MPPtype2 cells from NHC/nuocytes.

In

addition, IL-25-elicited MPPtype2 cells expressed the receptor for TSLP (TSLPR) and
upon stimulation with TSLP in combination with IL-33, IL-25-elicited MPPtype2 cells
differentiated into T1/ST2+ nuocytes, indicating that MPPtype2 cells represent direct
progenitors of NHC/nuocytes. Combined, these data not only indicate that MPP type2 cells
are distinct from NHC/nuocytes, but also demonstrate that MPPtype2 cells may represent
a progenitor of NHC/nuocyte cell populations.

MPPtype2 cells, NHCs, nuocytes and Ih2 cells are all responsive to IL-25 and/or IL-33,
and published reports have demonstrated that both IL-25 and IL-33 can similarly elicit ckit+ cell populations [13-17], but whether IL-25- versus IL-33-elicited cells are the same
or unique is not known. While administration of either IL-25 or IL-33 resulted in the
induction of T1/ST2+ c-kit+ nuocyte cells, administration of IL-33 resulted in a higher
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frequency of nuocytes, compared to treatment with IL-25. Moreover, compared to IL-25induced nuocytes, IL-33-elicited nuocytes exhibited higher expression levels of IL-7Rα,
CD90 and IL-4/eGFP, a potential indication of a more mature and/or activated
phenotype. Surprisingly, the majority of IL-25-elicited c-kit+ cells lacked expression of
T1/ST2, IL-7Rα, and CD90, a surface phenotype most consistent with MPPtype2 cells.
Combined, these data identify differences between IL-25- and IL-33-elicited innate
lymphoid cell populations and further indicate that while redundancy exists between IL25 and IL-33 in terms of eliciting similar innate cell populations, these two cytokines may
predominantly act through distinct cellular mechanisms to promote Th2 cytokine
responses at mucosal sites. Although IL-25 and IL-33 may act independently of one
another, there is evidence for cross-talk between these pathways. The finding that IL25-elicited MPPtype2 cells can differentiate into nuocytes in the presence of TSLP and IL33, but not with either TSLP or IL-33 alone, suggests that TSLP and IL-33 synergize to
promote nuocyte differentiation. This observation also suggests complex interactions
between these three epithelial cell-derived cytokines and demonstrates cross-regulation
between IL-25, IL-33 and TSLP. Taken together, these observations highlight the need
for more investigation into the identity, function and lineage relationships between
MPPtype2 cells, nuocytes, NHCs and Ih2 cells both in the steady state and in the context
of disease as well as the effects of IL-25, IL-33 and TSLP on all of these cell
populations.

While the identification of MPPtype2 cells, nuocytes, NHCs and Ih2 cells provides new
insights into understanding the cellular mechanisms through which CD4+ Th2 celldependent cytokine and associated effector responses at mucosal sites are initiated and
regulated, these innate lymphoid cell populations may play broader roles at mucosal
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sites.

Indeed, recent reports have described roles for NHCs/nuocytes in models of

airway hyperresponsiveness, during flu infection and in wound healing responses in the
lung [139, 247].

Moreover, the existence of NHCs/nuocytes has been described in

humans [248, 249], however human MPPtype2 cells have yet to be identified. Despite
these advances, the impact of MPPtype2 cells, nuocytes, NHCs and Ih2 cells in human
disease and the respective roles these cell populations play in other Th2 cytokineassociated diseases such as asthma and allergy has yet to be determined.

Thus,

understanding the early innate pathways involved in the induction of Th2-associated
immune responses may help establish novel therapeutic approaches for the treatment of
helminth infections and allergic diseases in humans.
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Table 2. Comparison of MPPtype2 cells, nuocytes, Ih2 cells and NHCs.
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Figure 21. IL-25-elicited c-kit+ cells are distinct from natural helper cells.

Figure 21. Expression of surface markers on c-kit+ GFPneg (blue line) or c-kit+
GFP+ (green line) cells from IL-25-treated mice analyzed by flow cytometry.
Shaded histograms indicate the positive control for each respective surface
marker. IL-7Rα, gated on CD4+ T cells; T1/ST2, gated on c-kit+ FcεRI+ mast
cells). Cells in (A) were surface stained ex vivo. Gata3, Junb, Maf, Stat6 and
Il1rl1 mRNA expression by naïve CD4+ T cells (N), IL-4/eGFP+ CD4+ T cells
from helminth-infected mice (Th2) or IL-25-elicited c-kit+ GFPneg or c-kit+ GFP+
cells was measured by real-time PCR (B). Data are representative of at least
two independent experiments.
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Figure 22. IL-25 elicits a c-kit+ cell population in the mesentery, but does
not affect natural helper cell populations.

Figure 22. A-C, WT mice were treated with IL-25 daily for 4 days and induction
of c-kit+ cells in the peritoneum (A) and mesentery (B) of control or IL-25treated mice was assessed by flow cytometry. Plots shown are gated on live
CD3εneg CD4neg CD19neg CD11bneg cell populations and in (A) gated to exclude
FcεRIα+ mast cells. Frequencies of natural helper cells in the mesentery of
control or IL-25-treated mice were assessed by flow cytometry (C). Plots
shown are gated on live CD3εneg CD4neg CD19neg CD11bneg. Data in A and B
are representative of at least two independent experiments. (control, n=7; IL25-treated, n=7). Data in (C) are representative of two control-treated and
three IL-25-treated mice.
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Figure 23. IL-25-elicited MPPtype2 cells, but not nuocytes, possess multipotent potential.

Figure 23. A, C, FACS-purification gating of IL-25-elicited MPPtype2 cells
(lineageneg T1/ST2neg c-kit+ GFPneg) (A) or nuocytes (lineageneg T1/ST2+ ckit+ GFP+) (C) from IL-25-treated IL-4/eGFP reporter mice. Plots shown are
gated on live, lineageneg cells (CD3ε, CD8α, CD19, CD11b, CD11c, Gr-1).
B, D, Flow cytometric analysis of myeloid, granulocyte and nuocyte
differentiation of FACS-purified live, MPPtype2 cells (lineageneg T1/ST2neg ckit+ GFPneg) (B) or nuocytes (lineageneg T1/ST2+ c-kit+ GFP+) (D) from IL-25treated IL-4/eGFP reporter mice following in vitro culture in SCF (50 ng mL-1)
and IL-3 (10 ng mL-1). Data in A-D are representative of three independent
experiments.
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Figure 24. IL-25 and IL-33 differentially elicit nuocytes and MPPtype2 cells in
the MLNs.

Figure 24. A, B, Frequency of c-kit+ cells in the NBNT cell compartment from
the mesenteric lymph node (MLN) of control, IL-25- or IL-33-treated IL-4/eGFP
reporter mice and their expression of T1/ST2 was assessed by flow cytometry
(A). Plots are gated on live, lineageneg (CD4, CD8, CD11b, CD11c, and CD19)
cells. IL-7Rα, CD90.2 (Thy1.2) and IL-4/eGFP expression on T1/ST2+ c-kit+
cells (black histograms) or T1/ST2neg c-kit+ cells (gray shaded histograms) from
IL-25- or IL-33-treated mice (B). Data in A and B are representative of 3
independent experiments (control, n=6; IL-25-treated, n=9; IL-33-treated, n=9).
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Figure 25. IL-33 signaling is not required for the IL-25-mediated induction
of MPPtype2 cell or nuocyte cell populations.

Figure 25. Frequency of c-kit+ cells and their expression of T1/ST2 in the NBNT
cell compartment from the mesenteric lymph node (mLN) of control or IL-25treated IL-4/eGFP reporter mice treated with either isotype (IgG) or anti-T1/ST2
monoclonal blocking antibodies (A) was assessed by flow cytometry. Plots are
gated on live, lineageneg (CD4, CD8, CD11b, CD11c, and CD19) cells. IL-7Rα,
CD90.2 (Thy1.2) and IL-4/eGFP expression on T1/ST2+ c-kit+ cells (black
histograms) or T1/ST2neg c-kit+ cells (gray shaded histograms) from isotype- or
anti-T1/ST2-treated IL-25-treated mice (B). Data in A and B are representative
of 3 independent experiments (control, n=6; IL-25-treated, n=9; anti-T1/ST2 IL25-treated, n=9).
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Figure 26. IL-25-elicits c-kitint cell populations independent of IL-33.

Figure 26. Frequency of c-kit+ cells in the NBNT cell compartment of MLN of
control or IL-25-treated WT and Il33-/- mice (A). The expression of T1/ST2 on
c-kit+ cells from IL-25-treated WT or Il33-/- mice (B). Expression of IL-7Rα and
CD90.2 (Thy1.2) on T1/ST2+ c-kit+ cells (black histograms) or T1/ST2neg c-kit+
cells (gray shaded histograms) from MLN (C). (control, n=4; IL-25-treated WT,
n=6; IL-25-treated Il33-/-, n=9).
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Figure 27. IL-25 signaling is not required for the IL-33-mediated induction of
c-kit+ nuocyte population.

Figure 27. Frequency of c-kit+ cells and their expression of T1/ST2 in the
NBNT cell compartment from the MLN of control or IL-33-treated IL-4/eGFP
reporter mice treated with either isotype (IgG) or anti-IL-25 monoclonal
antibodies (A) was assessed by flow cytometry. Plots are gated on live,
lineageneg (CD4, CD8, CD11b, CD11c, and CD19) cells. IL-7Rα, CD90.2
(Thy1.2) and IL-4/eGFP expression on T1/ST2+ c-kit+ cells (black histograms) or
T1/ST2neg c-kit+ cells (gray shaded histograms) from isotype- or anti-IL-25treated IL-33-treated mice (B). Data in A and B are representative of 3
independent experiments.
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Figure 28. IL-25-elicited MPPtype2 cells and nuocytes express the receptor
for TSLP.

Figure 28. TSLPRα expression on IL-25-elicited MPPtype2 cells or nuocytes in
the MLN. Frequency of c-kit+ cells in the NBNT cell compartment from the MLN
(A) of control or IL-25-treated IL-4/eGFP reporter mice. Expression of T1/ST2
on IL-25-elicited c-kit+ cells was assessed by flow cytometry (B). TSLPRα
expression on T1/ST2+ c-kit+ cells (black histograms) or T1/ST2neg c-kit+ cells
(dashed histograms) from MLN (B). Plots are gated on live, lineageneg (CD4,
CD8, CD11b, CD11c, and CD19) cells or as indicated. Shaded histograms in
b,d represent TSLPRα expression on bone marrow cells from TSLPR-deficient
mice. Data in A and B are representative of 2 independent experiments.
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Figure 29. IL-25-elicited MPPtype2 cells represent a direct progenitor
population of nuocytes.
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Figure 29. FACS-purification gating of IL-25-elicited MPPtype2 cells (lineageneg
T1/ST2neg c-kit+ GFPneg) from IL-25-treated IL-4/eGFP reporter mice (A). Flow
cytometric analysis of myeloid, granulocyte and nuocyte differentiation of
FACS-purified live, MPPtype2 cells (lineageneg T1/ST2neg c-kit+ GFPneg) following
in vitro culture in IL-33 alone (50 ng mL-1), TSLP alone (1 µg mL-1), IL-33 and
TSLP or IL-33 and TSLP in combination with SCF and IL-3 (B). Data in A and
B are representative of three independent experiments.
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Figure 30. IL-25-elicited nuocytes do not display multi-potent potential.

Figure 30. FACS-purification gating of IL-25-elicited nuocytes (lineageneg
T1/ST2+ c-kit+ GFP+) from IL-25-treated IL-4/eGFP reporter mice (A). Flow
cytometric analysis of myeloid, granulocyte and nuocyte differentiation of FACSpurified live, nuocytes following in vitro culture in IL-33 (50 ng mL-1) and TSLP (1
µg mL-1) in combination with SCF (50 ng mL-1) and IL-3 (10 ng mL-1) (B). Data
in A and B are representative of two independent experiments.
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Figure 31. IL-25-elicited MPPtype2 cells differentiate into T1/ST2+ IL-7Rα+
nuocytes in vivo.

Figure 31. A-C, CD45.1 congenic recipients were injected with a TSLP cDNA
encoding-plasmid via hydrodynamic tail vein injection. At day 7 post-cDNA
injection, mice were given 2-3 x104 MPPtype2 cells (c-kitint GFPneg) i.p. from IL25-treated CD45.2 mice. Recipient mice were then treated daily for 4 days with
0.5 µg IL-33 (A) and differentiation of donor cells isolated from the MLN (B) and
PP (C) was assessed on day 6 post-transfer. Plots shown are gated on live
cells or as indicated. Data are representative of two independent experiments.
(n=4).
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Chapter 5
Summary, Discussion and Future Directions
5.1 Characterization of the innate immune cell populations elicited by IL-25
CD4+ T helper (Th) 2 cytokine responses are responsible for the development of allergic
diseases, including asthma and allergy, and are critical for protective immunity against
helminth infections [72, 250-255]. Given the increasing prevalence of allergic disorders
in industrialized countries, and the estimated two billion individuals worldwide that are
infected with soil-transmitted helminth parasites [256-260], a more comprehensive
understanding of how Th2 cytokine responses are initiated and regulated could benefit
the design of new therapeutic strategies to prevent or treat these conditions. While the
mechanisms involved in the initiation of innate immune responses following exposure to
viral, bacterial or protozoan infections are well characterized [62-67], the innate immune
pathways that promote Th2 cytokine responses in the context of allergy or helminth
infection remain less well defined.

Previous in vitro studies have determined that

cognate interactions via major histocompatibility complex (MHC) class II, T cell receptors
(TCR) and interleukin (IL) -4 are required for optimal differentiation of naïve T cells into
Th2 cells [251, 261, 262]. Consistent with these data, dendritic cells (DCs), which lack
the ability to produce IL-4, in most circumstances appear to be insufficient to promote
Th2 cell differentiation in vivo [11, 106, 263, 264]. Historically, IL-4 producing innate cell
populations, such as basophils, eosinophils and mast cells were considered late-phase
effector cell populations, however, more recent studies have challenged this concept
through the demonstration that these innate cells can provide an early source of IL-4 and
influence the development of optimal Th2 cell responses. These observations have
provoked interest in the early cellular and molecular events that regulate the
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development and activation of IL-4-producing innate cell populations.

Based on the

findings that the epithelial cell-derived cytokines TSLP, IL-33 and IL-25 are known to
promote Th2 cytokine responses through the induction of distinct IL-4-, IL-5- and IL-13secreting innate cell populations [11, 14, 16, 17] (discussed in Chapter 1.4.1-1.4.3), the
goal of this thesis was to interrogate and define the cellular mechanisms through which
IL-25 promotes Th2 cytokine responses.

The results presented in this thesis identify a previously unrecognized multi-potent
progenitor (MPP) cell population and provide new insights into the cellular mechanisms
through which IL-25 initiates and regulates CD4+ Th2 cell-dependent immune responses
at mucosal sites. In Chapters 2 and 3, IL-25 was found to promote the accumulation of
a NBNT c-kit+ cell population that lacked expression of known lineage markers. This cell
population displayed a surface phenotype consistent with bone marrow-resident MPP
cells and possessed the capacity to differentiate into myeloid and granulocyte lineages
that could initiate CD4+ Th2 cell differentiation, and was therefore termed MPPtype2 cells.
In Chapter 4, MPPtype2 cells were found to be distinct from other recently identified c-kit+
innate cell populations (NHCs, nuocytes and Ih2 cells). In addition, MPPtype2 cells were
capable of differentiating into NHCs/nuocytes following stimulation with TSLP and IL-33,
indicating that MPPtyp2 cells possess both lymphoid and myeloid potential.

Despite several reports identifying IL-25-responsive innate cell populations [3, 16, 158,
171, 176], the cellular mechanisms through which IL-25 promoted Th2 cytokine
responses remained poorly characterized. In Chapter 2, IL-4/eGFP reporter mice were
employed to identify IL-4-competent innate cell populations elicited by IL-25.

While

administration of IL-25 resulted in a significant increase in total cell numbers in the
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MLNs, T cell, B cell, DC and macrophage populations were only increased 1.5-2 fold. In
contrast, IL-25 was shown to predominantly elicit a NBNT c-kit+ cell population, which
displayed a 56-fold increase compared to control treated mice. In addition, this cell
population also lacked expression of lineage-specific surface markers for basophil, mast
cell or eosinophil populations. Of all the innate cell populations reported, data from the
studies presented here are most consistent with the NBNT c-kit+ cell populations
identified by Fort et al. and Fallon et al. that was elicited following administration of
exogenous IL-25 [3, 16].

This IL-25-elicited NBNT c-kit+ cell population lacked

expression of FcεRIα and surface bound IgE, but was presumed to be a mast cell or
mast cell precursor population [11, 16].

However, data presented in this thesis

demonstrate that IL-25 was capable of eliciting this NBNT c-kit+ cell population and Th2
cytokine responses in two mast cell deficient mouse strains (Wsh or IL-3R-deficient mice)
(see Fig. 9). These findings suggested that IL-25-elicited c-kit+ cells were not mast cells
and that IL-25 could promote Th2 cytokine responses independently of mast cells.

The IL-25 elicited a c-kit+ cell population identified in this thesis displayed a surface
phenotype consistent with bone marrow-resident MPPs, being Linneg Sca1+ CD34+ but
lacking expression of CD150, suggesting that IL-25 promoted the expansion of an MPPlike cell population in the periphery. The IL-25-elicited c-kit+ GFP+ cells were found to
differentiate into mast cells, while, the c-kit+ GFPneg cells exhibited multi-potent capacity,
giving rise to cells of monocyte/macrophage and granulocyte lineages both in vitro and
in vivo.

In addition, progeny derived from IL-25-elicited c-kit+ GFPneg cells were

competent antigen presenting cells and could promote CD4+ Th2 cell differentiation.
Collectively, data presented in Chapters 2 and 3 indicate that the IL-25-elicited MPPtype2
cells are not T- or B-lymphocytes, NKT cells, basophils, eosinophils or mast cells, and
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suggests that they represent a previously unrecognized innate cell population through
which IL-25 promotes CD4+ Th2 cell differentiation.

5.2 Relationship(s) between the MPPtype2 cells and the other previously
unrecognized innate cell populations
When MPPtype2 cells were identified, three other independent laboratories had identified
previously unrecognized innate cell populations that are regulated by epithelial cellderived cytokines and promote CD4+ Th2 cytokine responses.

The identification of

NHCs, nuocytes and Ih2 cells has provided new insights into the cellular and molecular
mechanisms that initiate and regulate Th2 cytokine-dependent (type 2) inflammation at
mucosal sites [13-15]. However, these recent findings provoke fundamental questions
regarding the relationships between MPPtype2 cells, NHCs, nuocytes and Ih2 cells and
whether these are the same cell population described by four independent laboratories,
are potential precursors of one another or represent four distinct and unrelated cell
populations.

At the time MPPtype2 cells, NHCs, nuocytes and Ih2 cells were identified, the interrelationships between these innate cell populations was not known. While all these cell
populations shared a common functionality and phenotype based on cell morphology
and surface marker expression (being Lin- c-kit+ Sca1+), suggesting that these four
populations may be the same cell population, subsequent flow cytometric analyses
revealed differences in expression of some surface molecules.

For instance, the

majority of IL-25-elicited MPPtype2 cells in the MLNs did not express T1/ST2 (a subunit of
the IL-33 receptor) or IL-7Rα and were also negative for expression of CD90 (Thy1),
CD25 and CD44. In contrast, NHCs, nuocytes and Ih2 cells differed from MPPtype2 cells
in that they expressed T1/ST2 and IL-7Rα, CD90 and CD44 (summarized in Table 2).
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These differences in surface marker expression may indicate that MPPtype2 cells are less
differentiated than nuocytes, NHCs and Ih2 cells. Expression of specific transcription
factors is also associated with lineage commitment. In support of this hypothesis, while
all four cell populations displayed a surface phenotype most commonly associated with
hematopoietic stem cells (Lin- c-kit+ Sca1+) [227, 230], MPPtype2 cells expressed little or
no mRNA encoding GATA3, c-Maf, STAT6 and JunB in comparison to CD4+ Th2 cells,
whereas NHCs and Ih2 cells expressed Maf (c-Maf), Gata3, Junb and Stat6 as well as
Id2 and low levels of Tbx21 (T-bet). Furthermore, only MPPtype2 cells displayed multipotent potential, being able to yield progeny cells of the myelomonocyte or granulocyte
cell lineages (see Fig. 15). Therefore, based on expression of surface markers and
transcription factors, and their multi-potent potential, MPPtype2 cells appear to be distinct
from NHCs, nuocytes and Ih2 cells, a potential indication of a distinct developmental
and/or differentiation state of the MPPtype2 cell population.

However it is not known

whether MPPtype2 cells are progenitors of NHCs, nuocytes or Ih2 cells. One hypothesis
is that MPPtype2 cells cannot differentiate into NHCs, nuocytes or Ih2 cells and that IL-25
and IL-33 act to expand multiple distinct cell populations (Fig. 32A). This would be an
intriguing finding considering the similarities between these four cell populations as it
would suggest that either MPPtype2 cells are restricted in their capacity to generate
specific cell lineages or that NHCs, nuocytes and Ih2 cells develop from progenitor
populations unrelated to MPPtype2 cells.

An alternative possibility is that IL-25-elicited MPPtype2 cells can differentiate into NHCs,
nuocytes and Ih2 cells along with macrophages, basophils and mast cells (Fig. 32B).
This hypothesis was tested in Chapter 4 and, indeed MPPtype2 cells, under certain
conditions, differentiated into a T1/ST2+ IL-7Rα+ NHCs/nuocyte-like cell population. This
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is a somewhat surprising observation considering the proposed lymphoid lineage of
NHCs/nuocytes. This finding not only suggests that MPPtype2 cells possess myeloid and
granulocyte potential (macrophage, basophils and mast cells) but can also give rise to
cell populations of lymphoid lineages and highlights the multi-potent potential of MPPtype2
cells. This point will be discussed further below (see Chapter 5.3). While MPPtype2 cells
possess the capacity to differentiate into NHC/nuocytes, it is possible that MPPtype2 cells
are not the only source of NHC/nuocytes. However, whether BM-resident progenitors
including HSCs, MPP and common lymphoid progenitors (CLPs) can differentiate into
NHC/nuocytes and the cytokines or other factors that regulate this process is not known.

The similarity in surface marker expression on NHCs, nuocytes and Ih2 cells also raises
questions about the relationship between these cell populations with most striking
difference between them being their respective anatomical localization. It is possible
that nuocytes and NHCs are distinct, however it is also possible that the same cell
population was described independently. If the latter is correct, one possible explanation
of their different localization is that adipose tissues may serve as reservoirs for NHCs
and following stimulation with IL-25 or IL-33 NHCs residing in the FALC mobilize and
migrate into peripheral tissues such as the MLN and spleen, thereby becoming
nuocytes. However, if NHCs and nuocytes are distinct cell populations, one question
becomes whether NHCs are confined to the FALC or other adipose-associated tissues
and whether these cells are expanded following helminth infection or administration of
IL-25 or IL-33.

Additionally, are nuocytes or other innate cell populations restricted from entering the
FALC and, if so, by what mechanism? These are important questions that will need to
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be addressed in order to obtain a more comprehensive understanding of the lineage
relationship between MPPtype2 cells, nuocytes, Ih2 cells and NHCs.

One potential

indication that these cell populations are distinct is that Ih2 cells were not observed in
fat-associated lymphoid clusters (FALC) [15]. In addition, NHCs were found in FALC in
the mesentery and in fatty deposits in the peritoneal cavity and surrounding the kidneys
and it has been hypothesized that adipose tissue serves as a reservoir for HSCs that are
then able to mobilize into the periphery [265, 266]. However, NHCs and Ih2 cells were
not increased in frequency in the mesentery following administration of IL-25 or IL-33. In
light of the phenotypic similarities between NHCs and nuocytes, this observation raises
the possibility that NHCs represent a ‘quiescent’ IL-25- and/or IL-33-responsive cell
population resident in FALC that then enters the periphery following stimulation, thus
becoming a ‘nuocyte’.

IL-25 and IL-33 were reported to induce nuocytes at similar frequencies [14], however
whether IL-25- and IL-33-elicited nuocytes exhibited a similar surface phenotype was not
examined.

In Chapter 4, it was shown that IL-33 induces a significantly higher

frequency of T1/ST2+ c-kit+ nuocytes in the MLN compared to IL-25. In addition, we saw
similar effects in the caudal LNs, indicating that IL-33 elicits a more substantial nuocyte
population in the periphery compared to IL-25. Moreover, compared to IL-25-elicited
nuocytes, IL-33-induced nuocyte populations expressed higher levels of CD90 and IL4/eGFP suggesting that IL-33-elicited nuocytes exhibited a more differentiated/activated
surface phenotype. Whether this apparent difference in activation status correlates to
cytokine production or biological function remains to be seen, however this observation
highlights potential differences in IL-25- versus IL-33-elicited innate cell populations.
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In addition, the ability of MPPtype2 cells, NHCs, nuocytes and Ih2 cells to promote the
development of Th2 cytokine- and associated effector responses in vivo raises
fundamental questions regarding the interactions of these cell populations with other
hematopoietic and non-hematopoietic cell populations necessary to elicit type 2
inflammation. For example, MPPtype2 cells, nuocytes, Ih2 cells and NHCs are all elicited
in the absence of the adaptive immune system and can promote type 2 inflammation in
this setting [13-17], indicating that these populations can act on non-hematopoietic cell
lineages and independently of T cells and B cells. However, regarding MPP type2 cells
and NHCs, current data suggest that they are capable of influencing lymphocyte function
[13, 17]. For instance, progeny derived from MPPtype2 cells can interact with T cells and
NHCs can promote B cell proliferation and antibody production.

Whether these

interactions are required for their ability to promote type 2 inflammation and whether
nuocytes and Ih2 cells are able to interact with the adaptive immune system in the
mucosa or periphery has not yet been examined.

5.3 MPPtype2 cells and extramedullary hematopoiesis
Hematopoietic stem cells (HSCs) are a rare long-lived cell population with the capacity
for multi-lineage differentiation and self-renewal and progression from HSCs and
commitment to a specific lineage differentiation pathway is regulated by various growth
and differentiation factors, such as SCF, IL-7 and Notch signaling pathways.

HSC

populations constantly recirculate throughout peripheral tissues [203-205, 207, 208, 228,
267] and mobilization of HSCs into the periphery through the administration of
exogenous growth factors has been a common strategy used in the treatment of
leukemia or following chemotherapy [209-214]. Recent reports have hypothesized that
HSCs are not simply passively trafficking through peripheral tissues but may be acting in
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a role of immunosurveillance as they are able to recognize microbial products and
differentiate into effector cell populations [215, 216]. These reports suggest that HSCs,
and potentially other precursor cells, are able to recognize and respond to pathogenderived signals and through extramedullary hematopoiesis can initiate a very localized
and rapid immune response.

The identification of MPPtype2 cells as a previously

unrecognized multi-potent progenitor suggests that extramedullary hematopoiesis is
involved in licensing Th2 cytokine responses. However, whether this cell population
represents a homogeneous population of individual cells capable of differentiating into
multiple lineages or a heterogeneous population of lineage-committed precursors is still
unclear.

One possible scenario is that the MPPtype2 cell population consists of a homogeneous
pool of multi-potent cells whereby each individual cell is capable of giving rise to both
myelomonocytic and granulocyte cell lineages (Fig. 33A). An alternative model is that
MPPtype2 cells represent a heterogeneous population of cells comprised of multiple
distinct progenitors, each only capable of differentiating into either monocyte and
macrophage lineages or granulocyte lineages (Fig. 33B). Yet another scenario could
exist, which is a combination of the first two models, where MPPtype2 cells are a
heterogeneous mixture but contains both single lineage-restricted progenitor cells as
well as individual multi-potent progenitor cells. Further single cell analyses of the IL-25elicited MPPtype2 cells will be necessary to determine the homogeneity of this cell
population, however flow cytometric analysis has provided a possible indication that
MPPtype2 cells are a heterogeneous population. Examination of the IL-25-elicited c-kit+
cells revealed that approximately 25% of MPPtype2 cells (c-kit+ GFPneg) were Ly6C+, but
no Ly6C expression was observed in the c-kit+ GFP+ fraction (Fig. 34A and B). This is
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an intriguing finding given the myeloid potential of the MPPtype2 cell population and the
known expression of Ly6C on developing monocytes in the periphery [268]. Thus, this
Ly6C+ fraction of MPPtype2 cells may represent myeloid lineage-restricted progenitors,
while the Ly6Cneg cell may only differentiate into granulocyte lineages.

Additional

experiments will be necessary to test the hypothesis that MPPtype2 cells represent a
heterogeneous population comprised of multiple lineage-restricted progenitors.

Another report identified an IL-25-responsive CD11b+ Ly6C+ monocyte-like cell
population in a model of chronic airway hyper-responsiveness [176]. However, this cell
population lacked expression of c-kit. One possible explanation for this difference is the
site at which these cells are identified. While we observed increased frequencies of ckit+ cells in the lungs following administration of IL-25, chronic allergen exposure in the
lungs may result in the induction of unique innate cell populations. For example, CD4+
NKT cell populations have also been described in the lungs following allergen exposure
and have been shown to produce IL-4 in response to IL-25 [171], suggesting that in the
lungs IL-25 may elicit or act through various innate cell populations. Another possible
explanation for the differences observed is in the timing at which IL-25-responsive innate
cell populations are investigated. A chronic model of allergen exposure, in which mice
are sensitized and challenged with allergens over the course of 4 weeks, was used to
identify the CD11b+ Ly6C+ monocyte-like cell population. These disparate results may
indicate that at different timepoints (acute versus chronic) and in distinct tissues, IL-25
may act on different cell populations. Alternatively, these data may indicate that the
initial IL-25-elicited cells undergo differentiation to become different cell lineages at later
timepoints. Consistent with this, data presented in this thesis demonstrate that IL-25elicited MPPtype2 cells have the capacity to give rise to cells of myeloid lineages (see Fig.
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15) and, moreover, IL-25-elicited MPPtype2 cells cultured in the presence of SCF and IL-3
differentiate into CD11b+ M-CSFR+ monocyte/macrophage-like cell populations that coexpress Ly6C+ (see Fig. 16).

Therefore, it is possible that during chronic allergic

inflammation IL-25-elicited MPPtype2 cells differentiate into monocyte/macrophage
populations, however whether MPPtype2 cells and IL-25-responsive CD11b+ Ly6C+
monocyte populations are the same cell population or share a direct lineage relationship
and the role of MPPtype2 cells in allergic disorders still needs to be examined.

In addition, how distinct epithelial-derived cytokines regulate the relationships and
functions of MPPtype2 cells is still not well defined.

IL-33 (and IL-7) promote the

proliferation and/or cytokine production of NHCs and nuocytes [13, 14], yet as one would
expect, when cultured in the presence of IL-33 alone, MPPtype2 cells, which lack T1/ST2,
do not survive or differentiate in culture.

However, IL-25-elicited MPPtype2 cells do

express TSLPR (a subunit of the receptor for TSLP). This finding, combined with the
known homology of TSLP to IL-7 and the association between TSLP and B and T
lymphopoiesis (discussed in Chapter 1.5) indicated that TSLP may direct the lymphoid
differentiation of MPPtype2 cells. And while culturing MPPtype2 cells in the presence of
TSLP alone did not result in nuocyte differentiation, it did result in increased cell
recovery and increased expression of T1/ST2 on the resultant progeny. This finding
suggests that TSLP signaling promotes MPPtype2 cell survival/proliferation and indicates
that TSLP in synergy with IL-33, may influence the proliferation, survival, cytokine
production or differentiation of IL-25-elicited MPPtype2 cells.

When cultured in the presence of TSLP and IL-33, increased cell survival/recovery along
with the generation of a T1/ST2+ IL-7Rα+ nuocyte-like cell population was observed from
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cultures initially seeded with MPPtype2 cells, indicating that MPPtype2 cells possess
lymphoid potential. Interestingly, this synergistic effect between TSLP and IL-33 has
been reported previously in mast cells [108], as both IL-33 and TSLP stimulation are
required for mast cell activation [108, 269]. Of note, MPPtype2 cells did not differentiate
into nuocytes in the presence of SCF and IL-3, while TSLP and IL-33 stimulation did not
result in the development of macrophage, mast cell or basophil populations. Importantly,
however, the multi-potent potential of MPPtype2 cells can be confirmed, as culturing
MPPtype2 cells in a cocktail of cytokines including SCF, IL-3, IL-33 and TSLP resulted in
the generation of progeny consistent with macrophages, mast cells and nuocyte cell
populations. As discussed previously, IL-25 appears to be expanding MPPtype2 cells in
vivo and not influencing their lineage commitments. The implication of this observation
is that, similar to HSCs, IL-25-elicited MPPtype2 cells possess some level of plasticity in
their differentiation potential, which is regulated by secondary stimuli such as epithelial
cell-derived cytokines or other growth factors.

This implies that depending on the

context of infection, the subsequent local cytokine milieu can shape the effector cell
populations derived from MPPtype2 cells through extramedullary hematopoiesis and thus
immediately ‘adapting’ the immune response to the specific pathogen encountered.
While these data demonstrate the ability of MPPtype2 cells to differentiate into multiple cell
lineages, including both myeloid and lymphoid, the biological significance of the plasticity
of MPPtype2 cells and their propensity to differentiate into a specific cell lineages is still
unclear and warrants further investigation.

The ability of TSLP and IL-33 to synergize and act on the IL-25-elicited MPPtype2 cells
also suggests the existence of complex interactions between TSLP, IL-25 and IL-33 and
indicate possible mechanisms whereby TSLP, IL-25 and IL-33 can amplify Th2 cytokine
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responses initiated by each other. In support of this hypothesis, previous reports have
demonstrated that both IL-25 and IL-33 can induce TSLP mRNA and IL-33 treatment
induced increased levels of TSLPR [80, 112], while TSLP, IL-25 and IL-33 are each able
to upregulate IL-17RB [150, 177, 179] (see Fig. 3), indicating that sensitization to each of
these cytokines is able to increase the production of and responsiveness to the other
two cytokines. Collectively, the coordinated expression of this triad of EC-derived
cytokines, coupled with cross-regulation of expression of ligands and receptors,
suggests that a complex interplay exists between TSLP, IL-33 and IL-25. And while the
complexities of the relationships between these cytokines has not yet been clearly
defined, increasing our understanding of the interactions between TSLP, IL-33 and IL-25
may offer new, highly effective therapeutic approaches to modulate the onset,
progression or severity of Th2 cytokine-mediated inflammation associated with asthma,
allergic disorders, and helminth infections.

Another question raised by the observed multi-potent potential of MPPtype2 cells, is the
lineage potential of MPPtype2 cells found in naïve mice. While MPPtype2 cells are present
in naïve animals, only the lineage-potential of IL-25-elicited MPPtype2 cells was examined
in the current studies. It is not known whether MPPtype2 cells isolated from naïve mice
share similar lineage differentiation potential observed in IL-25-elicited MPPtype2 cells. It
is possible that IL-25 does not impart any lineage restriction on MPPtype2 cells but rather
serves as an activating signal to promote the population expansion of these cells and
that other cytokines influence their differentiation.

Alternatively, MPPtype2 cells from

naïve mice might possess a broader repertoire in terms of lineage differentiation and IL25 may restrict MPPtype2 cells to myelomonocytic and granulocyte lineages. Additional
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studies are necessary in order to address the lineage potential of MPP type2 cells from
naïve mice and the effects of IL-25 on the lineage potential of MPPtype2 cells.

5.4 Subsets of innate lymphoid cell populations
Given the evolutionarily conserved nature of the IL-17 cytokine family [163] as well as
common signaling pathways shared between IL-33 and the IL-1/TNF superfamily and
Toll-like receptors [2, 143, 145], the innate cell populations targeted by IL-25 and IL-33
may represent evolutionary conserved pathways for the generation of effector cell
populations that preceded the development of the adaptive immune response or
compartmentalization of hematopoiesis to the bone marrow.

In support of this

hypothesis, another member of the IL-17 cytokine family, IL-17A, has been shown to
influence granulopoiesis [240]. Moreover, similar to MPPtype2 cells, NHCs and nuocytes,
emerging evidence supports the presence of other populations of innate cells that serve
both protective and pathologic roles in host immunity. Among these is a population of
cells termed innate lymphoid cells (ILCs). ILCs represent a group of related, RORγtdependent innate cell populations that exhibit a very similar surface marker expression,
cytokine production and biological significance, including lymphoid tissue-inducer (LTi)
cells, ILC17 cells, NKp46+ cells and NK22.

These ILCs all arise from a common Id2-dependent precursor cell population and
depend on the common γ-chain signaling pathway, particularly IL-7 [13, 270, 271].
Based on these findings, ILCs were hypothesized to be of a lymphoid lineage and,
indeed, a recent report has demonstrated that adult ILC populations arise from a subset
of RORγtneg common lymphoid progenitors (CLPs) [272]. Consistent with the known
requirement of Notch signaling in lymphoid development, bone marrow-derived CLPs
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were dependent on the Notch2 signaling pathway to differentiation into RORγt+ ILCs
[272]. ILCs produce IL-17 and/or IL-22 and are involved in lymphoid tissue formation,
immunity to infectious microorganisms and in tissue remodeling. In particular, LTi cells
are characterized as Linneg c-kit+ IL-7Rα+, but can also express CD4 and CD90 and
induce the formation of lymph nodes during embryogenesis [273-275]. LTi cells persist
after birth and are important for immunity to extracellular bacterial infections and tissue
remodeling [276-278].

IL-17-producing ILCs express RORγt and T-bet, but are

distinguished from LTi cells by their lack of expression of CD4 and c-kit. In contrast to
other ILC populations, which appear to be protective in the context of bacterial
infections, ILC17 cells have been shown to promote IL-23-driven intestinal inflammation
[244].

NKp46+ cells and NK22 cells are another ILC subset that has been termed

‘ILC22’. These cells are similar to LTi and NK cells in that they express c-kit and IL-7Rα,
but also express NKp44 or NKp46 [241, 242, 277, 279, 280]. Again, similar to LTi cell,
recent reports have demonstrated that IL-22-producing NKp46+ cells or NK22 cells
mediate protective immune responses to the extracellular bacterium Citrobacter
rodentium [242, 281].

Collectively, the recent identification of ILCs along with MPPtype2 cells, NHC and
nuocytes combined with their respective association with Th17 and Th2 cytokine
responses, suggests that similar to T helper cells, functionally heterogeneous
populations of innate cell populations exist. If one classifies all innate cell populations as
‘ILCs’, it is apparent that distinct subsets exist. Within this concept of ILC subsets, Spits
and Di Santo have proposed that natural killer (NK) cells, which produce IFN-γ, can be
thought of as ‘ILC1’ cells, whereas based on their production of IL-5 and IL-13 and ability
to promote type 2 inflammation, MPPtype2 cells, NHCs and nuocytes, can be classified as
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‘ILC2’ [282].

Further, RORγt+ ILCs, which appear to be innate sources of Th17-

associated cytokines, represent the innate cell population analogous to Th17 cells. No
‘regulatory’ ILC population has been formally described, however ILC populations have
been demonstrated to limit influenza-mediated inflammation and play a role in tissue
repair response [247]. The remarkable analogy of ILC subsets to T helper cell subsets
is further highlighted by the transcription factor- and cytokine-regulated differentiation
programs of ILC subsets. NK cells and ILC17 cells arise from a common Id2-dependent
precursor, however of the ‘ILC2’ cell populations, only NHCs have been shown to
require Id2.

However, subsequent differentiation and development into specific ILC

subsets appears to be regulated by different cytokines and transcription factors. For
instance, in the case of NK cells (‘ILC1’), IL-15 (and to a lesser extent IL-7) promotes NK
cell proliferation and cytokine production. Further, as is true for Th1 cell, Tbet also
appears to be important for NK cell development and cytokine production. Alternatively,
IL-7 and IL-23 along with RORγt seem to regulate the development of ‘ILC17’ cells.
Although IL-25 and IL-33 have been shown to induce ‘ILC2’ populations, no transcription
factor has been identified that regulates the differentiation these cell populations.
Potential candidates include GATA3, however, previous reports have indicated that
other classic Th2-associated innate cell populations, such as basophils, eosinophils and
mast cells do not require GATA3 expression for their development or production of IL-4
[172]. Interestingly, within the ‘ILC2’ populations, MPP type2 cells appear to give rise to
NHCs and nuocytes, which are more effector-like cell populations, suggesting that
MPPtype2 cells may not be under the same transcription regulations as NHCs or
nuocytes.
similar

Thus, whether MPPtype2 cells are Id2-dependent and whether they share

transcription

factor-regulated

development/differentiation

NHCs/nuocytes still needs to be investigated.
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profiles

with

The similarities in function between MPPtype2 cells, NHCs and nuocytes within ‘ILC2’
populations and similar shared functions among the cell populations within ‘ILC17’
subset suggest that these are redundant populations.

However, this apparent

redundancy within these ILC subsets may in fact point to specificity. This hypothesis is
particularly evident in the ‘ILC17’ subset, where multiple cell populations with similar
cytokine expression profiles can either be protective or mediate intestinal inflammation.
Moreover, while IL-25 and IL-33 both elicit cell populations that promote Th2 cytokine
responses, data presented in Chapter 4 show that IL-33 preferentially elicits nuocytes.
Thus, the elicitation of multiple yet distinct innate cell populations may represent
mechanisms to generate specificity prior to the adaptive immune response. However,
whether distinct ILC subsets are involved in different disease models or are elicited in
response to specific pathogens has not been determined.

Another interesting

hypothesis is that similar to T helper cell subsets, ILC subsets may negatively regulate
one another. For instance, the development of ‘ILC2’ subsets may actively hinder the
development or survival of ‘ILC17’ subsets. Recent data has suggested that IL-25 can
dampen LTi responses in vivo [283]. Although this was attributed to an indirect effect on
LTi cells, it is possible that IL-25 also inhibits ‘ILC17’ development by promoting ‘ILC2’
subsets. Whether these ILC subsets antagonize one another and are mutually exclusive
in the steady-state or in the context of disease remains to be tested, but this presents an
attractive phenomenon to target in the context of Th17- or Th2-associated diseases in
humans.

Further, the identification of MPPtype2 cells, nuocytes and NHCs in murine systems has
posed the challenge to investigators to identify homologous cell populations in human
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patients. Recent reports have identified a Linneg CD56neg CD161+ CRTH2+ cell population
that is derived from CD34+ progenitor cells and expresses IL-5 and IL-13 in humans
[248, 249]. In addition, under certain circumstances Linneg c-kit+ IL-7Rα+ human lymphoid
tissue-inducer (LTi) –like cells are able to produce IL-5 and IL-13 [284]. These results
could simply be due to differences among human and murine ILCs or they could suggest
lineage relationships and/or plasticity between human ILC subsets.

Despite these

differences, several reports have identified progenitor cell populations in helminthinfected individuals and in asthmatic patients that exhibit effector functions [217, 239].
These reports, while mostly correlative, support the potential for progenitors and
extramedullary hematopoiesis as a mechanism to initiate the development of rapid and
local immune responses and/or to sustain effector cell populations required for the
elimination of pathogens from host tissues. While the existence of MPP type2 cells,
nuocytes or NHC populations in humans and their impact on other Th2 cytokineassociated diseases such as asthma and allergy has yet to be fully elucidated,
understanding the early innate pathways involved in the induction of Th2-associated
immune responses may help establish novel therapeutic approaches for the treatment of
helminth infections and allergic diseases in humans.

5.5 Concluding Remarks
The results presented in this thesis provide new insights into understanding the cellular
mechanisms through which IL-25 initiates and regulates CD4+ Th2 cell-dependent
cytokine responses at mucosal sites. The data presented in Chapter 2 demonstrate that
IL-25 promotes Th2 cytokine responses through the induction of a previously
unrecognized c-kit+ innate cell population.

Further, these data indicate that, despite

previous reports, this cell population is not a mast cell and IL-25 elicits this population
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and subsequent Th2 cytokine responses independently of SCF and IL-3 signaling
pathways.

In Chapter 3, we identified the c-kit+ cell population as a multi-potent

progenitor cell population with the capacity to differentiate into myeloid and granulocyte
lineages and contribute to the induction of CD4+ Th2 cell differentiation through
extramedullary hematopoiesis.

As such, these cells were termed MPPtype2 cells.

In

Chapter 4, we demonstrated that MPPtype2 cells are distinct from other recently identified
c-kit+ innate cell populations (NHCs and nuocytes). In addition, we showed that MPPtype2
cells represent direct progenitors of NHCs/nuocytes, and that TSLP and IL-33 synergize
to promote this differentiation event, identifying cross-regulatory pathways between IL25, TSLP and IL-33. Collectively, the data presented here identify possible mechanisms
whereby innate cell populations recognize and respond to extracellular pathogens or
allergens and are able to provide both antigen presentation and/or a source of IL-4, IL-5
or IL-13 thereby establishing conditions permissive for the development of CD4 + Th2
cells and type 2 inflammation.

Further, these data contribute to emerging literature

describing specialized innate cell populations that appear to provide distinct and specific
immune responses prior to the development of the adaptive immune system.
Understanding these early innate pathways involved in the induction of Th2 cytokineassociated immune responses may help establish novel therapeutic approaches for the
treatment of helminth infections and allergic diseases in humans.
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Figure 32. Potential lineage relationships between MPPtype2 cells, NHCs,
nuocytes and Ih2 cells.

Figure 32. The identification of MPPtype2 cells, nuocytes, Ih2 cells and NHCs
raises new questions about the lineage relationships between these previously
unrecognized innate cell populations. It is unclear whether MPPtype2 cells are
progenitors of NHCs, nuocytes and Ih2 cells. One potential outcome is that
MPPtype2 cells, in addition to macrophages, basophils and mast cells, give rise
to nuocytes, Ih2 cells or NHCs (A). A second possibility is that IL-25-elicited
MPPtype2 cells are not progenitors of NHCs, nuocytes or Ih2 cells and these four
cell types are unrelated cell populations (B).
144

Figure 33. Do MPPtype2 cells represent a homogeneous or heterogeneous
multi-potent progenitor cell population?

Figure 33. The multi-potent potential observed in IL-25-elicited MPPtype2 cell
populations raises the possibility that this is a homogeneous cell population in
which each single individual cell possesses the capacity to generate multiple
lineages (A). Alternatively, MPPtype2 cells may be a heterogeneous population
composed of distinct precursors that are committed to either myeloid or
granulocyte lineages (B). Importantly, however, within this hypothesis, the
possibility for the presence of a single multi-potent progenitor still exists.
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Figure 34. MPPtype2 cells display heterogeneous expression of Ly6C.

Figure 34. Frequency of c-kit+ cells in the NBNT cell compartment from the
mesenteric lymph node (MLN) of IL-25-treated IL-4/eGFP reporter mice. c-kit+
GFP+ and c-kit+ GFPneg cells were assessed for expression of Ly6C. Plots are
gated on live, lineageneg (CD4, CD8, CD11b, CD11c, and CD19) c-kit+ cells or
as indicated. Data are representative of at least 3 independent experiments.
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